The spike is real, and it’s big too. Revenues increased from $4.8 million during the fiscal year to December 2023, to $71.5 million during FY2024, and $74.1 million during FY2025. This is over fifteen times in two years. Not many publicly listed firms have a chart looking like this. But this type of a chart should rather increase the readers’ caution because such an incredible rate of growth rarely happens due to a lot of clients. Instead, it happened due to only one.

From a Shanghai supply-chain desk to an SGX listing

The company that will trade on the SGX Mainboard was incorporated in Singapore only on 24 December 2021, and became a public company as recently as 19 June 2026. It was set up as a joint venture between AGX Singapore, a subsidiary of the Bursa-listed logistics group AGX Group Berhad, and Mr. Xu Hao, a Chinese logistics entrepreneur. Mr. Xu Hao does not sit on the board. His wife does. Mdm. Tang Ying, formerly a vice-president at a Shanghai supply-chain company, is an Executive Director and, before the offering, the 70% controlling shareholder. AGX Singapore holds the other 30%.

The name came with the relationship. As per the prospectus, the name chosen by the company on incorporation was meant to indicate its origin and commercial relationship with All-Link PRC, a different Chinese-owned freight forwarding firm which Mr. Xu Hao owns through his 64.8% ownership and which the document is very careful to point out does not belong to the group to be listed. There are also at least two other firms trading under related names. Since then, All-Link has established its own customer base using the trade name, its own logo, and even filed an application for trademark registration of the name in Malaysia – the application remains pending – in the name of its Malaysian subsidiary rather than the company that is to be listed. Bear the relationship in mind, because it is the entire thesis. The listed company was incorporated to provide logistical services to the customers of All-Link PRC, moving the cargo of these customers into Southeast Asia and earning its money from doing so.

The operating history is short. Singapore operations began in 2022. A Philippines subsidiary was incorporated in September 2022. In 2024 the group was appointed a logistics provider to the TikTok Group. In 2025 it incorporated a Malaysian arm and, in August, bought the freight-forwarding business of a local operator called MF Logistics, which is the source of the only goodwill on its balance sheet. Headcount went from ten to seventy in about a year, and had reached 112 by the time the final prospectus was registered. This is a company that grew up around a single opportunity, very fast, and is now asking for permanent public capital on the strength of it.

What the offer actually contains

All-Link is selling 37,924,500 new shares at S$0.53 each, split into a 35,824,500-share placement and a small 2,100,000-share public tranche. The public offer opened on 28 July and closes at noon on 3 August, with trading expected to start on the Mainboard at 9.00 a.m. on 5 August 2026. Every share on offer is newly issued, so the money raised goes to the company rather than to the sellers, and the raise is sponsored, underwritten and placed by CGS International Securities Singapore. The prospectus expressly grants no over-allotment option, and discloses no cornerstone investor or tranche, which for a deal this size is worth noting rather than assuming.

At S$0.53, the 151,037,900 shares in issue after the offering value the whole company at about S$80 million. The offering represents 25.1% of that, so roughly three-quarters of the company stays with the people who already own it: Mdm. Tang Ying with 51.7% and AGX Singapore, and behind it the Bursa-listed AGX Group Berhad, with 23.2%. The public float is 25.1%, but the portion actually offered to retail investors through the public tranche is only 2.1 million shares, about 1.4% of the company. This is a placement-led listing with a thin retail slice, and the controllers keep firm control.

The proceeds, roughly S$17.7 million after expenses, are earmarked for expansion, for “strategic acquisitions” (part of which is intended to buy out Mr. Xu Hao’s 30% stake in a related Vietnamese operation), for technology, and for working capital to pay airlines and carriers. None of it goes to repaying debt, because there is essentially none.

One item in the offer deserves to be read slowly. In March and June 2026, in the months before the listing, the company declared a US$8.0 million dividend in respect of FY2025, split as a US$2.0 million interim and a US$6.0 million final payment. Roughly US$5.6 million of that flows to Mdm. Tang Ying and US$2.4 million to AGX Singapore. That US$8.0 million is about S$10.3 million, or close to 13% of the entire post-listing market value, paid out to the controllers on the way in. On a pro forma basis it cuts the group's cash from US$23.6 million to US$15.6 million and its net assets from US$16.2 million to US$8.2 million. New shareholders do not share in it. They are buying the company the morning after the payout, then supplying fresh capital of their own on top.

The revenue that is not quite the company’s own

The single most important disclosure in the prospectus is not a number in the accounts. It is the sentence that says roughly 90% to 99.9% of the group’s revenue over the three years came from customers referred by All-Link PRC. In FY2023 and FY2024 the figure was above 99%. In FY2025 it was 90.4%.

This is important since All-Link PRC is not the customer that has an agreement and a purchase order. This is the family-run Chinese firm that provides the listed firm with the orders. The agreement between the two is now under the Non-Compete and Collaboration Deed of 30 June 2026 where All-Link PRC promises to give priority to the group when shipping to ASEAN countries. However, the risk factors of the group itself are rather blunt about the fragile nature of this protection. The deed is terminable and it automatically terminates if the firm is delisted or if Mrs. Tang Ying and Mr. Xu Hao lose control of the firm. Beyond this, as stated in the prospectus, All-Link PRC may reduce, redirect or stop the referrals “without liability to our Group”. In other words, the source of almost all the revenues lies with a firm that is run by the controlling shareholder’s husband, and continues to function due to the family retaining control and not due to any commercial obligation.

The dependency runs the other way too. To service that referred business, the group buys freight-forwarding and related services back from All-Link PRC, about US$20.5 million worth in FY2025, a sum equal to roughly 139% of the group’s latest net tangible assets, for origin-side handling in China where the listed company has no operating presence. So the referrer is also a major supplier, accounting for 31.5% of last year’s cost of sales. Money flows to the family entity on both sides of the trade.

The cost side concentrates too, and around the same name. The group’s largest supplier, at 40.5% of last year’s cost of sales and 79.7% the year before, is a company called All-Link Air and Sea Company Limited, which the prospectus says is not part of the group and is managed independently. The document does not define it, does not say what country it is registered in, and does not name its owners, though it does state that no director or substantial shareholder holds an interest in any major supplier apart from Mr. Xu Hao’s stake in All-Link PRC. Between them, two separately managed businesses carrying the All-Link name supplied 72% of last year’s costs.

Who this company answers to

Ownership answers part of the question the offer poses. After listing, Mdm. Tang Ying holds 51.7% and AGX Singapore 23.2%, so roughly three-quarters of the company stays with the insiders, and the 25.1% float, most of it placed rather than offered to the public, carries little voting weight. A minority buying in here is a genuine minority.

The more unusual feature is who sits behind AGX Singapore. It is wholly owned by AGX Group Berhad, which is itself a listed company, on the ACE Market of Bursa Malaysia. The prospectus is explicit about what that parent does:

“AGX Group Berhad is a company listed on the ACE Market of Bursa Malaysia and is principally in the business of providing sea and air freight forwarding, aerospace logistics, warehousing, road transport and distribution services globally. Save for aerospace logistics, the AGX Group operates in substantially similar business segments as our Group in overlapping geographical markets, including Singapore, Malaysia and the Philippines.”

In plain terms, one of All-Link’s controlling shareholders is also a listed competitor. That is the company’s own disclosure, not our characterisation. The alignment of the people running it points the same way. Mr. Peter Neo, the chief executive, owns no All-Link shares at all; his 18.90% economic stake is in AGX, the competitor he co-founded and whose board he left only on 1 January 2026. Mr. Chang Poh Sheng sits on All-Link’s board while serving as chief financial officer of AGX and holding 2.36% of it. The hands on the wheel still have meaningful ties next door.

That overlap is managed by agreement rather than by competition. On 30 June 2026 the two companies undertook not to solicit each other’s ten largest customers, and the All-Link names covered by that pact accounted for 100%, 100% and 94.7% of the group’s revenue across FY2023 to FY2025. Almost the entire customer book, in other words, is fenced off from the parent by a private undertaking, and like the referral deed it lasts only while AGX stays in control and the company stays listed. Half of the six-person board is independent, which is the regulatory minimum rather than a comfort, and the controlling shareholders’ lock-ups run just six months. What a buyer is being offered is a quarter of a company controlled by a listed rival, fed by a private family entity, with its customers allocated by contract rather than won in the open market.

The financial scoreboard

Look past the revenue line and the picture is not one of a business getting stronger. Gross margin fell from 40.4% in FY2023, when the company was tiny, to 14.7% in FY2024 and 12.0% in FY2025. Profit attributable to owners, the figure that matters to a shareholder, fell 25% in FY2025 even as revenue edged higher, from US$8.4 million to US$6.3 million. Administrative expenses nearly tripled to US$1.8 million as the company built out and prepared to list. And roughly US$0.8 million of the US$7.9 million pre-tax profit was simply interest earned on the cash pile, much of which is now being paid out as the pre-IPO dividend.

Cash flow tells the sharpest version of the story. Operating cash flow was positive US$29.9 million in FY2024, then turned to negative US$8.0 million in FY2025, as a large swing in trade payables unwound. For a business with almost no fixed assets, working capital is the whole game, and in its most recent year the working-capital tide went out.

The loophole that closed

To understand why the economics turned, you have to understand what the TikTok cargo was. It was low-value e-commerce parcels moving by air from China to the United States, the same flow that powered the rise of Shein, Temu and TikTok Shop. That flow existed on the scale it did because of the United States de minimis exemption, which let goods worth under US$800 enter the country free of duties and taxes. Cheap parcels, cheap entry, enormous volume.

On 29 August 2025, the United States removed the exemption. Every shipment now attracts duty regardless of value, which raises the landed cost of exactly the parcels All-Link was flying. The prospectus does not hide the consequence. It states that the removal “materially and adversely impacted” the group’s performance through a decline in volumes for the TikTok Group. The number tells the story: TikTok went from about 98% of revenue in FY2024 to about 45% in FY2025. The company is listing into the aftermath of the event that made it.

The pivot the story now depends on

Management is not blind to any of this, and the FY2025 numbers already show the beginning of a pivot. A new customer, described only as a US-listed multinational technology company with over US$2 billion of annual profit, arrived and contributed 33.6% of FY2025 revenue. The Malaysian and Philippine arms, which were rounding errors a year earlier, together reached about 9.6% of revenue. The stated plan is to push into Vietnam and Thailand, buy the Vietnamese affiliate, and diversify away from both TikTok and, over time, the All-Link PRC referral channel.

It is the obvious strategy. Whether it is a moat is a different question, and honesty requires stating where the strategy is weaker. Swapping a 98% dependence on one customer for a 34% dependence on another is real progress, but it is still concentration. The Malaysian growth was bought, not built, which is a faster route but a more expensive and less certain one. And the deepest dependency, the referral relationship with a family-controlled entity, is not something the diversification plan removes so much as leans on, since the new customers are still being won inside a network the family assembled. A forwarder’s genuine edge is density and relationships in specific trade lanes, and All-Link does have a credible one, handling an estimated 12% of Vietnam-origin air cargo to the United States in 2025. The trouble is that its largest lane by far was the China-to-US e-commerce lane, and that lane is precisely the one policy has turned against.

The cross-border parcel question

Every sector has a cautionary tale, and All-Link’s is not a single failed company but a whole category. The China-to-US low-value parcel boom created a generation of logistics and e-commerce businesses whose unit economics quietly assumed the de minimis exemption would last. When the exemption went, the volume went with it, and the businesses built on top of it discovered that a regulatory subsidy is not the same as a competitive advantage. All-Link’s own industry report, prepared by Frost & Sullivan, acknowledges the shift, noting a sharp contraction in low-value direct-to-consumer parcels, partly offset by a move toward consolidated bulk freight.

What is genuinely different in All-Link’s favour is that it is small, nimble, profitable and debt-free, and that it saw the shift early enough to start diversifying before listing rather than after. What is not different is the structural lesson: a business whose scale came from a policy window should be valued as if that window can close, because in this case it already has. The honest verdict is that the pivot is plausible and underway, but unproven, and the burden of proof sits with the next two years of results, not with the FY2024 revenue peak.

What the market is asking you to pay

Now that the price is fixed, the question stops being abstract. At S$0.53, All-Link is valued at about S$80 million. Against FY2025 profit attributable to owners of US$6.3 million, roughly S$8.1 million at the prospectus reference rate, that is a trailing price-to-earnings multiple of about 9.9 times. The post-offering earnings-per-share the company itself discloses, US 4.17 cents, lands on the same 9.9 times, so the figure is internally consistent. Measured instead against the FY2024 peak, when owner profit was US$8.4 million, the multiple is about 7.4 times. In other words, the market is paying roughly ten times the earnings of a year in which those earnings had already fallen a quarter.

There is a second lens that matters for an asset-light, cash-rich company, and it cuts the other way. After the pre-IPO dividend and the fresh money raised, All-Link should sit on something like US$29 million of net cash and near-zero debt, against a market value of about US$62 million. Strip the cash out and the operating business is being valued at roughly US$33 million, or a little over five times its FY2025 owner earnings. That is a much less demanding number, and it is the honest way to see what you are paying for the franchise itself rather than for the bank balance that comes attached. The tension between those two figures, ten times on the headline and about five times net of cash, is the whole valuation debate in miniature: the cash is real and large, but it is the earnings power, not the cash, whose durability is in question.

On dividends, there is little for a new buyer to price yet. The US$8.0 million already declared went to the existing owners before listing, so new shareholders do not receive it. Going forward the board has stated an intention, though not a binding policy, to pay out at least 30% of profit attributable to shareholders for FY2026 through FY2028. Applied to last year’s profit, that would have come to roughly 1.6 Singapore cents a share, or about 3% at the offer price. Whether it comes to that again depends on a profit line that fell 25% in the year just reported, and on cash reaching the listed holding company itself, since dividends must be paid out of its own distributable profits rather than the group’s.

How that compares with the neighbours

A multiple means little without a comparison of similar size, since small companies trade at structurally lower multiples than large ones. Nine freight forwarders listed in Malaysia, Thailand and Vietnam sit within a third to four times All-Link’s S$80 million. Their median trailing multiple is 9.9 times. All-Link is being offered at 9.9 times. Against the companies it most resembles, it is priced almost exactly in line.

One name in that set breaks the pattern, and it is the one that matters most. AGX Group Berhad, All-Link’s own controlling shareholder, running substantially the same business in the same markets, trades at about 15.8 times. The subsidiary is being sold to the public roughly 40% cheaper than the parent that controls it. That gap is not the sector’s verdict, because the sector median is 9.9 times. It is a verdict on this company in particular.

Singapore itself offers little to measure against. The exchange has no listed pure freight forwarder, and the three groups that do carry forwarding businesses, Vibrant Group, GKE Corporation and Chasen Holdings, trade on 5.4 to 7.7 times earnings. But each owns its warehouses and plant, so what they price is asset-heavy logistics rather than forwarding.

On assets there is no such ambiguity. Price-to-book measures what a buyer pays against the accounting value of what a company owns, and All-Link is the most expensive name in the comparison by a wide margin: about 2.8 times book, after the pre-IPO dividend and the new proceeds, against a forwarder median just under 1.0. No other company in the set, the parent included at 2.0, reaches two times.

The two readings meet in the middle. An asset-light forwarder owns almost nothing, so its book is thin and its return on that book looks extraordinary for as long as the work keeps arriving: about 29% on post-listing equity in FY2025, against a peer median near 8%. That ought to command a premium to book, and it does. What it is not getting is any premium on earnings, which is the market’s way of saying it doubts the 29% survives. If the return holds, three times book will look cheap. If it drifts back toward the sector’s 8%, the buyer holds the premium with no earnings discount to cushion it.

The bull, the bear, and the honest answer

The bull thesis is simple.

• It is an asset-light, profitable, and cash flow generative company that started from scratch and generated US$74 million of revenue in two years, has no debt, has management with extensive local logistics experience, is already diversifying its customer base and geographically, and is going public with new money to fuel an ASEAN expansion into some of the fastest-growing airfreight markets in the world.

• It is trading at five times net of cash last year’s profits, which is not an ambitious valuation for a logistics company with growth potential. If the strategy succeeds, the small surprise may just be a growing pain.

The bear case is equally clear, and sits mostly in the ownership and dependency structure rather than the trading.

• The revenue engine is a related party the minority cannot control.

• The single biggest customer’s volumes have already halved on a policy change with no obvious reversal.

• Profitability is falling, not rising. Margins are thin and getting thinner.

• The controllers extracted US$8 million in dividends immediately before listing, kept three-quarters of the company, and floated only a sliver to the public, and

• the whole edifice of referrals rests on the family remaining in control, which is exactly what an eventual sell-down would erode.

• On the one measure where the peer comparison is unambiguous, the shares are being floated at roughly three times what comparable forwarders fetch for their book value, with no discount on earnings to offset it.

The honest answer is that both cases are true at once, and that the deciding question is not really about logistics. It is about whether you believe a business assembled around one family’s China relationships and one customer’s tariff-advantaged parcels can become a diversified, self-standing ASEAN forwarder now that the advantage is gone. The prospectus gives you the evidence for the attempt and, at last, the price of the ticket. What it cannot give you is the result. At close to ten times a falling earnings line, the market is asking investors to pay for a transition that has only just begun.

Data integrity notes

Items materially relevant to readers, including estimates, definitions and known limitations.

1. All company figures come from the offer documents. Financial data is drawn from the prospectus dated 28 July 2026 and the accompanying Product Highlights Sheet, covering audited results for the financial years ended 31 December 2023, 2024 and 2025 [1][2].

2. Currency conversions use the prospectus rate. The group reports in United States dollars while the offer is priced in Singapore dollars. Conversions use the prospectus reference rate of US$1.00 to S$1.2881 as at the Latest Practicable Date [1].

3. The valuation measures are our own calculations. Market capitalisation, the trailing price-to-earnings and price-to-book multiples, the post-listing net cash estimate and the illustrative dividend are calculated from disclosed figures at the S$0.53 offer price and the 151,037,900 shares in issue after the offering. Book value is struck after the pre-IPO dividend and the net proceeds [1][2].

4. Two concentration measures should not be read as one. The Major Customers table gives the combined share of customers that each contributed 5% or more of revenue, at 99.7%, 98.0% and 84.9% for FY2023 to FY2025. The risk factors give top-five customer concentration, at 99.7%, 99.8% and 89.9%. The series diverge because the fourth and fifth largest customers each fell below the 5% threshold in the later years [1].

5. Peer multiples are indicative. They rest on traded prices as at 10 July 2026 and will have moved, while All-Link’s rest on an offer price and audited figures. The comparison is limited to freight forwarders worth between a third and four times All-Link, since multiples are size-sensitive, and excludes loss-making and distorted-earnings names. Widening the size band would raise the earnings median from 9.9 to 11.0 times; the narrower and less flattering figure is the one used [4].

6. The three Singapore names are context, not comparables. Vibrant Group, GKE Corporation and Chasen Holdings each run freight forwarding alongside property, materials or relocation businesses and own their asset base, so they sit outside the medians [4].

7. The industry figures are from the commissioned report. Air-cargo corridor shares and market commentary come from the Frost & Sullivan report reproduced in the prospectus, not from independent verification [3].

8. No third-party research was used. No sell-side or analyst research was an input. The article draws no forward earnings estimate, valuation target or recommendation.

References

[1] All-Link Air & Sea Limited, “Prospectus dated 28 July 2026,” lodged with and registered by the Monetary Authority of Singapore (audited FY2023-FY2025 financial statements, offer terms, capitalisation, use of proceeds, major customers and major suppliers, interested person transactions, moratorium undertakings, dividends, risk factors). Primary source for all company figures.

[2] All-Link Air & Sea Limited, “Appendix 4 Product Highlights Sheet dated 28 July 2026.” Both documents are available via the SGX-ST website and the MAS OPERA portal.

[3] Frost & Sullivan (Singapore) Pte Ltd, “Independent Industry Report,” reproduced as Appendix G in the All-Link Air & Sea Limited prospectus (ASEAN air-cargo growth rates, corridor tonnage and market share, cross-border e-commerce commentary).

[4] Peer valuation data for listed ASEAN freight forwarders, from exchange filings and market data as at 10 July 2026. Median set: MPJ Logistics (SET MPJ), TASCO (Bursa 5140), Triple i Logistics (SET III), Sonic Interfreight (SET SONIC), FM Global Logistics (Bursa 7210), South Logistics (HOSE STG), AGX Group (Bursa 0299), Sino Logistics (SET SINO), WICE Logistics (SET WICE). Core forwarders outside the size band: Tri-Mode System (Bursa 0199), Transimex (HOSE TMS). Singapore-listed logistics groups shown for local context: Vibrant Group (SGX BIP), GKE Corporation (SGX 595), Chasen Holdings (SGX 5NV).

[5] United States executive action removing the de minimis exemption for imports valued under US$800, effective 29 August 2025, as described in the All-Link prospectus risk factors and industry report.

Important Disclaimers

This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore and this content is exempt under Regulation 34 of the Financial Advisers Regulations as a generally available publication. Consult a licensed adviser before investing. Past performance is not indicative of future results. The author holds no position in the securities discussed.

On the surface it looks bad.

• FY2025 revenue fell 9.2 percent to S$177.4 million,

• Net profit attributable to shareholders dropped 43 percent to S$5.8 million (S$6.1 million including non-controlling interests, the figure on the company’s highlights page [4]),

• Earnings per share went from 3.30 cents to 1.89, and

• Vietnam, until recently the second-largest market, collapsed 30.8 percent.

At S$0.35 [1] the market has filed Hyphens under “small-cap distributor in decline.”

Now the other line. The gross profit did not go down; rather, it increased to a new high of S$72.2 million from a new high margin of 40.7 percent, while the operating cash flow increased sharply to S$18.7 million, from practically nothing. Businesses in decline do not set new highs in gross profits and cash flow during the very year that revenues peak and decline. The problem is not whether FY2025 was bad. It was. The question is whether the bad year upgraded the earnings base.

Begin with understanding what Hyphens is – three businesses:

1. It in-licenses specialty drugs and aesthetics products and distributes them in more than five Southeast Asian countries;

2. It owns a growing set of brands like Ceradan and Ocean Health that carry a fatter margin; and

3. It operates docmedtech.com, a money-losing digital and wholesale business unit.

The point to remember here is that during the FY2025 period the company moved two products into the category of owned-brands and hence the reported figures showing 33% growth for that category are misleading along with an exaggerated 18% drop in the pharmaceuticals category.

Split the year in half, and the story becomes more compelling. Gross margin ended FY2025 at 42.0% in the second half of the year, versus around 39% in the first and 36% a year ago, the best in six years. The startling profit decline has been almost entirely contained within the first half of the year, when net profit plunged 66% compared to just 17% in the second half of the year. The first half decline is not attributable to a trading issue. While gross profit increased in the first half, this is because of problems further down the profit line due to Sterimar inventory write downs and foreign exchange losses, not loss of business.

The revenue bars are lumpy for reasons outside the thesis: the 2022 step up is the Novem acquisition consolidating for its first full year, and the 1H2024 peak was a post-disruption restocking bulge that then unwound. Gross profit, the steadier navy line, is the one that matters.

Let’s also be fair to the other side. The one thing that has mostly caused the decline in the revenue was Vietnam. This seems more like a regulatory problem caused by the obligatory reduction and not an optional one. According to management, the cause of the loss of the business in that country is due to them imposing stringent regulations on the pharmacies and the supply chain, which is evident through the new pharmacy laws in Vietnam and an inspection that will be carried out in 2025 [6].

The forward case rests on the owned brands. Hyphens in January 2026 did something that a pure distributor never does: it licensed its proprietary formula of Cerapro to a dermatology company from Switzerland for an up-front payment and royalties [2], demonstrating that owned technology has value. Medical aesthetics, via the Ardence acquisition, is the second pillar; though it remains small, it relies heavily on its founder’s presence. This is the best part of the portfolio, which explains why the gross margin can continue rising.

Now the number. Add back the genuine one-offs, chiefly a S$2.0 million Sterimar write-down plus smaller Vietnam and Ardence charges, about S$2.9 million before tax in total or roughly S$2.3 million after, and normalised earnings are about S$8.1 million against the S$5.8 million reported

On this basis, our FY2025 underlying earnings is down 15-20%, not 43%.

Given the currency headwind of S$2.8m needs to stay in the base as much as anything else (we’re assuming a currency effect annually whenever you do your buying in dollars and your selling in all sorts of other currencies around the region), a figure a bit above S$10.3m arises, which we will take to not be our base given that this is rather steep of a base to run on.

Yet, not all good business is a good stock. Hyphens, trading at 18.5x forward on S$0.35, sports P/E around the low teens to mid teens on our adjusted- earnings (and cash), while the market’s forward 8x P/E has it factoring a recovery of profits to S$13m-a level we think is too aggressive even on future predictions [2]. One free option sits on top: in 2022 a listed strategic, Metro Holdings, paid real cash for a slice of the digital-and-wholesale arm at a level the market now ignores [3], though the mark is stale and we credit it with nothing.

Three catches keep this honest.

To start, liquidity. Only 23.7 per cent of the stock, around S$25 million worth, is publicly held as two owners control the rest – more than two-thirds. This means no institution can add to a stake, or get rid of one, without affecting the market, and for long, so why shouldn’t the discount stay put and its causes perpetuate its presence.

Then, history. With S$10 million in net profit notched only twice in eight years as a listed company, the adjusted normalized base looks more like the midpoint of what it tends to deliver rather than a support floor.

Last, signals. Buying from CEO [5] deserves to be flagged, though against his existing control stake, it is trivial, and in a cash loaded, poorly performing public, it could mean either an inexpensive take private bid or re-rating. And don’t give the executive management’s promises much heed, as last year, for instance, it assured stakeholders the Vietnamese regulatory system would see no real shifts ahead - this was weeks before its collapse caused, it later insisted, by policy changes.

And what do you do with it? Not much, for a while. This is a watch-one-number scenario, and that one number is gross profit dollars. It is constructed to be a small position and watchlist candidate, not an investment; the float is just too thin to make a difference, the 4.3% dividend pays you to wait, and waiting may take a while.

The test is clean and close.

• The next results come out in mid-August, covering the first half of 2026. One number tells you most of what you need: is gross profit still growing, above the S$35.3 million the group made in the first half of 2025? But gross profit alone is not the answer. It only helps you if it reaches the bottom line, instead of being spent on the marketing needed to sell those brands. And that risk is real, not theoretical. In the second half of 2025 the owned-brands arm grew its sales but earned less, because growing it cost more than it brought in.

• So here is the good outcome: if gross profit keeps rising and this time reaches profit, then the market was ignoring a business that was quietly getting better, and that is exactly why you could buy it cheap.

• And the bad outcome: if the marketing eats the gain, then FY2025 just made the company smaller at a nicer margin, no richer, and the low share price was right all along.

Watch that line, all the way to the bottom one.

Data integrity notes

All figures are from Hyphens Pharma’s SGX filings, except share price and market data, which are from Yahoo Finance at the 23 July 2026 close [1]. Net profit is the attributable figure, S$5.8 million; the S$6.1 million on the company’s highlights page is the total before the 3.5 percent attributable to non-controlling interests [4]. Two caveats matter: the FY2025 segment reclassification means the 33 percent Proprietary Brands growth is not clean like-for-like, and the first-half figures we use are derived from full-year figures less the company’s reported second half. A basic governance and accounting red-flag screen did not show obvious issues, with goodwill tested without impairment, an unqualified audit, and operating cash flow above reported net profit.

References

[1] Hyphens Pharma International (1J5.SI), share price and market data via Yahoo Finance, at the 23 July 2026 close (S$0.35). https://finance.yahoo.com/quote/1J5.SI

[2] “Hyphens Pharma out-licences Cerapro MED Skin Barrier Cream for six European countries,” Hyphens Pharma media release, 5 January 2026. https://www.hyphensgroup.com/media-release-hyphens-pharma-out-licences-cerapro-med-skin-barrier-cream-for-six-european-countries/

[3] “Metro Holdings takes 10% stake in Hyphens Pharma subsidiary DocMed at $60 mil valuation,” The Edge Singapore, 27 May 2022. https://www.theedgesingapore.com/news/ma/metro-holdings-takes-10-stake-hyphens-pharma-subsidiary-docmed-60-mil-valuation

[4] Hyphens Pharma International, Financial Highlights. https://www.hyphensgroup.com/investor-relations/financial-highlights/

[5] “Directors increase stakes in Aspial Lifestyle, Raffles Medical Group, Centurion, among others,” The Business Times, 24 May 2026. https://www.businesstimes.com.sg/companies-markets/directors-increase-stakes-aspial-lifestyle-raffles-medical-group-centurion-among-others

Primary filings (SGX disclosures, no inline citation): Hyphens Pharma International Limited, FY2025 full-year results (24 February 2026); FY2020 to FY2024 results and half-year results; Annual Report 2025; and Responses to Substantial and Relevant Questions from Shareholders for the 2026 AGM.

Disclaimer and holdings

This article is published for informational and educational purposes only. It does not constitute financial advice, a recommendation, or a solicitation to buy, sell or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore and this content is exempt under Regulation 34 of the Financial Advisers Regulations as a generally available publication. Consult a licensed adviser before investing. Past performance is not indicative of future results. The author holds no position in the securities discussed.

The mirage

In January 2026, Jollibee Foods Corporation said it would separate its international business from its Philippine operations and list the overseas arm on a United States exchange, handing existing shareholders stock in the new company. It was something no Philippine consumer company had attempted at this scale, and local brokers greeted it as a way to unlock the value of a global restaurant group the Manila market had never fully credited. Investors liked it at once, and the shares rose around 16 percent [2]. Two-thirds of Jollibee's more than 10,000 stores sit outside the Philippines, and the pitch was simple: put that fast-growing global business in front of American investors who pay up for restaurant growth, keep the steady Philippine cash machine at home, and the sum of the parts is worth more than the blended company trading in Manila. The logic was easy to follow, and for a few days the market bought all of it.

Six months later the enthusiasm had cooled. At its June annual meeting the company no longer described a spin-off and a 2027 US listing but an “ongoing strategic review” with “multiple pathways to unlock value over time,” one that would proceed “regardless of the outcome,” and the venue had drifted from New York toward Hong Kong [3]. The company’s annual-meeting messaging placed the separation inside a broader strategic review rather than repeating January’s firm transaction language. The shares gave back the excitement and now trade in the 140s, about a third below their level a year ago.

Most of the debate since has been about whether the spin happens. That is the wrong question. The more important one, which almost nobody asks, is whether it would deliver the thing it is premised on: a Wall Street re-rating of the international arm. And there is evidence to test it, because the market has already run several versions of the experiment.

The spin-off can crystallise value, but the listing alone cannot durably multiply it. The reason is simple: the closest available US-listed precedents, each Chinese or Chinese-origin, have not sustained US growth multiples. Chagee IPO’d on Nasdaq in 2025 at roughly 2.5 to 3 times sales on an enterprise basis and, as its growth cooled, fell to about 0.7; Yum China, spun off and NYSE-listed, sits near 1.3.

That matters because the bull case depends on a venue re-rating. Jollibee’s international arm may be valuable, but its value is already explainable on Asian marks. The mirage is not the business; it is the idea that New York changes the multiple. What follows builds that case from the filings up: what Jollibee is, where its profit sits, what it has bought, and then the test itself.

What Jollibee really is

Built from a single ice cream parlour the Tan family opened in 1975, Jollibee is now one of Asia’s largest restaurant operators, with more than 10,400 stores across 33 countries and around 20 brands. When customers at that ice cream parlour kept asking for hot meals, the founders switched the menu to burgers and fried chicken and incorporated the business as Jollibee in 1978. The defining moment came in 1981, when McDonald’s entered the Philippines and, against every expectation, failed to dislodge the local upstart: Jollibee had tuned its food to a Filipino palate, sweeter burgers and saltier fried chicken, that global chains never quite matched. To this day the Philippines is one of the very few markets on earth where the home-grown chain outsells McDonald’s on its own ground, and Brand Finance ranks Jollibee the most valuable restaurant brand in Southeast Asia [4]. That victory taught the company two lessons that still shape it: that local taste and habit beat global scale, which is why the domestic business is so hard to dislodge; and that the formula does not automatically travel, because the home-turf advantage is exactly what it lacks everywhere else.

Underneath the brands sit three businesses. The first is operating restaurants, some company-owned, most franchised, and the distinction drives the economics. A franchised store sends Jollibee a royalty with almost no incremental cost or capital; a company-owned store carries the full weight of rent, staff and fit-out. Jollibee’s mature domestic brands lean heavily franchised, which is why the home business throws off cash, while several overseas businesses are more company-operated, which is one reason they consume it. The flagship makes the split visible: of the 1,279 Jollibee-branded stores in the Philippines at the end of 2024, about two-thirds were franchised; of the 480 abroad, three-quarters were company-owned. Same brand, inverted model.

The second business is the commissary and supply chain, a network of central kitchens and distribution centres that manufactures the standardised sauces, marinades and frozen components which make a Chickenjoy in Davao taste like one in Manila. It is unglamorous, and it is a real moat: it enforces consistency, captures manufacturing margin a pure franchisor would hand to suppliers, and cannot be cheaply copied. A competitor can clone a recipe; it cannot clone a nationwide commissary built over four decades.

The third business, increasingly central, is capital allocation, which is to say buying restaurant companies. The domestic portfolio was assembled partly by acquisition; the international arm almost wholly so. This makes Jollibee as much an acquirer and operator of brands as a single chain, and it is the fact that most shapes how the overseas business should be valued. Management has spoken for years of becoming one of the largest restaurant companies in the world, so the spin-off is the logical endpoint of a decades-long ambition rather than a sudden idea, which is part of why the company is reluctant to abandon it even as the mechanics turn out to be hard. Two familiar Singapore touchpoints, for orientation: Jollibee owns The Coffee Bean & Tea Leaf, controls Tim Ho Wan through an investment fund, and through a joint venture took Tiong Bahru Bakery and Common Man Coffee Roasters to the Philippines [5].

Around the flagship sits a portfolio built to cover the whole Filipino table: Chowking for Chinese-style fast food, Mang Inasal for grilled-chicken value, Greenwich for pizza, Red Ribbon for cakes and bread, together roughly 3,500 outlets. That breadth captures the eating-out peso across occasions and price points and gives the commissary the volume that makes it efficient. Stack the layers and the domestic moat comes into focus: a brand that is a cultural default, a portfolio that spans the table, a franchised structure that turns dominance into high-return royalties, and a supply chain that enforces quality while capturing manufacturing margin. It is the combination, not any single layer, that a competitor finds hard to match, and it still has room to run as the group pushes into higher-growth provincial markets behind new commissary capacity in the Visayas.

The pattern to carry forward is that all of this is local. Brand affection, portfolio breadth, franchised density and commissary scale are built on Filipino habit and Philippine geography, and those things do not travel. Everywhere except Vietnam, Jollibee competes abroad without the home-turf advantage, as one more challenger buying its way into crowded markets. That is the deeper reason the profit sits where it does.

The profit is still Philippine

Almost all of Jollibee’s profit is Philippine, a fact the “clean unlock” framing skates over.

The six-year record contains a violent shock and an incomplete recovery. Revenue fell to about ₱129bn in the 2020 pandemic year, when dining rooms shut and the group posted its first-ever annual loss, roughly ₱11.5bn. It then recovered hard, to ₱154bn, ₱212bn, ₱244bn, ₱270bn and ₱305bn in the five years to 2025, more than doubling the top line. The bottom line came back more slowly and has since flattened: net income to shareholders climbed from that loss to about ₱10.9bn, but the step from ₱10.3bn in 2024 to ₱10.9bn in 2025 was small, and momentum turned negative in early 2026. Reported profit is also flattered slightly by deferred tax assets recognised on the overseas units’ accumulated losses, an entry that lifts net income without adding a peso of cash, and one more reason to read the segment detail rather than the headline.

On the company’s own FY2025 geographic figures, the Philippine business earned about 112 percent of group net income to shareholders; the international arm, taken together, was a small net loss, about minus 12 percent. The overseas arm made an operating profit, roughly 19 percent of group operating income, but a net loss once financing and acquisition costs were counted, so the Philippine business had to out-earn the whole group to offset it. The pattern held the year before, at plus 111 and minus 11 percent, and it worsened at the net line in early 2026: in the first quarter the international operations lost roughly ₱0.7bn, about minus 52 percent of a depressed group net income, and attributable net income fell about 39 percent, to roughly ₱1.5bn [8].

The home engine is strong but maturing. Philippine same-store sales growth has stepped down from about 7.5 percent in 2024 to 5.2 percent in 2025 to 3.2 percent in the first quarter of 2026, the last against a base lifted by election-related spending, and domestic margins felt cost pressure early in 2026. This is a dominant, franchised, cash-generative business that is also slowing, not an annuity that compounds untouched, which is part of why management keeps reaching abroad.

The point this sharpens is what the separation actually is. It is not two profitable halves going their separate ways. It is a profitable Philippine business that has quietly subsidised a global build-out, and a proposed separation that would hand at least part of that build-out to public investors abroad. The question the rest of this piece works through is what the shareholder left holding the Philippine business receives in exchange, and what it costs to deliver.

The international arm is real, but mixed

This does not make the international arm bad. It makes it early, and real. International EBITDA grew about 20 percent in FY2025 to ₱14.1bn, its operating margin rose from 2.0 to 3.0 percent, and its share of group operating income climbed from 13 to 19 percent. The engine is coffee: of that ₱14.1bn, ₱8.6bn, more than 60 percent, is Coffee and Tea, led by Compose in Korea (EBITDA up 156 percent in its first full year inside the group), The Coffee Bean & Tea Leaf, and Highlands in Vietnam. Around it sit the newer Asian brands and a scatter of turnarounds still dragging, China (international EBITDA down 69 percent) and Smashburger (EBITDA of about minus ₱1.0bn) among them. Jollibee’s international business is, first and foremost, a coffee platform with a Vietnamese quick-service winner attached, not a scaled-down replica of the chicken chain at home.

One caveat on the brand itself, precisely because it is easy to overstate. Where the Jollibee brand has travelled abroad, it has historically done so on the back of Filipinos rather than by winning locals: its overseas stores cluster where the diaspora is thick, and the company’s own push to reach mainstream American customers concedes as much [9]. Vietnam is the telling exception, with only a small Filipino population but more than two hundred stores selling to local diners. Kept in proportion, this applies to the Jollibee brand abroad, a few hundred of the arm’s thousands of stores; the arm’s growth case rests on the acquired local brands, Compose, Highlands and The Coffee Bean & Tea Leaf, where Filipino demand is beside the point. The value is not the brand’s diaspora pull but the businesses it has bought.

Because the arm is bought rather than built, judging it means judging Jollibee as an acquirer, and the record is genuinely mixed. The domestic template worked: Mang Inasal, bought in 2010, became one of the group’s best growth engines, a heavily franchised grilled-chicken chain that still posts some of the fastest same-store growth in the portfolio. That is the template the bulls hope repeats abroad, buy a strong local concept and scale it through franchising, though the domestic deals had the home-turf advantages working for them, which is exactly why they are weak evidence for what happens overseas. Abroad the results are harder to read. Smashburger, the American “better burger” chain taken to full ownership by 2018, has underperformed for years and was still being reformatted in 2026; The Coffee Bean & Tea Leaf, bought in 2019, has been a turnaround more than a growth story; China has been a repeated cycle of openings and closures. Against those sit the clear winners, and they cluster in Asia and in the newest deals. Vietnam is the standout, with systemwide sales up more than 40 percent last year; Tim Ho Wan more than doubled its Hong Kong store count within a year of full integration; and above all Compose, bought in 2024 for about US$340m [6] at roughly eight times its annual operating earnings, grew its underlying product sales more than 10 percent in 2025 [15], even as its reported contribution to the group jumped far more on its first full year of consolidation. Tellingly, Highlands is pursuing a parallel Vietnam listing at a reported US$400m [7], a separate monetisation path that could complicate, or potentially thin, the eventual international perimeter, depending on how the two transactions are structured. The honest reading is that the arm is some winners and some turnarounds wearing a single growth label, and the separation is partly an attempt to let the market price the winners without the drag.

The exits tell their own story. Over the past decade the group has quietly walked away from a US subsidiary, China’s Dunkin’ and a hotpot venture, and Vietnam’s Pho24, none large alone but together the mark of a company that buys often and is willing to cut its losers. That is healthier than clinging to them, but it is not the effortless compounding the “global growth company” label implies. Compose is the counter-example the bulls lean on hardest: almost entirely franchised, close to debt-free and high-margin, it is the asset-light model the group wants to define its international future. And the buying has not stopped, which is a tell in itself. In February 2026, well into the “strategic review,” the group agreed to acquire the South Korean hot pot chain Shabu All Day for about US$87m [6], a second Korean deal in under two years that sits awkwardly against the idea that the arm is being frozen and readied for a clean carve-out.

Management knows this ceiling, and its answer is instructive. It has been expanding its US franchising programme, aiming for a majority-franchised American footprint and courting mainstream customers rather than only Filipinos [9]. That is a genuine point in the separation’s favour. The open question is whether the strong US unit economics the company advertises hold beyond a handful of high-traffic destination outlets in areas of dense Filipino settlement; that is the diaspora question restated, and we flag it as our reading rather than a proven claim, since we lack the store-level customer data to settle it either way.

All of this sits on the balance sheet as about ₱78.8bn of goodwill and brand intangibles, more than a quarter of the group’s total assets, the accumulated price of a decade of buying. It is not a cost that recurs, but it is capital that has to earn a return, and at the group’s net line the international business has not yet earned one on it. Judging Jollibee therefore means judging its record as a buyer, which is why the mixed record above weighs as much as the growth rate.

What the closest US-listed Asian precedents show

Here is the mechanism the bull case needs, stated plainly. Today the international arm is buried inside a Manila-listed chicken chain and the market gives it little; the whole company trades at roughly what the Philippine business alone is worth. Separate it, list it in New York where investors pay rich multiples for restaurant growth, and the same business re-rates to a US growth multiple. The gap between “nothing” and “US growth multiple” is the unlock, and the venue-driven bull narrative maps that supposed re-rating onto the gap between the current price and bullish valuation scenarios, from the consensus mean near ₱211 [1] to the ₱287 top of the current range and the ₱330-plus targets seen before the recent de-rating.

Everything hinges on one link: a US listing produces a US multiple. It is the single testable claim on which the whole bull case rests, and it has been tested, because several Asian restaurant and coffee companies have already reached a US exchange by different routes, and we can see what the market paid. The closest to Jollibee’s proposed transaction is Yum China, which Yum Brands spun off and listed on the New York Stock Exchange in 2016: a carved-out, Asia-focused restaurant operator, made independent and primarily US-listed. It is large, profitable, dividend-paying and cleanly run, and it trades at about 1.3 times sales and nine times EBITDA. A fresher test arrived in April 2025, when Chagee, a Chinese premium-tea chain, listed directly on Nasdaq in a primary IPO; it trades near 0.7 times sales. And Haidilao carved out its own international arm as Super Hi and added a Nasdaq line in 2024; it sits near one times sales. Three routes onto a US exchange, a spin-off, a primary IPO and a carve-out, and the same answer each time:

Read down the Asian names and the pattern is hard to miss: across these three precedents, the current valuations sit at roughly 0.7 to 1.3 times sales, while the American growth names command three to eight. Chagee is the sharpest test, and it cuts both ways. When it IPO’d on Nasdaq in April 2025 the market did hand it a substantial US-style listing premium, valuing it at roughly 2.4 times sales on an enterprise basis at its IPO price and nearer 3 times at the opening pop, depending on the treatment of its IPO cash; as its growth cooled, that premium drained away and it now trades near 0.7 times EV/sales, like the rest. So the honest lesson is not that a US listing can never confer a substantial listing premium, it plainly can at the moment of listing, but that the venue cannot sustain one the underlying economics do not support.

Each Asian name has its own story, Chagee’s cooling growth, Yum China’s China-market risk, Super Hi’s dual listing, and that is exactly why the pattern persuades: the explanations differ, but the durable multiple is missing in every case. We are not claiming the venue is worth nothing; a genuine US listing can add liquidity, disclosure and investor access, and the research on cross-listing premiums says those are worth something. We are claiming something narrower and sturdier: no plausible venue benefit durably turns a one-times-sales Asian platform into a five-times-sales American one. Absent materially better growth, margins and capital efficiency than it shows today, Jollibee’s coffee-led Asian arm belongs nearer one to two times sales than to the multiples of US growth chains. The re-rating the bull case needs is the part that does not last.

There is a real limitation to this comparison, and it is worth stating plainly. Each of the three closest US-listed precedents used here is Chinese or Chinese-origin: Yum China operates almost entirely in China, Chagee is a Shanghai-based chain, and Super Hi is the carved-out international arm of a Chinese hotpot operator. Part of their discount may therefore be China-specific, reflecting US-China delisting risk, governance perceptions around Chinese issuers, capital controls and single-market concentration, rather than a generic Asian penalty. Jollibee’s arm is Philippine-controlled and spread across Korea, Vietnam, China and North America, and could on that basis command a somewhat higher multiple than a pure-China name. So our claim is not that these precedents prove an immutable Asian ceiling. It is narrower and harder to dispute: they offer no support for assuming an automatic leap to US growth-chain valuations, and any durable premium Jollibee’s arm earns will have to come from its own growth, margins and capital efficiency, not from the ticker. On that score its own record, loss-making at the net line, minority-laden and built by acquisition, argues for caution rather than a premium.

So a US listing crystallises value without multiplying it. That leaves the two questions that decide whether the stock is actually cheap: what are Jollibee’s parts really worth, and how much of that ever reaches the person holding the shares in Manila?

Below, for paid subscribers: the sum-of-the-parts, and how far the per-share value drops once the arm carries its real share of JWPL's debt; the leaks between enterprise value and a Manila shareholder's pocket; the bull case at full strength; and the evidence that would prove us wrong.

Read more

The most expensive silicon in the world does not ship when it leaves the fab. It ships when someone proves it works.

For AI accelerators, that proof is getting harder, longer and more valuable [2]. A modern accelerator has to be probed, packaged, burned in, and increasingly run through a full system-level rehearsal before it goes anywhere near a data centre. The result is that test is moving from a back-end afterthought to a front-line bottleneck, and as customers diversify their back-end supply chains away from Greater China, more of that bottleneck is being relieved in Southeast Asia.

That sets up a simple investment question: who actually captures the AI-test dollar, the independent tester, the turnkey OSAT, the equipment supplier, or the customer that owns the tools? The answer is not “every OSAT.” Pure-play testers, integrated packaging houses and equipment suppliers sit in different layers of the stack, run on different qualification clocks, and trade at very different valuations. Some independent testers still trade like cyclical back-end shops; some AI-adjacent names already trade at equipment-like multiples.

This is not a screen of Southeast Asia-listed companies only. It is a map of who captures the test economics of Southeast Asian back-end migration: local listed names across independent test, OSAT and equipment (KESM, Inari, Unisem, MPI, AEM), foreign names building regional capacity (KYEC, ASE, Chipbond, Trio-Tech), and the equipment leaders and specialists whose tools set the margin pool (Advantest, Teradyne, Aehr). We map who does what, who catches the first wave, and, for paying subscribers, where the valuation gap looks most interesting.

What semiconductor test is, in plain English

Think of the back end as four gates. Probe the die while it is still on the wafer, package it, test the finished package, then stress it under real-world conditions. AI makes those gates more valuable because the parts passing through them are worth thousands of dollars each, and because a modern accelerator is not one chip but a stack of chiplets and high-bandwidth memory (HBM) bonded onto an interposer, the small slab that wires them together. Once those pieces are bonded, rework is essentially impossible, so every die has to be proven good first. Some industry estimates put test at roughly 5% to 10% of the cost of a leading-edge AI part, up from low-single digits for a conventional chip [6][7]. Test has moved from the end of the line toward the front of it.

Two distinctions run through the whole piece. First, whoever owns the tester matters: the core testers, the automated test equipment (ATE), are dominated by Japan's Advantest and America's Teradyne, on the order of 80% of the high-end tester market between them, though share estimates vary by how the market is defined [1][3], and a test house either owns its machines or runs them on consignment for a customer, which changes the margin. Second, an independent test house (also called a merchant tester) sells test as a service and is not owned by or affiliated with a chip customer, while an integrated OSAT folds it into packaging. Those two compete for the same AI work by different routes.

It helps to see the whole thing as a stack, because the Southeast Asian listed opportunity is not spread evenly across it. It is thin in the tester layer, which is a foreign duopoly, and thickest in the test-service layer and in the handler and system-level-test niche where Singapore's AEM sits.

One honest caveat frames everything. The most leading-edge packaging, the CoWoS-class interposers (TSMC’s advanced chip-on-wafer-on-substrate method) and the HBM stacking closest to the AI die, largely stays captive inside the foundries and IDMs (TSMC, Intel, Samsung, SK hynix), because it is too tightly coupled to the front end to hand off [11][35]. What actually outsources to independent houses in Southeast Asia is chiefly final test, burn-in and mid-tier packaging. Even at the leading edge, testing is the minority of the dollar: ASE puts its own advanced packaging-and-test revenue at roughly 75% packaging and 25% testing [24]. That is why test, not packaging, is the right lens here.

The money is following the difficulty. SEMI expects semiconductor test-equipment sales to rise about 48% to roughly US$11.2 billion in 2025 [8]; the broader outsourced assembly-and-test market is put near US$47 billion now, heading toward US$71 billion by 2030 [9]; and the slice that matters most, burn-in and system-level test for accelerators, is smaller but growing faster still [10]. That is the demand pull under everything that follows.

Subscribe now

Why Southeast Asia, why now

The pull is policy as much as economics. US export controls tightened through 2023 and 2024, and the volatility that followed through 2025 and 2026 kept pushing customers to qualify test sites outside China [14]. The leverage in that is arithmetic. Greater China ran about 75% of global OSAT in 2023, so the pool of back-end work that policy could dislodge is enormous, while Malaysia handles an estimated 13% of global chip assembly and test, the largest established cluster outside China and Taiwan [9]. When the big pool is what moves and the smaller base is where it lands, even a modest share shifting south is an outsized gain for Southeast Asia. That asymmetry, not the region's size today, is why the timing matters.

Why not just keep test next to the fab? Because it does not have to be there. A finished wafer is small and hugely valuable per gram, so shipping it to a cheaper site costs little, whereas test and burn-in are labour-, power- and capacity-hungry and lower-margin, work that gravitates away from high-cost, resource-constrained Taiwan. The packaging that must stay coupled to the fab does stay put, the CoWoS interposer and the HBM stacking remain captive at the foundries and memory makers. Korea’s memory giants make the point in concrete: rather than outsource, SK hynix and Samsung are pouring billions into captive HBM packaging-and-test at home, SK hynix’s roughly US$13 billion Cheongju plant and Samsung’s Cheonan and Onyang lines [35]. What travels is the separable test and mid-tier packaging, and it travels to wherever is cheapest and most neutral.

The migration is not abstract. KYEC, Taiwan’s largest independent tester, divested its entire China testing operation during 2025 even as it built a new plant in Singapore [12]. Test-equipment maker Teradyne pulled roughly US$1 billion of production out of Suzhou under the same pressure [13]. Trio-Tech shows the other side of the same move: its China revenue fell about 84% over the nine months to March 2026 while group revenue rose 85%, consistent with AI final-test work leaving China for its Singapore and Malaysia labs [39]. The rules themselves keep shifting, though. A January 2025 rule that would have swept Malaysia into a tiered AI-chip export regime was rescinded that May, and Washington has drafted and pulled back further AI-chip export measures since, most recently a broad rule withdrawn in March 2026 [14]. No single rule has stuck. The signal is the pattern, not the particulars: the regulatory line can be redrawn at short notice, and that uncertainty pushes customers to spread their back-end work across several countries rather than bet on one, which is exactly what favours the region.

Southeast Asia is where that capacity is landing. The table below is the map at a glance.

The countries are not competing on the same terms; each pulls a different policy lever at a different point on the chain. Malaysia leans on the deepest existing ecosystem and its National Semiconductor Strategy, which had drawn RM85 billion of approved investment by the end of 2025 against a 60,000-worker target, and is nudging local firms up-market through programmes like SemiconStart [36]. Singapore competes on value and neutrality rather than cost, winning the equipment and high-end test slice, AEM’s tooling and KYEC’s neutral Singapore plant [4][21]. Vietnam is the aggressive challenger, with a national target of ten advanced test-and-packaging plants by 2030 and incentives that have pulled in Samsung, Intel and Amkor [28][31]. Thailand’s Board of Investment has drafted a national roadmap targeting more than 2.5 trillion baht of investment and a “chip made in Thailand” by 2050, skewed toward power electronics and automotive [37]. The Philippines offers CREATE-era incentives over a large but mostly foreign-owned assembly-and-test base [31], and Indonesia is earliest-stage, a government test house and a joint-venture push from a low, import-dependent base [28][31]. For an equity investor the map compresses further: Malaysia is where the listed cluster actually sits (KESM, Inari, Unisem, MPI), Singapore adds AEM and KYEC’s site extension, and Vietnam, the Philippines and Indonesia matter strategically but offer little directly listed exposure because their new capacity is largely foreign or captive.

Penang is the anchor, and it straddles the island and the mainland. On the island, at Bayan Lepas, sit KESM’s independent burn-in lines, and Cohu, a US test-equipment and handler company adjacent to Singapore’s AEM, opened a test-design centre there in June 2024, deepening the local engineering base [16]. Across the water on the mainland, in Seberang Perai and specifically Batu Kawan, the heavy new capacity is going up: SPIL’s roughly RM6 billion (about US$1.27 billion) packaging-and-test plant at Bandar Cassia, the captive TF-AMD joint venture that runs AMD’s Penang assembly and test, Inari’s P34 line serving a new US memory customer, Micron’s assembly-and-test operations, and now Chipbond’s new plant, with Intel investing on the order of US$7 billion in captive advanced packaging in Penang alongside them [9][17][18][22]. Smaller but riding the same thesis, Trio-Tech runs a new leased final-test facility in Perai, where the single AI customer behind its recent revenue surge is served [39]. The split matters: the island holds the legacy base, while the mainland at Batu Kawan is where most of the new capacity is rising, a strait apart rather than one campus. Not all of it is AI, ASE's newer Bayan Lepas plant, P5, is wire-bond for automotive and edge, not accelerators [19], and the AI share is selective. But taken together, it is one of the densest back-end clusters outside Taiwan.

Two business models

The capacity race is really a contest between two models.

The turnkey OSAT channel bundles packaging and test on one floor and captures the test work once its own line is online. SPIL, an ASE subsidiary, is the local example: it broke ground at Batu Kawan in May 2024 on a plant meant to offer turnkey packaging-and-test under one roof [17].

The independent-test channel is the standalone tester extending qualified capacity into a new geography. KYEC is the textbook case: test is roughly 95% of its revenue, and it opened a S$100 million plant in Singapore in 2026 [12][21]. It is no longer alone; Chipbond, a Taiwanese driver-IC bumping-and-test specialist, opened a plant of close to US$200 million at Batu Kawan in early 2026 [22].

The two do not move at the same speed, and the reason is qualification. Putting a new test supplier into a customer’s flow is a months-long proof of yield and reliability, framed by KESM’s own management as a six-to-twenty-four-month exercise [23]. An independent tester opening a site for customers it already qualifies elsewhere runs a site extension, not a cold qualification, so it moves first. A turnkey OSAT only wins the test work once its own floor is built and proven. That head start is, in practice, the whole game.

The players, by role

One filter runs through every name below: how close is the AI link, really? It helps to keep three tiers apart. Direct AI test is burn-in, final test and system-level test for accelerators and HPC chips. AI-infrastructure adjacent is the optical transceivers, power, analog, sockets and inspection that surround those chips without testing them. General back-end is the automotive, RF, industrial, consumer and EMS work that dominates most of these companies’ revenue today. Very few of these names are in the first tier; the market too often prices them as if they were.

Independent testers (the purest bet on the theme). KESM Industries (Bursa: 9334) is the regional anchor, a listed independent burn-in and reliability-test house that describes itself as the world’s largest independent provider in that niche, defining independent as not related to any of its customers, with an automotive base, lines at Bayan Lepas on Penang island and a Malaysian footprint extending to Petaling Jaya, and for the first time it named “artificial intelligence related chips” as a demand driver in its 2026 filings while tripling capex [15]. KYEC (TWSE: 2449) is the Taiwanese pure-play now Singapore-relevant, serving 48% of the world’s fifty largest chipmakers with NVIDIA among named customers and building its own high-power burn-in ovens [12]. Trio-Tech International (NYSE American: TRT) is a small US-listed final-test and burn-in house with regional operations, and the clearest China-plus-one case in the group: its recent revenue surge is one customer's AI final-test work relocated out of China [39]. Chipbond (TWSE: 6147) is the newest entrant, the second Taiwanese tester to plant capacity in Penang [22].

Turnkey OSATs (packaging plus test). ASE Technology Holding (NYSE: ASX; TWSE: 3711), parent of SPIL, is the mega-cap shown for scale; its 2025 revenue of about NT$645 billion splits roughly 59% semiconductor packaging-and-test and 40% electronic manufacturing services, a reminder that even the group flagbearer is only part test [24]. Among listed Malaysian OSATs, Inari Amertron (Bursa: 0166) is the largest but is really an RF and optoelectronics specialist: radio-frequency work was about 61% of revenue in its most recent quarter, optoelectronics about a third. Inari does not disclose its largest customer’s share, but roughly 87% of FY2025 revenue was booked in Singapore, a widely used proxy for its heavy reliance on one principal customer, generally identified by analysts as Broadcom. Its AI angle is real but specific, 800-gigabit optical transceivers for data-centre interconnect rather than accelerator test [20]. Unisem (Bursa: 5005) is a broad assembly-and-test house leaning on a single large US analog customer that brokers identify as Monolithic Power Systems (its 2024 annual report discloses one customer above 10% of revenue), and it is raising up to RM742 million through a placement to expand [25][26]. Malaysian Pacific Industries (Bursa: 3867), through Carsem, is automotive-heavy and bought Infineon’s Bangkok/Nonthaburi back-end plant in 2026 with a long-term supply agreement attached, the second Infineon back-end site to pass to a Southeast Asian OSAT after ASE’s 2024 Cavite deal, which gives its Thai expansion built-in offtake [9][27][28].

Equipment and adjacent names. AEM Holdings (SGX: AWX) is the most direct equipment play, but it sits a layer below the testers: it builds the handlers, system-level-test cells and burn-in equipment that work with the tester. It has been Intel’s principal test-handling supplier for over a decade, with more than 35,000 system-level-test sites deployed, and its active thermal control, which keeps high-power AI die cool during test, sits directly in the accelerator’s path; a 2025 Intel Foundry partnership and a high-volume ramp for an AI/HPC customer lifted FY2025 revenue 5% to S$399 million, driven by its Test Cell Solutions segment. The flip side is concentration: one customer was about 38% of group revenue in 2025 [4]. ViTrox (Bursa: 0097) and Pentamaster (Bursa: 7160) are inspection and automated-test equipment makers; JF Technology (Bursa: 0146) makes the sockets and contactors [5]; Globetronics (Bursa: 7022) is a sensor-led OSAT now shrinking [29]. In Thailand, Hana Microelectronics (SET: HANA) is a hybrid EMS-and-OSAT: about 63% of 2025 sales was board-level PCBA (printed-circuit-board assembly) and 31% IC assembly-and-test, at an 8% gross margin. Tellingly, it cut capital spending sharply in 2025 as IC demand softened, a useful reminder that not every regional back-end name is riding the AI wave [30]. None of these is an independent test house, and treating them as one is the easiest mistake in this sector.

Put the roster against the numbers and the theme separates cleanly: the AI-exposed testers are growing, and the consumer- and RF-cyclical names are not.

So where does that leave the roster? Before valuation enters the picture, the names sort into three buckets by exposure:

The theme, in other words, is not “buy Southeast Asian back-end.” It is to find where the pricing and the durability disagree. That is what the rest of this piece is for.

The free map tells you who is exposed. The paid question is what the market is already paying for, where that looks wrong, and which exposures are durable enough to deserve the multiple. Below, for paying subscribers, we compare the names on valuation and EBITDA margin, weigh customer concentration and the hidden margin question of who owns the tools, and set out what we are watching into the 2027 capacity wall.

The moat, the clock and the 2027 risk

Read more

That is the demand backdrop for Singapore’s largest home-grown recruiter, and it shows up in the filings with some precision. HRnetGroup’s gross profit from its Singapore operations has now fallen for four consecutive years. In FY2025 it dropped another S$4.1 million. The company still reported its highest net profit since FY2023, S$51.2 million, up 15% year on year. Both of those statements are true at the same time, and reconciling them is the entire exercise.

The headline most readers will have seen is the one about the cash. Management describes a “cash moat” of about S$336 million, which against a market value of roughly S$737 million is a striking figure: close to half the company’s market capitalisation sits in cash and near-cash. The number is real. What is less examined is how much of it a minority shareholder can actually reach, what the operating business looks like once you strip the income that cash throws off, and whether the dividend that pays you to wait is as secure as the balance sheet makes it look.

Those questions live in the segments, not the headline profit. We start there.

How the Company Was Built

HRnetGroup was founded in Singapore in 1992 by Peter Sim, who remains executive chairman at roughly 73 years of age and who, his daughter notes, “has always said he wants to work until he’s 100.” [1] The business began as a single recruitment firm and grew into what the company describes as the largest Asia-based recruitment agency in the Asia-Pacific outside Japan, operating today across 18 Asian cities.

The structural decision that defines the company came early: the co-ownership model. Rather than running branches staffed by salaried managers, HRnetGroup makes its senior people part-owners of the specific city-business they run. These “Business Leaders” hold equity in their own units; their appointments are disclosed individually through SGX filings, and by April 2026 the count had reached 47, up from 22 at the 2017 IPO. Management attributes the company’s consistency, having stayed profitable through every major crisis in its 33-year history, to this structure, and the mechanism is plausible: the people generating the gross profit have a direct claim on it and a strong reason not to leave. We cannot prove the model caused the profitability rather than accompanying it, but it is the most credible explanation on offer, and it is the organising principle of the whole company.

HRnetGroup listed on the SGX mainboard on 16 June 2017 at an offer price of S$0.90, opening at S$0.95. It was nearly a Hong Kong listing instead. By Adeline Sim’s account, cornerstone investors offered the same valuation in either venue and the family chose Singapore because it is headquartered there: “why not be where we are wanted.” [1] The stock has spent most of its listed life below its offer price, touching an all-time low of S$0.41 in March 2020 during the COVID crash and, on management’s own description, hovering between 75 and 80 cents since mid-2021. [1]

Gross profit plateaued at its peak across FY2021 and FY2022, S$174.9 million and S$174.2 million respectively, with attributable profit around S$67.5 million in FY2022, a figure Adeline Sim confirmed directly in a July 2024 interview. [2] What followed was a sustained decline in the core business that the headline profit number has since partly masked. Gross profit fell to S$139.0 million in FY2023, then S$122.2 million in FY2024, and was essentially flat at S$122.9 million in FY2025. That is a 29% fall in gross profit from the peak. Net profit fell less dramatically, from S$67.5 million to a low of S$44.5 million in FY2024, before recovering to S$51.2 million in FY2025, and the reason it recovered is the heart of this article.

The most recent piece of corporate history is the September 2025 incorporation of AllwaysFirst in Ho Chi Minh City, the group's 18th city and its entry into Vietnam, a wholly owned subsidiary focused on professional recruitment in technology. [4] Management has said directly that "any immediate contribution from the new subsidiary may not be material." [4] We treat it accordingly.

What the Company Actually Does

HRnetGroup sells two things, and they look almost nothing alike in the accounts.

The first is Professional Recruitment, the placement of permanent staff, typically mid-to-senior white-collar roles. The company is paid by the employer, not the candidate, and the standard form is a one-time placement fee set as a percentage of the successful hire’s first-year remuneration. Most of that work is contingency-based, meaning the fee is earned only if the client actually hires the candidate, with senior executive search more often run on staged retainers. In FY2025 this segment produced revenue of S$55.8 million and gross profit of S$55.6 million. The reported gross margin of about 99.6% is an accounting artefact, not an economic one: in permanent placement there is no separately allocated cost of sales, so the fee is essentially all “gross profit,” and the cost of the consultants who earn it sits below the gross-profit line as employee expense. The consultant who makes the placement is paid a base salary plus commission on the fees they bring in, and under the co-ownership model the Business Leader running that desk owns a share of the unit’s profit, which is the alignment mechanism described earlier. So the right way to judge this segment is not its headline margin but its gross profit per consultant and its placement volume. On that basis FY2025 was flat: PR gross profit grew S$0.7 million, or 1.3%, and placement volumes were modest. This is the high-margin, cyclical engine, and right now it is idling.

The second is Flexible Staffing, the supply of contract and temporary workers, where HRnetGroup employs the worker itself and bills the client. The economics are a spread: HRnetGroup pays the contractor a wage and bills the client a charge rate set above it, keeping the difference. The contractor wage is the cost of sales here, which is why the FY2025 gross margin was only 12.2%, down from 12.6%, against the near-100% optical margin of permanent placement. Because HRnetGroup pays the worker before the client pays HRnetGroup, it also funds the payroll float across a one-week-to-two-month billing cycle, so this engine ties up working capital as well as earning a thinner margin. In FY2025 it produced revenue of S$524.1 million, up 3.2%, and gross profit of S$63.8 million, down marginally. This is the lower-margin, higher-volume, more defensive engine. It is also where Singapore's weakness is most visible, because Singapore is where most of the flexible-staffing book sits.

A third line, reported as "Others," houses Octomate and assorted payroll and employer-of-record services. It produced revenue of S$4.1 million, broadly flat, and gross profit of S$3.5 million, up about 7%, in FY2025. Octomate is a cloud workforce-management and instant-payment platform that HRnetGroup took a 51% stake in during October 2022; its payment engine integrates with HRnetGroup's own Ease Works app to give contractors earned-wage access the moment a timesheet is approved. [3] Daily active users have grown from about 3,000 at acquisition to, on the company's own reporting, roughly 15,000 by January 2026 [14], with Amazon, H&M and Hyundai among named users. [3] We read Octomate less as a standalone software business than as an internal tool that lowers friction and supports retention in flexible staffing, which is why the flat "Others" revenue (a line that also bundles payroll outsourcing and employer-of-record services) is probably the wrong test of its value. Either way we attach no number to it, and the investment case does not need it.

A client has alternatives, and they differ by segment. For permanent recruitment it can run the search in-house, use a rival agency, or lean on AI sourcing tools. For flexible staffing, which is closer to a commodity, large clients run vendor-management systems that pit suppliers against each other on price, or bring payroll in-house. That commodity dynamic is what the 12.2% flexible-staffing margin, and its slippage, looks like in the accounts. What actually defends the business against these alternatives, and where AI helps rather than hurts, is the subject of the moat section.

Geographically, FY2025 is where the real story sits.

Read across the bottom row first. Group gross profit grew S$0.7 million, six-tenths of one percent. Now read the column above it. Singapore gross profit fell S$4.1 million. Everything outside Singapore grew S$4.8 million, almost exactly offsetting the decline. That near-perfect cancellation is the company in FY2025: a shrinking home market held level by a growing regional one. The blended gross margin outside Singapore, about 27.3%, is materially higher than Singapore’s 17.3%, so as the mix shifts away from Singapore the group’s average margin quality improves even when total volume does not. That improvement is not purely geographic, though. North Asia’s higher margin reflects a heavier weighting to permanent recruitment, which carries a near-100% accounting margin, while Singapore’s lower margin reflects its heavier flexible-staffing mix at about 12%. So the shift out of Singapore is also a shift from lower-margin, defensive flexible staffing toward higher-margin but more cyclical permanent recruitment. That lifts margin quality and, at the same time, makes the earnings mix less defensive than the income framing implies. It is also the only thing standing between the group and an outright decline in gross profit.

The last structural fact a reader needs concerns the treasury, because it dominates the valuation. We deal with the precise composition in the investment case. Here we state only what it is: as at end-FY2025 the group held S$262.9 million of cash and equivalents, plus credit-linked notes and government securities of S$62.7 million and S$10.7 million of gold and commodity-linked assets, which management aggregates to a “cash moat” of about S$336 million. [1] Strategically held quoted equities are excluded from that figure. There is no bank debt. The only borrowings are S$14.7 million of lease liabilities under accounting rules for office space.

The Industry: A Cycle Down and a Structural Question

Two forces act on this business, and they should not be confused. One is cyclical and global. The other is structural and local.

The cyclical force is the worldwide downturn in professional recruitment that began after the 2021 to 2022 hiring boom. It is not specific to HRnetGroup, and the peer numbers make that clear. Hays, the UK-listed global recruiter, reported net fees (its term for gross profit) of £972.4 million for the year to June 2025, down 13% year on year, and cut its core dividend by 59%. [7] PageGroup reported gross profit of £769.5 million for 2025, down 7.6%, with operating profit down 59%. [8] Robert Half’s revenue fell 7.2% to US$5.38 billion, with operating income down roughly two-thirds. [9] Against that field, HRnetGroup’s flat gross profit is, relatively, a good outcome: it held up better than the three large global recruiters, though not better than Staffline, which grew gross profit 10.6% after restructuring out of a loss-making division. [10]

The structural force is the one that should hold an investor's attention, because it is specific to where HRnetGroup makes most of its money. Singapore gross profit has fallen for four straight years. The proximate cause in FY2025 was a soft labour market: by the first quarter of 2026, Singapore job vacancies had eased to 73,300 from 77,700 three months earlier, the ratio of vacancies to unemployed persons had slipped to 1.46 from 1.58, and the share of firms expecting to hire in the next three months had dropped sharply, from 54.6% in February to 44.6% in March. [12] A forward-looking read points the same way: employers' net hiring outlook for Singapore in the third quarter of 2026 fell to 13%, down 11 points both on the quarter and on the year, with the decline led by large organisations, whose outlook was a net negative 26% on what the survey calls optimization-led consolidation. [22]

That is cyclical softness. But layered underneath it is something management describes as a change in kind, not degree: AI is making clients more selective about whether a role exists at all, undercutting even the old labour-arbitrage logic of sending a Singapore role to a cheaper market. [1] AI cuts both ways for a recruiter, though, and we should be even-handed about it. It automates the junior, high-volume, searchable end of hiring and lets large clients source directly, which is a real threat; but it raises the value of agencies at the other end, in senior and specialist search where relationships matter, and in candidate verification, as AI-generated CVs, forged credentials and deepfake interviews make trust scarcer. [17] Which side HRnetGroup lands on depends on whether it keeps migrating its gross profit toward the specialist end, which is the stated aim of its senior-executive pivot.

One caution on the labour read: the easing in Singapore vacancies through early 2026 was concentrated in non-PMET roles, while professional and technical roles actually became harder to fill, so aggregate labour softness does not by itself prove that professional-recruitment demand is structurally weakening. [18] We cannot prove from filings how much of Singapore's decline is cyclical and how much is permanent, and we treat it as structural in the base case until the company shows stabilisation.

The offset to Singapore is geographic, and it is shifting the group's centre of gravity: North Asia's share of gross profit is rising as Singapore's falls, and it earns far more per dollar of revenue than the home market. North Asia spans seven mainland Chinese cities, the three Taiwan cities, Hong Kong, Tokyo and Seoul. The overseas shift is contractor-led: average monthly contractors rose 5.6% to 16,421, the increase coming from Taiwan, Indonesia and Mainland China (Indonesia sits in Rest of Asia) while Singapore's headcount fell. North Asia specifically drew stronger professional-recruitment placement activity in Taiwan, Mainland China and South Korea, with Thailand and Malaysia adding to the wider offset against a softer Singapore. Group-wide, demand is spread across industries rather than concentrated in any one: IT and technology is 24% of the business, of which 12% is AI-related roles, financial and insurance about 21%, and healthcare and life sciences and retail and consumer roughly 14% each. On the group's own brand job boards the overseas book runs the full range, from operational and retail staffing to executive search. [13] Rest of Asia contributed too, off a small base, with Vietnam a new market.

One scheme-level detail matters and is easy to get wrong. Singapore's Progressive Wage Credit Scheme, under which the government co-funds wage increases for lower-paid local workers, pays HRnetGroup meaningful grant income, and it runs through 2028: Budget 2026 set the co-funding rate at 30% for 2026 and 2027 wage increases, and 20% in the final year, 2028. [11] So the scheme is supported, not tapering, over the next two years. Why the S$9.2 million FY2025 grant figure still overstates the recurring level, and how that feeds the valuation, is in the normalised-earnings section.

The Moat: What Is Real and What the Numbers Will Not Support

A company with this balance sheet and this dividend invites the assumption that it must have a strong competitive position. Some of that assumption is warranted. Some of it is contradicted by the company’s own gross-margin history.

What is defensible is the co-ownership model. Making Business Leaders part-owners of their city-units creates retention a branch-and-salary rival cannot easily copy, because what holds a team in place is equity in the unit, not a salary another firm can beat. The observation the bullish reading skips is that the model has a recurring cash cost: recycling ownership interests as Business Leaders join, leave or change stakes consumed S$3.3 million in FY2025. The alignment is genuine; it is not free.

Also defensible, though not measurable from filings, is network depth in specific niches, executive and professional search in Hong Kong and mainland China, the breadth of an integrated group of around twenty brands spanning executive search, flexible staffing, employer-of-record and payroll across 18 Asian cities, and reach into the people who are not actively looking. Management's claim, which we cannot verify from the filings, is that roughly 90% of strong performers are not job-hunting, so the value is in knowing and attracting them. [1] This is also where AI sorts the business rather than simply threatening it: it commoditises the junior, high-volume, easily-sourced end, where clients can self-serve, and spares senior and specialist search, where the relationship still carries weight, which is the stated reason management is moving up-market toward C-suite roles. External evidence points the same way: in the same employer survey, having a person review resumes ranked as the most valued hiring resource, above AI screening and sourcing tools, consistent with the relationship end of recruitment holding its value even as the high-volume end is automated. [22]

The third advantage is the balance sheet, and it is the most concrete. The cash position lets HRnetGroup fund the contractor float described earlier, win large contracts capital-light competitors cannot, and acquire without raising money. Trade receivables of S$93.9 million carry a loss allowance of only S$104,000, consistent with strong collection history and a generally creditworthy client base. Part of that quality is structural: public-sector clients, which carry no credit risk, are 16% of revenue and rising, no single customer is a tenth of revenue, and the top five clients, at 17.2% of revenue between them, have been with the group an average of eighteen years. Ample working capital plus exceptional credit quality is a competitive advantage, not just a defensive buffer. In flexible staffing, which has the thinnest moat because the service is close to a commodity, these are the real defences, scale, the compliance and payroll machinery, and the capacity to fund contracts a thin rival cannot; and the cross-cutting AI disruption is met on the technology side through Octomate, the internal tool described earlier, rather than only absorbed.

What the record will not support is the claim that brand or scale protects pricing. Group gross margin has fallen from 29.6% in FY2021 to 21.0% in FY2025. That is not the margin path of a business with pricing power. Some of the fall is mix, as lower-margin flexible staffing grows relative to high-margin permanent placement, and some is genuine competitive and AI-driven pressure on the Singapore core. Either way, an 8.6 percentage-point gross-margin decline over four years is the single fact that disciplines any moat argument here. The advantages above are real. They have not prevented margin compression, and an honest moat assessment has to hold both ideas at once.

The Financial Scoreboard

Every figure below is from the company's filings, including the audited FY2021 results; FY2022's S$67.5 million attributable profit was confirmed by management directly. [2]

The shape is clear without commentary. Revenue has been range-bound around S$580 to S$610 million for five years. Gross profit and gross margin have fallen steadily. Net profit fell to FY2024 and then recovered in FY2025. The dividend has been held at 4.0 cents for four years and was raised to 4.2 cents for FY2025. A company that grows revenue slightly, earns less gross profit each year, and still raises the dividend is telling you where its priorities sit, and where the risk sits too.

Returns on Capital, Read Two Ways

On a reported basis, FY2025 return on equity was S$51.2 million of PATMI on S$402.1 million of equity attributable to owners, about 12.7% on year-end equity (13.1% on average); total equity including S$12.0 million of non-controlling interests was S$414.1 million, and we use the attributable figure throughout. That 12.7% misleads in two directions. The equity base is inflated by the treasury: roughly S$270 million earns a low yield and does almost nothing for operating returns, so the underlying operating business, which is capital-light, earns far more than 12.7% on the little capital it actually uses. Pulling the other way, the S$51.2 million is flattered by non-operating income; on normalised attributable profit of about S$38.3 million (the bridge is built in the investment case below), return on attributable equity is about 9.5% year-end, or 9.8% on average, and it is earned by a business whose gross profit has not grown in two years.

So the capital story is two-sided: a high-return operating business sitting inside a company whose blended return is mediocre because most of its capital is idle cash. Which fact matters depends on whether that idle cash ever returns to shareholders, the governance question we take up below and do not resolve in the company’s favour.

What Management Does With the Cash

For a company defined by its balance sheet, the record of what it actually does with capital is more revealing than any statement of policy, so we pulled it from the share-capital note and the statement of changes in equity rather than the headline tables.

The dividend is the primary channel and it is consistent: 4.0 cents held through FY2022 to FY2024, raised to 4.2 cents for FY2025, with a one-cent special paid in FY2021 on top of the ordinary 4.0. Cash dividends paid have run between roughly S$39 million and S$40 million in the last two years, with a higher figure of about S$52 million passing through FY2023 on dividend timing. The payout has absorbed roughly 80% of reported earnings each year.

The buyback channel tells a more pointed story. The S$30 million programme launched in June 2022, near the price the stock still trades around, and the spend has fallen every year since, to just S$0.9 million in FY2025; cumulatively S$19.7 million of the S$30 million programme is used, S$10.3 million unspent. More striking, FY2025 was a net-seller year: against S$0.9 million repurchased, the company sold S$7.2 million of treasury shares, principally the October 2025 placement of 9,780,800 shares at S$0.714 to enhance liquidity and free float following a reverse inquiry. [15] The liquidity rationale is real, and a discounted placement does not by itself mean management judged S$0.714 to be fair value. But it sits awkwardly beside the rhetoric: a company that calls its shares undervalued, holding cash worth close to half its market value, was adding to supply at a discount while its buyback programme sat idle.

Keep the facts, the explanation, and the inference apart. The observed facts: the company distributed about 80% of earnings as dividends, reduced its buyback spend every year to near zero, was a net seller of its own stock in FY2025, and retained S$336 million on the balance sheet, deploying capital into growth only at the small scale of the September 2025 Vietnam start-up. Management's stated explanation is that the treasury is strategic optionality it intends to keep rather than distribute. Our inference, labelled as such, is that the declining buyback and the discounted placement are hard to reconcile with a strong conviction that the shares are cheap, and that the treasury looks retained for the long term rather than positioned for near-term return to minorities. On the facts as they stand, a minority's return comes from the dividend and operating progress, not from the treasury being put to work on their behalf, and nothing in the record points to that changing without a decision only the family can make.

The Investment Case

The central tension: reported profit versus the operating reality

In FY2025, PATMI, the profit attributable to owners of the company, rose 15.0%, from S$44.5 million to S$51.2 million. Gross profit rose 0.6%. A business whose gross profit is flat does not generate a 15% rise in attributable profit from operations. The increase came almost entirely from below the gross-profit line,

Read more

If you have seen a specialist at Mount Elizabeth Novena, Gleneagles, Farrer Park or Mount Alvernia in the past two years, there is a fair chance that doctor now works, indirectly, for a company Temasek helped seed in 2022. In under four years Foundation Healthcare Holdings has bought control of established specialist practices across Singapore, and it is now asking the market to value the result at S$1.01 billion to S$1.20 billion: a price range of S$0.76 to S$0.92 a share, raising around S$242 million, with SGX Mainboard trading expected from 8 July 2026 [3].

The headline numbers are genuinely impressive. Revenue grew from S$112.4 million in FY2023 to S$231.2 million in FY2025. Group profit rose from S$7.3 million to S$41.2 million over the same two years. Among the key private specialist groups in Frost & Sullivan’s comparison, it is the largest by number of doctors and clinics, and the fastest growing by revenue from FY2024 to FY2025 [2]. Ten cornerstone investors, including the International Finance Corporation, Manulife, RBC, UBS and Lion Global, have committed S$118.2 million between them.

The number that matters most, though, is none of those. Of the S$41.2 million the group earned in FY2025, only S$14.0 million was attributable to shareholders of the parent company. The other S$27.2 million, two thirds of the total, was attributable to non-controlling shareholders, principally the minority owners of its part-owned specialist practices. How the company closes that gap, and what closing it costs, is the question the rest of this piece is about.

From a Temasek bet to Singapore’s largest specialist platform

Foundation Healthcare was incorporated in August 2022, but its founders had worked together far longer. CEO Liaw Yit Ming was a vice president at Khazanah Nasional, then ran strategy and M&A at IHH Healthcare, owner of the Parkway and Gleneagles hospitals. COO Dr Lee Hong Huei spent almost two decades in senior roles at Parkway Pantai. CCO Choy Shook Yee came through IHH and AIA. Liaw had co-founded Smarter Health, an insurtech in which Lee and Choy were also shareholders and which is now a wholly owned subsidiary. They know the Singapore private-hospital world from the inside.

The capital came from SeaTown Private Capital Master Fund, part of Seviora Holdings and ultimately Temasek-owned, which committed S$150 million of preference funding in 2022, completed in 2023. With that and a S$192.5 million debt facility from March 2023, the company moved fast: in FY2023 alone it bought effective 60% stakes in 23 specialist practices plus a medical centre for S$337.2 million cash, adding the Care IVF fertility clinic and the Orchard day-surgery centre. By 31 March 2026 it ran 108 specialists across 16 specialties, 74 clinics and four medical centres, including a new Novena day-surgery centre that management, citing Frost & Sullivan, calls the largest standalone facility of its kind in Singapore [2].

The structure across almost every acquisition was the same: buy 60%, leave 40% with the selling doctor. That single design choice is the key to reading the financials.

What the offer actually contains

The offer mixes new shares from the company with vendor shares sold by SeaTown and the founders, plus an over-allotment option (UBS is stabilising manager). The company’s net proceeds are earmarked, in order, for more clinic and medical-centre acquisitions in Singapore, for expansion into Malaysia and Hong Kong (the IFC’s cornerstone money is tagged to Malaysia), and for working capital. None goes to repaying debt.

The cornerstone tranche is worth pausing on. S$118.2 million across ten credible institutions is genuine institutional validation of the offer. One structural detail the marketing will not emphasise, though, is that the cornerstones carry no lock-up: the six-month lock-up binds the company, and longer moratoria bind SeaTown and the two founder-directors, but the institutions that anchored the book are free to sell from day one. That is not a prediction about the aftermarket, only a reminder that a cornerstone book signals confidence at the offer price, not a floor under it once trading begins.

The S$27 million that did not reach shareholders

Notice what is missing from the group’s reported profit. In FY2025, Foundation earned S$41.2 million after tax, but S$27.2 million of that, fully 66%, was attributable to non-controlling interests, principally the minority owners of the group’s part-owned operating companies, above all the 60%-owned specialist practices. Only S$14.0 million flowed to equity holders of the parent. Basic earnings were 2.13 cents per share. This is the honest starting point, and it is far less flattering than the group revenue line.

The prospectus addresses this with a step taken just before listing, the Share Swap: the company issues 477,101,524 new shares to 82 Swap Shareholders and 10 Employee Specialists to acquire the remaining interests in 35 specialist-practice companies and the Orchard medical-centre company, lifting its effective ownership to 100%. The stake bought in is generally 40%, except for the Orchard centre at 39.5%. After that, all of each practice's profit belongs to the listed group rather than leaking to non-controlling interests, and on a pro forma basis attributable profit jumps to S$48.8 million, or 4.08 cents per share. Pro forma simply means "as if": it restates the year as though the swap and all the year's acquisitions had been in place on 1 January 2025, rather than counting each clinic only from the date its deal closed. Think of totting up a full year's pay on a salary you only started in September. The prospectus calls this information illustrative and not necessarily indicative of future results, which is the right way to read it. Adjusted profit after tax, the company's preferred measure, which strips out acquisition and capital-raising costs, the FY2023 warrant charge, derivative fair-value movements, impairments and other company-defined one-offs, is S$51.4 million pro forma.

Both numbers are real. The swap genuinely completes before the shares trade. But the swap is not free, and the price is not paid in cash. It is paid in alignment, and in dilution.

The dilution is worth seeing as a bridge, because for this IPO the share count is almost as important as the income statement.

The arithmetic is striking. The swap shares alone, about 477 million, are roughly 37% of the post-listing company, issued to the selling Swap Shareholders and Employee Specialists. Assuming the Founder Warrant Shares are issued under the reported offer terms, SeaTown, on 88.6% before the offer, is diluted below half even before selling a single vendor share. The swap reduces the pre-swap shareholders' collective ownership to a little over half, before the primary IPO issuance dilutes it further. For new investors, that dilution is the price of turning the leaky 60/40 structure into one where every dollar of profit counts: the same trade-off as before, seen from the share count rather than the income statement. The exact primary, vendor and over-allotment splits, and SeaTown's final stake, stay blank until the final prospectus sets the price; the bridge also leaves out small pre-IPO award-share tranches [1].

There is a flip side to that dilution, and it cuts against the idea that the doctors are getting a rich deal. Those 477 million shares are worth S$363 million to S$439 million across the offer range, struck against the S$27.2 million the bought-in 40% earned in FY2025: an acquisition multiple of roughly 13 to 16 times. That is well below the 21 to 25 times the IPO asks new investors to pay for the company as a whole, so the swap is accretive. Absorbing the 40% lifts earnings per share from about 2.1 cents to about 3.6 cents before any new money is raised. The doctors are, in effect, bought in below the listing multiple, trading a higher private valuation for liquidity, a listed currency and continued pay, with the lock-ups and clawbacks attached. A like-for-like read has limits, since an acquired, locked-up minority would normally fetch less than a freely traded share, but the direction is clear: on these terms the swap favours the incoming shareholder more than the selling doctor.

The trade-off is also about incentives, though it is less binary than it first looks. Under the 60/40 model a surgeon retained a 40% equity interest in the clinic they ran. After the swap they hold shares in a roughly 1.3 billion-share group, with most of the Swap Shares (472 of the 477 million; the Orchard-centre shares are excluded) under moratoria and performance-linked release of varying lengths, backed by a clawback through the escrow agent (UOB Kay Hian) if targets are missed. Crucially, the doctors also keep being paid: the prospectus says specialists receive a base salary and/or a variable component tied to the financial performance of the specialist clinic group in which they practise, with the restricted shares layered on top. So the real question is narrower than "ownership versus shares": does base-plus-clinic-performance pay, together with locked equity in the wider group, preserve the same owner-operator intensity as a direct 40% stake in one's own practice? It is the valuation case, not the pro forma accounting, that assumes it does, through the lock-up years.

The financial scoreboard

Set the ownership question aside for a moment, because the underlying business is clearly growing and clearly profitable at the operating level.

Revenue compounded at roughly 43% a year over two years, mostly from acquisitions rather than organic growth, and the pace is slowing (up 77.0% in FY2024, 16.2% in FY2025). Adjusted EBITDA margins held in a tight 37% to 40% band, high for healthcare services and a function of a surgical, procedure-heavy mix. Company-defined adjusted return on equity (Adjusted PAT over total equity) was 18.9%, or 22.0% pro forma, and free cash flow conversion ran at 76.5% of adjusted EBITDA. The business throws off cash.

The caution sits one layer down. For the three months to 31 March 2026 the company said preliminary trends pointed to higher revenue and slightly higher Adjusted EBITDA, but lower profit and Adjusted PAT than a year earlier. The disclosed drivers: a third of its 108 specialists (34) are now “Emerging Specialists” still building their books; headquarters headcount rose from 43 to 71 for listed life; the new Novena centre is ramping; and Orchard closed in March for refurbishment. Management attributes much of the pressure to investment and ramp-up costs, though the preliminary data is not enough to rule out other operating effects. The ramp does have a rough timeline. The prospectus classifies a doctor as “Established” only after five years in private practice, and a defined cohort of Emerging Specialists employed at least twelve months generated about S$1.3 million each, against the S$2.7 million a comparable Established Specialist averaged. That points to a multi-year development period, though it does not prove revenue rises evenly or takes the full five years; either way the recovery runs over years, not a couple of quarters, which is why a doctor-heavy year depresses margins before lifting them. It also means the pro forma S$51.4 million is an everything-acquired, full-year snapshot, not a run rate proven quarter after quarter.

The cash flow and the debt

This is where the model asks for vigilance. The growth was bought, and it was bought substantially with borrowed money. At the end of FY2025, borrowings excluding lease liabilities were S$302.0 million, against S$85.3 million of cash and equivalents plus S$11.1 million of restricted cash. On the pro forma balance sheet, total borrowings including leases were S$348.0 million and cash and bank balances were S$71.6 million, implying simple net debt of about S$276.4 million, or 2.8 times pro forma Adjusted EBITDA (S$99.1 million); this is our own calculation, not the banking covenant measure. Finance expense alone was S$17.8 million in FY2025, a meaningful claim on operating cash flow. The senior facility carries interest at SORA (Singapore’s benchmark interest rate) plus a margin of 2.25% to 3.00%, with covenants that include a maximum total leverage ratio of 4.0 times and an interest-cover floor of 1.75 to 2.0 times.

Two features deserve attention. First, the facility blocks the subsidiaries from paying dividends up to the parent if that would breach the covenants, which is why the prospectus warns the company “may be constrained from paying dividends”: the cash is earned in the subsidiaries, but the listed shell sits above the covenant gate. Second, the interest-rate swaps hedging S$247 million at about 5.5% are not designated as hedges, so their mark-to-market swings run through the income statement as the “fair value loss on derivatives”, the source of those line items, not any option owed to the doctors.

The balance sheet is also unusually intangible. Goodwill represented 70.6% of total assets at the end of FY2025. That is the natural arithmetic of a roll-up that pays for established practices, and it leaves tangible asset backing thin. The pre-offering pro forma net asset value (the accounting book value per share, before the primary cash from the offer comes in) was just S$0.18; the post-offering figure will be disclosed in the final prospectus once pricing and the number of new shares are fixed. Either way, the value here is the earnings stream and the network, not the assets on the page.

The controller, the board, and negative tangible net worth

Governance is better than the typical new Singapore listing in some respects, and worth watching in others. The board is genuinely independent in form: an independent non-executive chairman (Stephen Lim), four of six directors independent, and an Audit and Risk Committee chaired by Max Loh, a former Ernst & Young Singapore managing partner. Despite owning 88.6% before the offer, SeaTown places no nominee director on the board, and Temasek’s stated policy is not to direct its portfolio companies’ operations. Executive cash pay is modest (the chief executive in the S$500,000 to S$750,000 band), and the disclosed related-party dealings are small and on ordinary commercial terms (Singtel telecoms, a SeaTown-linked medical-supplies distributor, each under S$200,000 a year). No clinics are leased from insiders.

Two things deserve a second look. The first is that the technology effort behind the platform story was bought in from related parties. Smarter Health, the insurtech Liaw co-founded, was acquired into the group in exchange for shares; the prospectus lists 27 sellers, among them Liaw, Lee and entities associated with them. It says the deal was struck on the same terms as with an unrelated party, but the founders and their associates sat on both sides of it.

The second is the balance sheet, and it is worth slowing down for. Most of what Foundation “owns” is goodwill: the premium it paid to buy profitable clinics over and above the value of their physical assets like equipment and cash. Strip that goodwill out and the company’s tangible net worth is negative, roughly S$206 million in the red at the end of FY2025. That has an unusual side-effect for small shareholders. Normally, when a listed company wants to do a sizeable deal with one of its own insiders (its controlling owner, a director, or a related party), that deal must be put to a vote of the other shareholders once it crosses 5% of the company’s tangible net worth, a built-in check against insiders extracting value. With that net worth below zero, the percentage cannot be calculated, so the SGX has let Foundation measure the limit against its market value (around S$1.1 billion) instead, until it reports its FY2026 results. That keeps the rule working, but it raises the dollar value of the 5% shareholder-approval threshold, so larger insider deals can clear on audit-committee review alone; transactions at or above that threshold still go to a shareholder vote [1].

A moat that depends on the people it just bought out

Foundation’s competitive case is real. Scale gives it buying power on drugs, supplies and payment processing, and a centralised patient funnel through its Health Connective Programme and the AVA technology platform that smaller visiting-specialist groups cannot match. Employing its doctors full-time, rather than the visiting or sessional model used by certain peer platforms, allows tighter coordination and lets it capture facility and diagnostic fees at its own medical centres. Its pro forma 18.2% net margin comfortably beats Frost & Sullivan’s anonymised peers, whose margins ran from 9.3% down to 5.2% [2].

The payor relationships are the most defensible layer. The April 2025 Great Eastern partnership and the empanelment of more than 97% of its specialists (excluding anaesthesiologists and radiologists) with two or more insurers and third-party administrators make Foundation a preferred network just as medical costs climb. The widely cited 16.9% inflation figure for 2026 (15.5% for 2025) [2][4] needs care: it traces to WTW’s Global Medical Trends survey, the most aggressive of the consultancy forecasts (Aon put 2026 at 13%, Mercer Marsh at 14%), and measures an insurer “medical trend” of utilisation and case-mix shifts, not pure prices; the Ministry of Health puts the actual Healthcare Consumer Price Index nearer 3% in 2025 [5]. Either way, insurers are squeezed and pushing toward cost containment and day-surgery settings, so a platform offering predictable pricing and cheaper outpatient procedures has a structural reason to exist.

That same pressure cuts the other way, though, and this is where the payor layer is less of a moat than it looks. To contain costs, insurers are narrowing their networks: Prudential and Great Eastern now name partner-hospital panels, and in 2025 Great Eastern briefly suspended pre-authorisation at the two Mount Elizabeth hospitals after finding bills there ran 20% to 30% above comparable facilities [5]. Foundation’s clinic footprint is heavily concentrated in exactly those higher-cost hospitals: 22 clinics at Mount Elizabeth Novena and 16 at Mount Elizabeth Orchard. The relationship that the prospectus frames as a moat is the same lever insurers are using to steer patients toward cheaper venues. It can be an advantage and an exposure at once.

One feature of the revenue base is worth being careful about. The prospectus emphasises Singapore-based channels, a funnel of local residents, insurer and third-party-administrator empanelment and GP referrals, and it contemplates patients paying providers directly and then seeking reimbursement [1]. What it does not disclose is the split of revenue by patient nationality, by insurer versus self-pay, or any foreign-patient share. So the business is clearly Singapore-centric, but the absence of any medical-tourism discussion is not evidence that there are no foreign or cash-paying patients. Unlike the hospital majors, Foundation does not market itself on foreign-patient inflows; how much that insulates it, or limits it, when insurers tighten panels is not something the filing lets us quantify.

Where the moat is weaker is the same place the earnings come from. A specialist group is, ultimately, its specialists, and the average doctor here is around 52 years old with 25 years of experience. The relationships, the referrals and the reputations belong to individuals. The Share Swap and its moratoria are explicitly designed to bind those individuals to the platform, which is an admission that, without contractual lock-ins, they could walk. A moat that has to be written into an escrow agreement is a moat under construction, not one that has weathered a cycle.

The roll-up question the prospectus does not ask

There is a precedent for buying up doctors’ practices at scale on debt and listing the result on a growth multiple. In the United States in the 1990s, physician practice management companies such as MedPartners, PhyCor and PhyMatrix did exactly that, were valued as compounders, then collapsed when acquired-practice productivity faded and the bought-in doctors’ incentives drifted from shareholders’. The lesson was not that the model cannot work, since IHH and others built durable specialist businesses, but that the moment of maximum optimism is usually the listing, while the acquisition machine is still running and the incentives are fresh. Foundation is genuinely different in important ways: a single, highly regulated, high-margin market, Temasek governance, covenant discipline, real margins and cash today, and a moratorium-with-clawback more thoughtful than a simple earnout.

The closer-to-home precedent is more pointed. The previous generation of SGX-listed medical-group roll-ups has almost all left the exchange, usually cheaply: Singapore Medical Group taken private in 2022 [8], Healthway Medical delisted in 2023 [9], TalkMed privatised at S$0.456 (about S$606 million) in 2025 [10], and Singapore Paincare’s buyout collapsing at the end of 2025, leaving a loss-making shell [11]. Singapore’s public market has not historically held a premium multiple on a listed specialist roll-up; the usual end-state has been a take-private at a modest price. Neither the 584-page prospectus nor its Frost & Sullivan market-research appendix mentions any of this. Investors should supply the history themselves.

What the market is asking you to pay

Here is the valuation stated plainly, and it depends entirely on which earnings number you accept. Across the S$0.76 to S$0.92 offer range, the company is valued at

Read more

Somewhere in a Singapore operating theatre this week, a surgeon will inject a few milligrams of green powder dissolved in sterile water into a patient’s bloodstream. Under a near-infrared camera, the compound, indocyanine green, will light up the patient’s blood vessels and tissue perfusion in real time: a glowing map of where blood is flowing and where it is not. The surgeon uses that map to decide where to cut, what to reconnect, and whether a newly joined section of bowel will survive. The dye has been in clinical use since the 1950s. The camera, the regulatory approvals, the distribution network and, increasingly, the data captured around each procedure belong to a company most Singapore investors had never heard of before December 2025.

UltraGreen.ai Limited listed on the SGX Mainboard on 3 December 2025 at US$1.45 per share, the largest non-REIT listing in Singapore since 2017 [12]. It sells roughly 83% of all indocyanine green (”ICG”) vials used in the United States and about 94% of those used in Europe, with no approved substitute for the fluorescence-guided surgery (”FGS”) indications it dominates [2]. It earned an 85.0% gross margin in FY2025. Its revenue has compounded at 43% a year since FY2022. As at 10 June 2026 the shares trade at US$1.42 [1], 2% below the IPO price and 24% below the February peak of US$1.86.

The market’s implied verdict is that this is a fully priced, mid-growth medtech: at US$1.42, roughly 18x our estimate of FY2026 earnings, against the premium multiples global medtech peers command, which published comp sets put anywhere from about 20x to 32x forward [8]. We think that verdict rests on a misreading of one income statement. FY2025’s reported numbers simultaneously overstate the group’s tax burden, through a one-time US$8.5 million provision that is the subject of a pending exemption application, and understate its interest income, because the US$150.0 million of IPO proceeds arrived in the final month of the financial year and earned almost nothing. One distortion reverses mechanically in FY2026; the other awaits a ministerial ruling, with both outcomes computable today. Together they could add roughly US$13–15 million of net profit, a 20–24% uplift on the underlying FY2025 base of US$63.8 million, before a single additional vial is sold.

This article works through three questions in sequence. First, are FY2025 earnings temporarily depressed? We will show the arithmetic says yes, and quantify it. Second, does UltraGreen’s US pricing hold through the hospital purchasing cycle? That is genuinely open, and we will name the one undisclosed variable that matters most. Third, can the ICG cash engine fund a credible platform business in data and imaging? That is conditional, and we will treat it as optionality rather than earnings. Along the way we will also explain why the share price fell 24% from its peak, why we think much of that fall was macro rather than company-specific, and what one number, due in August 2026, would make us abandon the thesis entirely.

From Frame Relay to fluorescent dye

Ravinder Sajwan, 64, did not invent anything UltraGreen sells. That is worth stating plainly at the outset, because the company’s moat makes more sense once you stop looking for the patent. Sajwan’s career is a Silicon Valley operator’s résumé: a 2,400bps modem design early on, a universal network-testing device acquired by Tektronix, senior technical roles at StrataCom, whose Frame Relay technology Cisco bought for US$4 billion in 1996, then the co-founding of Acclaim Communications, sold to Level One for US$120 million in 1998, shortly before Intel bought Level One for US$2.2 billion [3][19]. Between telecoms and medtech came a long, lucrative interlude producing 5-Hour Energy drinks, a business connected to founder Manoj Bhargava, which threw off dividends that capitalised the family’s Renew Group [3].

The ICG story began, by Sajwan’s own telling, around 2013, when he encountered the dye through a German medical device company using it to measure holes in hearts [3]. What he saw was not a molecule but a market structure. ICG itself is an old, unpatentable compound; Sajwan has compared it to matcha powder, an everyday-seeming ingredient with an outsized value per use [19]. The product is cheap to make, sells for a small fraction of the cost of the surgery it supports, and is protected not by intellectual property but by regulatory approvals, manufacturing accreditation, distribution relationships and surgeon habit. From 2015, Renew built UltraGreen by buying, partnering with and consolidating the companies that held those positions: the moat was assembled, not invented [3]. The group even founded the International Society of Fluorescence-Guided Surgery, a surgeon education body that, whatever its scientific merits, functions commercially as a standard-of-care flywheel for ICG procedures [19].

The capital structure history matters for what comes later in this article, so we set it out here. UltraGreen took no outside investors at all until 2025, when 65 Equity Partners (a Temasek-backed vehicle investing from a fund with an explicit mandate to groom companies for SGX listings) and Vitruvian Partners invested in a pre-IPO round [10]. Before that, in November 2024, the company issued a US$142.8 million promissory note to its immediate holding company RGPL, in effect a distribution to the controlling shareholder funded by an IOU, which pushed group equity negative (total equity at 31 December 2024 was negative US$26.0 million). In August 2025, the note was settled by issuing RGPL 142.8 million new shares at US$1.00 apiece. In the same pre-IPO window the company paid US$39.8 million of FY2025 dividends to its pre-listing shareholders and sold its UltraLinQ cardiology software business for a US$23.7 million gain. Then came the December IPO: US$150.0 million of primary proceeds at US$1.45 per share, within a roughly US$400 million total offering including a US$237.5 million cornerstone tranche taken up by sixteen institutions, among them abrdn, AIA, Eastspring and Lion Global [11][12].

The debut was respectable but not euphoric: the stock opened at US$1.51, touched US$1.62 intraday, and closed at US$1.52 [12]. Within nine trading days it was at US$1.31, and the stabilising manager deployed its full 20.7 million share mandate; the over-allotment option was never exercised [13]. The stock then rallied to US$1.86 by 23 February 2026, sold off through a risk-averse March, and slid to a US$1.20 low in late May after a first-quarter print the market misread [7], both of which we return to below; it sits at US$1.42 as we write [1]. A listing that was priced at 28.6x FY2024 earnings [12] now trades, on our normalised arithmetic, at a multiple in the high teens against earnings that have since grown.

What the company actually sells

UltraGreen is best understood as three layers stacked on one molecule.

The first layer is the dye itself, and it is almost the whole income statement today. The group sells ICG vials under the IC-GREEN brand in the US and Verdye elsewhere, through two geographic segments. DxG–Americas generated US$106.5 million of net revenue in FY2025, 74.8% of the group total, up 23.9% year on year. DxG–Rest of the World generated US$31.0 million, up 40.7%. Volumes tell the same story with less noise: 667,800 vials shipped in the Americas in FY2025 and 319,900 elsewhere, 987,700 in total, up 13.2% on FY2024. Cumulatively the group had sold about 5.3 million vials since 2015 as at June 2025 [11]. Gross margin on all of this was 85.0% in FY2025, up from 75.5% in FY2022, a function of price increases falling through to a largely fixed cost of goods.

The second layer is hardware: the IC-Flow imaging system, a handheld near-infrared camera that makes the dye visible. UltraGreen’s German subsidiary Diagnostic Green GmbH is the license holder and manufacturer of record. The camera is not currently a profit centre; it is an ecosystem device, and the group’s Asia strategy makes that explicit. In Asia, UltraGreen will lease cameras to hospitals rather than sell them, lowering the entry cost for adoption while keeping the recurring vial sales and, importantly, the procedure data [10]. Camera manufacturing is being relocated from Germany and Ireland to Singapore, at the group’s MacPherson headquarters [10]. Commercial responsibility is split between two Chief Commercial Officers, one for the Americas and one, Fidelma Callanan, based in Ireland, covering everything else; the Asia build-out reports to her [10].

The third layer is the platform ambition that justifies the “.ai” in the name: the UltraGreen Data Platform, the PerfusionWorks perfusion-analytics software acquired with Denmark’s Perfusion Tech ApS (the remaining 72.6% was bought in June 2025 for US$5.6 million net of cash, adding US$3.7 million of goodwill and US$8.2 million of intangibles), and a small UltraGreen Data Systems (”UGDS”) segment created in 2025 from retained UltraLinQ staff. UGDS also distributes biosensor products from LifeSignals Inc., an associate of the controlling shareholder’s private group, a related-party arrangement we examine in the governance section. The platform layer is currently a cost: UGDS recorded US$0.4 million of revenue and a US$1.6 million operating loss in FY2025, and PerfusionWorks is targeted for commercial launch in 2027, a management target rather than a committed date. The regulatory groundwork is further along than the revenue line suggests: the IC-Flow system and the UltraGreen Data Platform carry US 510(k) clearance and CE marking, and PerfusionWorks has been filed for approval in Europe, with management indicating a potential European launch as early as 2026 and progress through the EU MDR and FDA pathways during the year. In April 2026 the group also branded its cardiology distribution business UltraGreen Cardiac Technologies, the commercial wrapper for the LifeSignals biosensor arrangement. There is also Ferronova, a 26.9%-owned Australian associate developing iron-oxide nanoparticle devices for sentinel lymph node biopsy, an adjacent modality that costs the group roughly US$0.5 million a year through the associates line. We note it here and set it aside: it is not material to the valuation.

One business is deliberately absent from this list. UltraLinQ, the cardiology image-management software the group sold in August 2025 for a US$23.7 million gain, contributed US$4.4 million of revenue in FY2025 before disposal and US$6.7 million in FY2024. Reported FY2025 revenue of US$142.4 million therefore overstates the continuing perimeter; the comparable core figure is US$137.9 million. We use the core figure throughout this article when we discuss growth.

The industry: a standard of care still in its first quarter

Fluorescence-guided surgery is one of those rare medical technologies whose clinical evidence base is enormous while its adoption remains shallow. More than 20,000 peer-reviewed publications and over 780 clinical trials involve ICG [5], and the dye has US FDA approval history stretching back decades. Yet FGS penetration is still below 25% of addressable procedures in the United States, and lower again in Asia-Pacific [8]. At UltraGreen’s April 2026 AGM, the CEO put the addressable market for just the four core procedures, laparoscopic cholecystectomy, colorectal surgery, breast sentinel lymph node biopsy and breast reconstruction, at roughly 10 million surgical procedures a year, of which the group currently serves a small fraction, with procedure growth running at mid-to-high single digits. Frost & Sullivan frames the same runway in dollars: it sizes the global ICG market at about US$173 million in 2024, against a total addressable market of roughly US$925 million were FGS and ICG adopted across every eligible procedure, which leaves the category only about 19% penetrated [2].

The competitive map is unusually concentrated. By Frost & Sullivan’s count, UltraGreen held about 68% of the global ICG market by vials and 63% by revenue in 2024, with 83% of US vials and a 94% share in Europe [2]; Sajwan has put the US figure at 85% in interviews [3]. The company’s revenue is roughly 2.6 times that of the second-largest player [18]. In the US, the remaining ~17% of the vial market belongs to Stryker Corp, the Michigan-based devices group [4]. Daiichi Sankyo, the original Japanese incumbent, retains only a minor global role [4]. There is no other FDA-approved fluorescent agent for the broad FGS indications ICG covers; emerging agents target specific procedures, and management’s stated view at the AGM was that ICG’s safety profile keeps it the default across the majority of use cases.

Two industry developments in 2026 bear directly on the investment case. The first is regulatory: UltraGreen’s approval footprint expanded from 35 territories in 2024 to 45 by mid-2026. The composition of those approvals deserves precision, because dye and camera travel on separate regulatory tracks. The Verdye dye itself was approved in the Philippines (December 2025) and Singapore (May 2026); the March 2026 four-country sweep across India, Thailand, the Philippines and Bangladesh, like the December 2025 Malaysia clearance, covers the IC-Flow V2 imaging system, with the dye still to follow in most of those markets. The camera approvals lay regulatory groundwork; meaningful revenue in those territories waits on the corresponding ICG registrations, and the company says approvals are being sought in roughly 20 further markets across Asia and the Middle East. Asia is the growth frontier, and the entry indications are deliberately chosen for emerging-market epidemiology: diabetic foot ulcer assessment and lymphedema, ahead of the surgical oncology uses that dominate Western volumes. Sajwan’s framing of the wound-care opportunity is worth quoting: “Five per cent penetration of the diabetic foot ulcer market is twice our current total addressable market.” [9]

The second development is the misfortune of the only US competitor. On 11 March 2026, a hacking group calling itself Handala, claiming Iran-linked motives, attacked Stryker’s Microsoft IT environment; the company’s SEC filing disclosed disruption to order processing, manufacturing and shipping [20]. Recovery was quick by the standards of such incidents: electronic ordering was restored for customers by 26 March, with most manufacturing sites and critical lines back and order reconciliation still under way [21], and by 9 April the company reported itself fully operational [25]. Brief as it was, the disruption was not trivial: Stryker’s amended SEC filing formally determined the incident had a material impact on its first-quarter 2026 operations and financial results, while leaving full-year guidance intact [25]. Hospitals buying a consumable that sits on the critical path of scheduled surgery prioritise supply reliability above almost everything, and a two-week ordering outage is long enough to force substitution decisions. We treat the possibility that displaced Stryker orders flowed to UltraGreen as a hypothesis bounded by that two-week window, to be tested by the next volume print, not as an accrued benefit; the timing arithmetic is in the deep dive. But the episode illustrates the asymmetry of this market: when 83% leans on 17%, disruption at the small player consolidates the large one.

The moat: three layers, one weak seam

Asserting a moat is cheap; the financial record either corroborates it or it does not. UltraGreen’s record corroborates three distinct layers of advantage, and exposes precisely where the structure is least tested.

The first layer is regulatory and clinical entrenchment. ICG is not proprietary, and management says so plainly: at the April 2026 AGM the CEO identified the group’s advantages as its regulatory approvals, manufacturing processes, ownership of the FDA drug master file, and accumulated clinical data, not the molecule. A would-be competitor needs an approved abbreviated new drug application, accredited sterile manufacturing, and a reason for surgeons to switch a consumable that costs a rounding error within a surgical bill. IC-GREEN has been FDA-approved since 1959 and remains the Reference Listed Drug other ICG products are measured against (we develop this point, and what the FDA register shows about would-be generics, in the risks section), and the publication and training flywheel around the group’s surgeon society raises the switching bar each year.

The second layer is distribution. In the US, the Big Three pharmaceutical wholesalers, Cencora, McKesson and Cardinal Health, collectively accounted for 67.8% of group revenue in FY2025. We will argue later that this concentration is more benign than it looks, because wholesalers are logistics and credit conduits rather than buyers with pricing power. But as a barrier it is real: shelf position inside the ordering systems of effectively every US hospital is something a new entrant cannot replicate quickly at any price.

The third layer is the one the income statement proves: pricing power, exercised in three rounds and absorbed each time. UltraGreen raised US prices by an average of 60% per vial in August 2023 and another 30% in April 2024, then implemented a further round of US pricing initiatives in the third quarter of 2025 that lifted US average selling prices 22% to about US$158 per vial that year. Over the period the global blended ASP went from US$70.3 per vial in FY2022 to US$139.3 in FY2025 [4], and volumes did not fall; Americas vials grew from 470,400 in FY2022 to 667,800 in FY2025, and total vials from 699,600 to 987,700. A 98% cumulative increase in the blended ASP met 41% volume growth over the same three years. Demand for ICG is, on this evidence, about as price-inelastic as consumables get, which is what you would expect for a product that enables a procedure billed at two or three orders of magnitude above the vial price.

The weak seam runs through the second and third layers where they meet:

Read more

The first is the completion of the Ann Arbor Dental Surgery acquisition, announced on 10 June. The second, from 5 June, is the FY2025 profit guarantee results for Aoxin Q&M’s three legacy northern China subsidiaries: all met, and the last outstanding shortfall from the pre-FY2023 period has been repaid in full.

A quick note on scope: Ann Arbor did not appear in our initiation article. It is one of three small Singapore bolt-on acquisitions (alongside Sengkang Dental Surgery, completed January 2026, and Southbank Private Limited / TEETH @ Tiong Bahru, binding MOU February 2026) that Q&M has been running in parallel with the headline international deals. Each is too small individually to feature in an S$130M thesis, and none changes the international expansion story. But together they confirm that the Singapore accretion engine, the model that built Q&M from one clinic to 110+ over thirty years, is still running while management pursues the larger bets.

Neither event is material in isolation. Together they clear two items that were sitting open on the bear checklist.

Read more

Walk into the Rolex boutique on the casino floor at Crown in Perth, or into Tong Building at the top of Orchard Road in Singapore, and the experience is engineered to feel timeless. A salesperson who knows your collection. A display of steel sports models you cannot simply buy off the shelf. A waiting list that is itself a status object. None of it looks like a listed company, and that is the point. The business behind that boutique floor is one of the oldest continuously operating luxury watch retailers in Asia, and it has been run by the same family for forty-six years.

The Hour Glass Limited (SGX:AGS) was founded in 1979 by Dr Henry Tay and Dato’ Dr Jannie Tay. It listed on the Singapore Exchange in 1988 and has not raised a dollar of equity from public markets in more than three decades. For the financial year ended 31 March 2026 it earned a headline net profit of S$179.5 million on revenue of S$1,338 million, both records, and it closed the year with no bank debt or bonds for the first time in at least a decade. Its book value per share has risen every single year for seven consecutive years, from S$0.86 to S$1.67. At the 3 June 2026 close of S$2.63, the market values the whole company at roughly S$1,685 million.

The most interesting fact about The Hour Glass right now is the acquisition it completed in 2025, and the reason the seller gave for selling. In a deal worth AUD90 million, The Hour Glass bought THGRAU, the Australian Rolex authorised-dealer business previously owned by Kennedy Watches & Jewellery: four Rolex flagship boutiques in Melbourne, Sydney and Perth. The seller, James Kennedy, told the Australian Financial Review that the timing was right to sell the licence because Rolex “may sell directly to shoppers in the future” [1]. An informed seller cashed out of the exact relationship The Hour Glass paid AUD90 million to acquire, and told the press why. That tension is the question the institutional-length version of this analysis sets out to resolve in full; here we lay out why the franchise behind it is real, and where the market may be giving it too little credit.

That tension is the question the institutional-length version of this analysis sets out to resolve in full; here we lay out why the franchise behind it is real, and where the market may be giving it too little credit. Link below.

Forty-Six Years, Zero Equity Raises

The Hour Glass began in 1979 as a single boutique. Dr Henry Tay, a Monash-trained doctor who had practised before moving into business, and Dato’ Dr Jannie Tay built the company around an idea unusual for its time and place: sell luxury Swiss watches in Southeast Asia as objects of taste rather than as commodities, in retail environments that matched the brands’ own standards. The two founders were husband and wife, married in 1969, and they built The Hour Glass together for three decades before divorcing in 2010; both have remained substantial shareholders since, and their son Michael Tay now leads the group. Jannie Tay is today often known as Jannie Chan. The watch trade was already in Dr Tay’s family: his forebears ran Lee Chay & Co on North Bridge Road from 1946, one of the Singapore retailers Rolex appointed in 1950, so the group’s Rolex relationship is closer to seventy-five years old than to the company’s own forty-six [14]. The name itself sets the character of the company. An hour glass measures time by letting it run out grain by grain, a fitting emblem for a business that sells mechanical timekeeping and thinks in decades.

The company listed in 1988, and the most telling fact about the thirty-eight years since is a negative one: it has not issued a single new share to raise capital. Growth has been funded from retained earnings and modest borrowing that has now been fully repaid. A retailer that expands across eight countries without diluting its owners is doing something deliberate.

The growth came in layers. The first Australian boutique opened on the Gold Coast in 1988, at Marina Mirage. The Thai business that became THG Prima Times was built as a joint venture and is now a 49 per cent associate spanning Bangkok and, more recently, Vietnam. Japan followed, with a Ginza presence dating to the 1990s. The two acquisitions that matter most to the current story are recent: Mansors Jewellers in Auckland in February 2020, New Zealand’s oldest authorised Rolex retailer, as part of a New Zealand entry of more than NZ$80 million that also took in two Auckland commercial properties; and THGRAU in Australia in 2025. Both were Rolex dealerships, and both were acquired with Rolex’s explicit blessing.

Michael Tay, Dr Henry Tay’s son, became sole Group Managing Director in April 2020, taking day-to-day management into the pandemic. The timing matters: he assumed full control at the bottom, ran the business through the extraordinary boom of FY2022 and FY2023, through the correction of FY2024 and FY2025, and into the record FY2026. That is a complete cycle under one leader, and the company came out of it with more cash, less debt, and a larger network than it entered with. His own description of how the business is built is the one worth remembering: “It’s like kueh lapis, where you bake layer by layer. After that, you will have multiple layers, and our business is just like that” [9].

What The Hour Glass Actually Does

For reporting purposes The Hour Glass has one business segment: the retail and distribution of watches, jewellery and other luxury products across Singapore, Malaysia, Thailand, Vietnam, Hong Kong, Japan, Australia and New Zealand. It sells brands including Rolex, Patek Philippe, Tudor, Cartier, Hublot and F.P. Journe. There are no factories and no own-brand product of consequence. The company buys watches at wholesale and sells them at retail, and the entire economics of the business sit in that spread, in the inventory it carries to earn it, and in the relationships that determine which watches it is allowed to sell at all.

Geographically the group reports two segments. Southeast Asia and Oceania produced S$1,165 million of FY2026 revenue, about 87 per cent of the total; North East Asia, principally Japan and Hong Kong, produced S$174 million, about 13 per cent. There is no Mainland China operation, which over the last two years has been a feature rather than a gap: Mainland China and Hong Kong were the two worst markets in the global Swiss watch trade, and The Hour Glass does not sell into either at scale.

One distinction matters for reading the numbers. THGRAU, the Australian Rolex business, is wholly owned and fully consolidated, so its revenue and costs flow straight into the group accounts. THG Prima Times, the 49 per cent Thai and Vietnamese associate, is not controlled, so accounting rules bring in only the group’s share of its profit, S$15.6 million in FY2026, not its revenue. A reader who misses that distinction will misread both the growth and the risk.

A Shrinking Industry, Concentrating Upward

The backdrop is a Swiss watch industry contracting in aggregate while the top of it holds up. Swiss watch exports fell to CHF26.0 billion in 2024, down 2.8 per cent in value and 9.4 per cent in volume, then to CHF25.6 billion in 2025, a second consecutive annual decline [2][3]. The pain has been concentrated in Greater China: after Mainland China exports collapsed 25.8 per cent in 2024, 2025 brought a further 12.1 per cent fall there and a 6.5 per cent decline in Hong Kong, while the United States held up to become the single largest destination at about 17 per cent of all Swiss watch exports [3]. Fewer watches, more expensive ones: mix is moving upward.

The secondary market tells the same story. The Bloomberg Subdial Watch Index, which tracks resale prices of the most heavily traded Rolex, Patek Philippe and Audemars Piguet models, fell about 6 per cent in 2024 to a three-year low, then recovered about 8 per cent in 2025 on stronger holiday demand [4][5]. For a retailer, the secondary market is a sentiment gauge and a margin signal: when resale prices rise, retail demand is firm and discounting is absent; when they fall, the grey market widens.

Singapore as a market remains healthy. The Singapore Tourism Board reported 16.9 million international visitor arrivals in 2025, up 2.3 per cent, and record tourism receipts of S$32.8 billion for the full year, [7]; shopping has historically accounted for roughly a third of those receipts, with watches a named category in the STB breakdown. Chinese visitors were the largest source market at 3.1 million arrivals. A Singapore-headquartered luxury watch retailer with no direct Mainland exposure, capturing Chinese demand as it travels rather than at home, is positioned more sensibly in 2026 than it might have looked five years ago.

Behind the tourism numbers is a structural driver: new wealth is concentrating in The Hour Glass’s home market. Single family offices receiving tax incentives from the Monetary Authority of Singapore rose from about 400 at the end of 2020 to roughly 1,400 by the end of 2023 and continued toward 2,000 through 2024, the principals drawn heavily from China, India and Indonesia [11]. Knight Frank’s 2026 Wealth Report projects the global ultra-high-net-worth population to grow about 27 per cent over the five years to 2031, with several of The Hour Glass’s markets among the fastest: Australia close to 60 per cent, Vietnam 59 per cent, and Indonesia, a key source of its Singapore clientele, around 82 per cent [12]. This is a slow tailwind rather than a quarterly catalyst, but it puts the group’s flagship boutiques in the path of the new wealth arriving on their doorstep.

The Moat: Relationships You Cannot Buy

The competitive advantage of The Hour Glass has four parts, and most of them cannot be bought at any price.

The first is the brand relationships themselves. The right to sell Rolex and Patek Philippe as an authorised dealer is not for sale on the open market. It is granted, slowly, to retailers the maisons trust, and withdrawn from those they do not. The Hour Glass has held its Rolex relationship for about seventy-five years, since the founder’s family firm was among the retailers Rolex appointed in 1950, and operates one of roughly eighty Patek Philippe mono-brand boutiques in the world. A competitor with unlimited capital cannot simply buy an equivalent position; it would have to be invited into it over many years, and the brands have every incentive to keep the invitations few.

The second is the family, and it is the part most easily underestimated from a spreadsheet. The Hour Glass’s relationships with Rolex and Patek Philippe were built by the Tay family across forty-six years, through downturns weathered without dumping inventory and through consistent representation of the brands at the highest level. When Rolex approved the Mansors acquisition in 2020 and the THGRAU acquisition in 2025, it was approving transactions by people it knew, not by an abstract listed entity. Any change of ownership would introduce a transition risk that the current structure avoids entirely. This is the one competitive advantage in the business that cannot be acquired, replicated, or read off a balance sheet.

The third is the balance sheet as a strategic instrument. Zero financial debt, S$157.5 million of cash and S$225 million of unencumbered property give the company the capacity to act when a motivated seller appears and competitors are retrenching. That property is not a recent manoeuvre: the group bought its first building in Australia around 1992 and assembled the S$225 million position over more than thirty years, to occupy rather than to trade. That is exactly what happened with THGRAU: The Hour Glass built balance-sheet strength through the boom while others over-extended, then deployed it when Kennedy decided to exit.

The fourth part is the one most easily missed, because it produces little revenue and almost no headline: The Hour Glass is the regional curator of the ultra-premium independent watchmakers. Alongside Rolex and Patek Philippe, the group carries names such as F.P. Journe, Akrivia, Urwerk and MB&F, brands that Cortina and the mainstream Southeast Asian retailers do not stock. Its credentials here run deep: the group once owned the watchmakers Gerald Genta and Daniel Roth outright, buying them in the 1990s and selling both to Bulgari in 2000 [15]. It has also been one of MB&F’s original retail partners since the brand’s early days, stayed with it through the lean years, and now co-operates the world’s first MB&F Lab in Singapore, the kind of flagship partnership a new entrant cannot buy [16]. These watches are not allocated on a waiting list and are not arbitraged on the grey market; they are placed with collectors who have demonstrated taste and a relationship with the retailer, which means they carry the highest margins in the business with no brand quota and no competing regional retailer. The group’s ambition to be “the watch world’s leading cultural retail enterprise” is built on this layer, through collector events and the free IAMWATCH public lectures that cultivate a younger, more educated audience long before its members have the budget to buy. That audience is the client pipeline for the next five to ten years, and spending today to build it is the kind of long-horizon thinking that compounds a business over decades. With the group reporting a single segment, this layer cannot be sized from the disclosures; it is unpriced optionality and a competitive position no regional rival holds, not a number anyone can yet put in a model.

Where the moat is weaker is worth stating plainly. The brand relationships that cannot be bought also cannot be owned: they are licences, not property, and the maisons hold the right to change the terms. The family that built the trust is also the single point of failure if succession is mishandled. And the balance sheet that funds acquisitions earns a low operating return while it waits. The closest listed comparison, Cortina Holdings (SGX:C41), runs a similar model at a materially lower margin, roughly 6.6 per cent net against The Hour Glass’s roughly 12 per cent on recurring earnings [10]. The premium The Hour Glass earns is real, but it has to keep being earned through brand concentration and mix.

A sharper version of the same question comes from Hong Kong. Emperor Watch & Jewellery (HKEX:0887), a listed Greater China retailer that carries the same top brands, Rolex and Patek Philippe included, trades far more cheaply than The Hour Glass on every headline measure, and it is not a failing business: its revenue and profit both grew in the year to December 2025 [13]. The reasons it trades where it does are precisely the things The Hour Glass is not. Its recent profit growth is led by gold jewellery rather than watches, which makes it a less pure read on the watch franchise. It is concentrated in Hong Kong, Macau and Mainland China, the part of the market most exposed to the structural questions over Chinese luxury demand, where The Hour Glass spreads across eight markets and has just added Australia. And it is a tightly controlled family company that retains most of its earnings rather than returning them, with a 60 per cent controlling stake and related-party dealings, the kind of structure the market has long discounted. The Hour Glass is family-controlled too, but it has not issued a share in thirty-eight years and cancels the stock it buys back. The cheaper peer is real, and an investor who wants Greater China watch exposure at a low multiple can find it there. What they cannot find there is the combination of brand concentration, better geographies and capital discipline that the rest of this article describes.

The Scoreboard: Seven Years of Rising Book Value

The seven-year record holds the whole story in one table: a doubling of revenue through a boom, a real correction in the middle, and a return to record earnings, with book value per share rising in every single year regardless of what the profit line did.

The arc reads in four parts. FY2022 and FY2023 were the boom: revenue jumped above the billion-dollar mark, gross margin peaked at 33.6 per cent, and headline profit reached S$174 million as the pandemic-era frenzy for waitlisted steel sports models ran at full force. FY2024 and FY2025 were the correction: the secondary market normalised, sentiment softened, a New Zealand deferred-tax charge bit, and headline profit fell 22 per cent from the FY2023 peak to S$136 million. FY2026 was the re-acceleration: revenue rose 15 per cent to a record S$1,338 million and headline profit reached a record S$179.5 million, helped by the consolidation of THGRAU.

The single number that survives all four phases is book value per share. It rose from S$0.86 to S$1.67 across the seven years, an increase of 94 per cent, compounding at roughly 11.7 per cent a year, and it rose in the correction years as well as the boom years. A retailer that keeps growing its net asset value per share through a 22 per cent earnings drawdown is retaining and reinvesting capital faster than the cycle can erode it. That is the financial signature of the business.

One caution on the headline profit belongs here. The FY2026 figure of S$179.5 million includes a S$20.3 million non-cash gain from revaluing the investment-property portfolio upward, which under Singapore accounting standards runs through the income statement. Strip it out and recurring profit is nearer S$162 million. The reported 9.4 times earnings is therefore closer to 10.5 times on recurring earnings, which matters for how cheap the stock really is.

Capital Allocation: Paid Every Year, Never Diluted

It is tempting to look at the 2.3 per cent yield and dismiss The Hour Glass as nothing special for income. That misreads it. The dividend is the residual left after the company funds inventory, boutiques, property, buybacks and the occasional acquisition, and the residual has a remarkable record: paid every single year, without exception, through the global financial crisis, the FY2016 to FY2018 luxury downturn [17], and the COVID closures of FY2020. In the boom years it has gone further, paying special dividends on top of the ordinary one, including a one-time special in the FY2008 boom that was four times the size of that year’s final dividend.

The global financial crisis shows the model under stress. FY2009 headline profit fell 57 per cent, but S$14.1 million of that was a one-off impairment on a listed investment unrelated to watch retail; the core business fell only about 13 per cent and recovered above its pre-crisis peak the very next year, with the dividend maintained throughout. Across fifteen years, book value per share has compounded at roughly 11 per cent a year on a split-adjusted basis, rising through every downturn. A shareholder who bought during the FY2016 luxury downturn, when the stock traded around or below S$0.60 split-adjusted, would have more than quadrupled their capital by today’s S$2.63, before a single dividend.

None of that came from yield. It came from a business that reinvests retained earnings at a mid-teens return on equity, has not issued a new share to raise capital in over three decades, and has been shrinking its share count rather than growing it, from about 705 million shares after the 2014 subdivision to roughly 646 million today, including S$112.3 million of treasury shares cancelled outright in FY2026. The 2.3 per cent yield is the by-product of that machine, not the reason to own it.

The Two Things the Market Has Not Yet Tested

Two specific developments sit behind the FY2026 numbers, and neither has been seen across a full clean year yet.

The first is THGRAU. The Australian Rolex business consolidated from 30 April 2025, so FY2026 captured only eleven months of it, and the purchase-price allocation was still provisional at the half-year. FY2027 will be the first clean twelve-month contribution, and the first year in which the audited standalone economics of the four boutiques are visible. The Southeast Asia and Oceania segment grew by S$167 million in FY2026, and THGRAU is the dominant contributor, although organic growth, currency and other movements are folded into the same segment line, so a clean THGRAU-only figure is not available until the FY2026 annual report is filed, expected in July 2026.

The second is the conversion of multi-brand stores into single-brand boutiques. The clearest delivery so far is the Patek Philippe Boutique Tokyo Ginza, which opened on 29 January 2025, one of roughly eighty Patek mono-brand boutiques worldwide and the second in Japan, built at around 200 square metres from the shell of the former multi-brand store [8]. A mono-brand conversion deepens the relationship with the maison, removes cannibalisation between brands on the same floor, and signals a franchise credential a new entrant cannot match. The capital cost is limited to fit-out, and the benefit shows up as mix rather than as a new revenue line, which is part of why it is easy to miss.

We have built the segment-level arithmetic on what a full year of THGRAU plus the conversion programme does to forward earnings, and it produces a figure that sits meaningfully above what the trailing numbers imply. The detailed forward build, and what it does to the valuation, is held back from this article. What can be said here is that the gap between the trailing multiple and the forward economics is the heart of the case, and it is the part the market has the least basis to have priced, because the audited numbers do not yet exist.

The One Risk That Matters Most

If the bull points are real, so is the central risk, and it is the same transaction that drives the upside. The Hour Glass paid AUD90 million for THGRAU and put S$66.5 million of it on the balance sheet as “distribution rights” with an indefinite useful life, an accounting treatment that says the asset does not wear out. The man who sold it said he sold precisely because that future looked uncertain, that Rolex “may sell directly to shoppers in the future” [1]. The buyer booked permanence; the seller cited impermanence as his reason for leaving.

The uncomfortable part is the contract. The actual agreement between Rolex and the THGRAU boutiques is not public, but comparable Rolex authorised-dealer agreements that have surfaced elsewhere typically allow either party to terminate without cause on short notice. An asset carried as indefinite-life on the balance sheet may, in contractual reality, sit on a notice period measured in weeks. Set against that is the pattern of behaviour: Rolex has not, in any documented case, internalised a major mono-brand flagship dealer of the kind The Hour Glass now runs, its chief executive said publicly in November 2025 that it intends to keep authorised dealers as its primary channel [6], and it approved not one but two acquisitions by The Hour Glass in five years. The same variable, Rolex’s assessment of The Hour Glass as a partner, drives both the downside and the upside. The realistic risk is not dramatic termination but slow erosion, through allocation and capex pressure and the ordinary margin cycle of luxury retail. The full risk register, and the specific signals that would break the thesis, are deliberately held back from this shorter analysis; this is the one risk every holder should understand.

Valuation: Why the Headline Multiple Is Not the Whole Story

At the 3 June 2026 close of S$2.63, The Hour Glass trades at 9.4 times reported earnings, or about 10.5 times once the property revaluation is stripped out, at 1.58 times book value, and on a total shareholder yield of about 3.1 per cent including buybacks. None of that is a deep-value signal. Ten-and-a-half times recurring earnings for a debt-free, high-quality luxury watch retailer is a fair-to-modest price, not an obvious bargain, and the honest version of the case does not pretend otherwise.

The reason the stock is interesting anyway is what sits behind the earnings. A buyer at S$2.63 is acquiring a business with zero financial debt, S$157.5 million of cash, S$225 million of investment property carried at fair value, and a S$107.1 million stake in the Thai associate, none of which earns an operating return in the recurring profit line but all of which is real asset backing. The working capital is disciplined too, which matters for a watch retailer where cash can get trapped in slow-moving stock: The Hour Glass turns its inventory about 2.4 times a year against roughly 1.8 times at its listed peer Cortina, both on their latest FY2025 accounts, tying up materially less cash per dollar of sales. A sum-of-parts that values the operating business on earnings and adds the cash, property and associate at sensible haircuts produces a range of implied values that brackets the current price, with the downside protected by the assets rather than by the multiple. Those assets are not dollar-for-dollar, to be clear: the property is illiquid and tax-affected, the 49 per cent stake in the Thai associate cannot be monetised without selling it, and the thin family float means minorities depend on the family’s capital-allocation choices rather than on any forced distribution. They cushion the downside; they do not set a hard floor. The full sum-of-parts build, the bear-base-bull range, and the resulting implied value are deliberately held back from this article. The conclusion that can be shared is the shape of it: a modest, asset-protected downside against a wider upside that depends on the THGRAU full year and the acquisition optionality delivering.

The Bottom Line

The Hour Glass is a high-quality, balance-sheet-protected luxury watch retailer at a fair price. It is debt-free, it has compounded book value per share at roughly 11 per cent a year for fifteen years, it has paid a dividend every single year through three downturns without once raising equity, and it holds Rolex and Patek Philippe relationships that no amount of capital can simply buy. It is not an obvious bargain at roughly 10.5 times recurring earnings, and the protection on the downside comes from the cash and property rather than from the multiple. The near-term upside comes from the first full year of THGRAU, the mono-brand conversion programme, and the optionality of a third Rolex acquisition the balance sheet can already fund. The longer-term upside comes from two things the earnings screen cannot see: a curated-independent position no regional competitor occupies, and a structural wave of new Asian wealth concentrating in the group’s home market.

The central tension is the one the seller handed us. The buyer booked the Rolex distribution rights as permanent; the seller left because he thought they were not. The reconciliation is the family: the relationship that earned two acquisition approvals in five years is the same relationship that makes outright expropriation unlikely, and it is the one asset in this business that cannot be valued from a balance sheet. Whether that is enough, at this price, to make the stock more than a fair-value holding depends on the forward earnings build and the valuation range that this article has deliberately stopped short of. The franchise is real. What it is worth, to the dollar, is the question the full analysis answers.

The forward earnings build, the complete sum-of-parts and implied value, the full risk register and the specific signals to monitor are available in the institutional-length version of this analysis. Link below.

Notes on Data Integrity

1. Source of FY2026 figures. Drawn from The Hour Glass’s unaudited condensed full-year results filed with SGX in May 2026 and the H1 FY2026 half-year results. The full FY2026 Annual Report, with complete notes, is expected around July 2026, so the THGRAU purchase-price allocation and standalone economics, the THG Prima Times FY2026 financials, and the detailed investment-property composition remain provisional.

2. Recurring earnings are author-derived. Recurring profit strips the S$20.3 million property fair-value gain and its deferred tax, and is an approximation.

3. THGRAU contribution. The S$167 million segment increase is the total segment movement, not a verified THGRAU-only figure.

4. Rolex agreement terms. The reference to short-notice termination is drawn from comparable public Rolex dealer agreements in other jurisdictions, not from the THGRAU contract, which is not public.

5. Market data. Retrieved on 3 June 2026 via yfinance (AGS.SI). The peer comparison with Emperor Watch & Jewellery uses operating figures from Emperor’s FY2025 annual report (year ended 31 December 2025) [13], not a data vendor.

6. Macro context. Singapore family-office figures are from the Monetary Authority of Singapore and the wealth-growth projections from Knight Frank’s 2026 Wealth Report, used as context rather than valuation inputs.

7. Analytical independence. No third-party analyst research, rating or price target was used as an input; the conclusions derive from primary filings and market data.

References

[1] Primrose Riordan, "Kennedy family sells off Rolex dealership to Singapore," The Australian Financial Review, 27 June 2025. https://www.afr.com/companies/retail/kennedy-family-sells-off-rolex-dealership-to-singapore-20250625-p5ma97

[2] Federation of the Swiss Watch Industry, 2024 export statistics, 30 January 2025. https://www.fhs.swiss/eng/2025_01_30_00_statistics.html

[3] Federation of the Swiss Watch Industry, 2025 export statistics, 29 January 2026. https://www.fhs.swiss/eng/2026_01_29_statistics.html

[4] Bloomberg, "Rolex, Patek, Audemars Piguet Used-Watch Prices Hit Three-Year Low," 7 January 2025. https://www.bloomberg.com/news/articles/2025-01-07/rolex-patek-audemars-piguet-used-watch-prices-hit-three-year-low

[5] Bloomberg, "Luxury Watch Prices Hit a Two-Year High in the Secondary Market," 8 January 2026. https://www.bloomberg.com/news/articles/2026-01-08/luxury-watch-prices-hit-a-two-year-high-in-the-secondary-market

[6] Rolex CEO Jean-Frédéric Dufour at Dubai Watch Week, November 2025. https://news.centurionjewelry.com/articles/detail/rolex-ceo-says-brand-will-stick-with-authorized-dealers-limits-retail-expansion

[7] Singapore Tourism Board, 2025 full-year tourism performance (16.9 million visitor arrivals; record S$32.8 billion in tourism receipts), announced at the Tourism Industry Conference 2026 on 8 May 2026. https://stan.stb.gov.sg/content/stan/en/tourism-statistics.html

[8] The Hour Glass, "Patek Philippe Boutique Ginza Tokyo." https://www.thehourglass.com/story/patek-philippe-ginza-tokyo-boutique

[9] Samantha Chiew, "The Hour Glass sees lower demand amid market uncertainties; sticks to fundamentals," The Edge Singapore, 24 October 2024. https://www.theedgesingapore.com/news/luxury/hour-glass-sees-lower-demand-amid-market-uncertainties-sticks-fundamentals

[10] Cortina Holdings (SGX:C41) FY2026 results, SGX filings.

[11] Monetary Authority of Singapore, single family office incentive data and the speech "Building a Stronger Tomorrow: Family Offices in our Flourishing Wealth Management Landscape," 16 September 2024. https://www.mas.gov.sg/news/speeches/2024/building-a-stronger-tomorrow---family-offices-in-our-flourishing-wealth-management-landscape

[12] Knight Frank, The Wealth Report 2026 (20th edition, April 2026; global and country ultra-high-net-worth growth projections to 2031). https://www.knightfrank.com/research/reports/wealthreport

[13] Emperor Watch & Jewellery Limited (HKEX:0887), Annual Report for the year ended 31 December 2025 (results announced 25 March 2026).

[14] The Hour Glass, "Our Rolex History" (Lee Chay & Co, North Bridge Road, from 1946; Rolex appointment 1950). https://www.thehourglass.com/rolex/our-rolex-history

[15] Federation of the Swiss Watch Industry, "Bulgari to acquire Gerald Genta and Daniel Roth," 5 July 2000 (acquired from The Hour Glass). https://www.fhs.swiss/eng/2000-07-05_44.html

[16] "Maximilian Büsser on the MB&F Lab and venturing beyond watchmaking," Tatler Asia, 2022 (MB&F Lab founded and operated in partnership with The Hour Glass; Singapore the largest MB&F collector community). https://www.tatlerasia.com/style/watches/mbf-lab-maximilian-busser-creative-process-venturing-beyond-watchmaking-interview

[17] The Hour Glass, FY2019 Annual Report, five-year financial highlights (FY2015–FY2019), showing the revenue and profit decline into the FY2017–FY2018 trough and the FY2019 recovery.

All The Hour Glass financial figures are sourced from SGX filings and the company’s investor relations site.

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author holds no position in The Hour Glass (SGX: AGS) as of the date of publication. This does not constitute a recommendation. This publication has received no compensation from The Hour Glass or any related party.

Walk into the Rolex boutique on the casino floor at Crown in Perth, or into Tong Building at the top of Orchard Road in Singapore, and the experience is engineered to feel timeless. A salesperson who knows your collection. A display of steel sports models you cannot simply buy off the shelf. A waiting list that is itself a status object. None of it looks like a listed company, and that is the point. The business behind that boutique floor is one of the oldest continuously operating luxury watch retailers in Asia, and it has been run by the same family for forty-six years.

The Hour Glass Limited (SGX:AGS) was founded in 1979 by Dr Henry Tay and Dato’ Dr Jannie Tay. It listed on the Singapore Exchange in 1988 and has not raised a dollar of equity from public markets in more than three decades. For the financial year ended 31 March 2026 it earned a headline net profit of S$179.5 million on revenue of S$1,338 million, both records, and it closed the year with no bank debt or bonds for the first time in at least a decade. Its book value per share has risen every single year for seven consecutive years, from S$0.86 to S$1.67. At the 3 June 2026 close of S$2.63, the market values the whole company at roughly S$1,685 million.

The most interesting fact about The Hour Glass right now is the acquisition it completed in 2025, and the reason the seller gave for selling. In a deal worth AUD90 million, The Hour Glass bought THGRAU, the Australian Rolex authorised-dealer business previously owned by Kennedy Watches & Jewellery: four Rolex flagship boutiques in Melbourne, Sydney and Perth. The seller, James Kennedy, told the Australian Financial Review that the timing was right to sell the licence because Rolex “may sell directly to shoppers in the future” [1]. An informed seller cashed out of the exact relationship The Hour Glass paid AUD90 million to acquire, and told the press why. That is the central tension of this company, and most of this article is an attempt to work out what it is worth.

The headline valuation looks cheap. Nine-point-four times earnings for a debt-free, record-earning, family-run franchise sounds like a bargain. It is not quite that. Backing out a S$20.3 million non-cash property revaluation that runs through the income statement, recurring earnings are nearer S$162 million, which puts the recurring multiple closer to 10.5 times. That is a fair price, not an obvious bargain. The case for the stock does not rest on the multiple being wrong. It rests on three things the multiple does not capture: a balance sheet with zero financial debt and S$225 million of real estate sitting behind the earnings; the first full year of the THGRAU acquisition, which has not yet been tested across twelve months; and a quiet programme of converting multi-brand stores into single-brand boutiques that improves the mix without showing up as a separate line.

Behind those near-term features sits a slower story the earnings screen cannot see at all. The brief that underwrites this stock is fundamentally defensive: the balance sheet protects the downside, and THGRAU drives the near-term upside. The offensive case is structural and longer-dated. The Hour Glass is not only a Rolex and Patek Philippe distribution machine. It is the Southeast Asian curator of the ultra-premium independent watchmakers that serious collectors graduate into, and it sits in the path of the fastest-growing pool of new wealth in the world. Whether those features are worth paying up for, and how durable the Rolex relationship at the centre of the near-term case really is, is the question the rest of this piece works through.

Read more

Sunright’s own share price, meanwhile, has pulled back 15.6% from our 7 May 2026 publication close of S$0.895 to S$0.755 as of 30 May 2026. The operating asset improved. The price fell. The entry is better.

This note runs the data, checks the thesis breakers, refreshes the look-through valuation, and identifies what to watch next.

The numbers

The 9M PBT swing, from a RM8.4 million loss to a RM9.1 million profit, is not a marginal result. It is a full-cycle reversal on three quarters of data, covering the most operationally intensive months of the fiscal year. Revenue growth of 3% to RM161.3 million is incremental rather than transformative, but the cost-structure improvement did the heavier lifting: other expenses declined 15% (RM8.9 million lower year-on-year) from cost reductions in utilities, repairs and maintenance, and lower fair-value losses on investment securities. Employee expense fell 3% or RM1.8 million. Depreciation rose 8% as newly commissioned machinery and test equipment entered service.

The sequential read is softer: Q3 profit before tax of RM2.4 million was below Q2’s RM4.1 million. Management attribute this to a RM2.3 million net fair-value loss on investment securities (the equity portfolio KESM holds on its balance sheet) and the absence of a RM0.8 million impairment reversal that boosted Q2. Revenue was flat quarter-on-quarter (RM53.3 million versus RM54.9 million). The operating business has not deteriorated; the sequential dip is non-operating noise from the investment portfolio and one-time items.

Thesis breaker check

Five watchlist triggers were established at the time of the initiation.

Two consecutive flat or negative-growth revenue quarters. Q3 revenue grew 1% year-on-year (RM53.3 million versus RM52.8 million). Q2 grew 7% year-on-year. Neither quarter is flat or negative. ✓

Full-year FY2026 KESM revenue below RM215 million. Nine months produced RM161.3 million. Q4 requires RM53.7 million to clear the threshold, in line with Q3’s RM53.3 million and requiring no acceleration. ✓ On track.

FY2026 attributable net profit below RM4 million. Nine months produced RM6.6 million attributable. This threshold is cleared for the full year absent a material Q4 impairment. ✓

Employee/revenue ratio above 44%. Nine-month employee expense of RM61.9 million against RM161.3 million revenue gives 38.4%. This is well below the 44% structural-labour trigger. Operating leverage is running in the right direction. ✓

Total FY2026 dividend substantially above 6 sen. The interim dividend of 6.0 sen per share was paid on 28 October 2025. No additional dividend was declared in Q3. ✓ Consistent with reinvestment thesis.

None of the five triggers fired. All are tracking in the expected direction.

What management said for the first time

In prior quarterly announcements, KESM management described demand improvements in general terms: volume growth, customer mix, utilisation trends. In Q3 FY2026, the filing uses specific language in both the individual quarter and year-to-date discussions: “primarily driven by higher demand for the Group’s services in artificial intelligence (AI) related chips.” This is the first explicit AI attribution in a primary Bursa filing.

For the look-through thesis on Sunright, this matters. The initiation framed KESM’s AI exposure as probabilistic: a plausible demand driver validated externally by Aehr Test Systems’ USD 41 million hyperscale win, but not yet confirmed by the operating entity’s own language. That confirmation has now arrived. The RM28.4 million of outstanding capex commitments, layered on top of the RM39.5 million already deployed in 9M, reflect management’s confidence that the demand is durable enough to justify a capacity build-out ahead of the revenue.

The prospects section of the filing adds context: worldwide semiconductor revenue is expected to exceed USD 1.3 trillion in 2026, up 64% from 2025, driven by AI processing, data centre networking and power, and memory price inflation. AI semiconductors are projected to account for nearly 30% of total semiconductor revenue. KESM’s customer introductions are described as “closely aligned” with this cycle.

Look-through and valuation refresh

The headline compression since publication: S71 is down 15.6% while the operating entity improved. At publication, the core valuation tension was a 1.52x P/Attributable NAV on the SGX versus 0.58x P/Book on Bursa. That gap has narrowed modestly from the S71 side: the SGX multiple compressed to 1.28x as the price pulled back from near the 52-week high. The Bursa discount edged up marginally to 0.60x on slightly higher book value. The structure of the trade is unchanged: the KESM discount and the net cash floor are the same; the premium you pay for that optionality is lower.

The look-through decomposition at current prices: Sunright’s 48.41% KESM stake is worth S$31.9 million at Bursa market (versus S$30.7 million at publication). Subtract that from the S$92.7 million market cap and the implied value of Sunright’s Singapore parent entity (equipment manufacturing, management fees, and S$0.55/share in net cash) is S$60.8 million. The attributable book attributable to the non-KESM parent is roughly S$22 million. Implied ex-KESM P/Book: 2.74x, compressed from 3.6x at publication. The anomaly is smaller than it was; it persists.

The convergence-trade math: if KESM rerated to 1.0x book (MYR 7.97, +68% from MYR 4.74), Sunright’s KESM stake rises to S$53.6 million, a S$21.7 million uplift, or S$0.177 per Sunright share. At S$0.755, that delivers S$0.932, within range of the 52-week high. That scenario has not changed since the initiation; the book value it targets has grown, and the starting price is lower.

What to watch next

KESM Q4 FY2026 (estimated filing September 2026) is the confirmation quarter. If Q4 revenue holds at RM53 million or above, full-year FY2026 KESM revenue clears the RM215 million threshold. If PATMI holds near Q3’s quarterly rate, full-year attributable net profit will land around RM8 million, double the RM4 million minimum. The Q4 filing will also resolve whether a final dividend is declared for FY2026: any step-up above the 6 sen interim total would be the first dividend increase since FY2024.

Sunright FY2026 full-year results (estimated September–October 2026) will provide the consolidated picture: Sunright Singapore equipment revenue, intercompany management fees, and the attributable share of KESM’s full-year performance on one statement. That is the filing where the bull case (group revenue above S$90 million, attributable net profit above S$5 million) either clears or doesn’t.

Bottom line

KESM Q3 FY2026 is an operationally clean result: profitable through nine months, AI demand explicitly confirmed in primary filing language, capex tripled with capacity commitments signalling confidence in forward volume, and all five thesis breakers untriggered. S71 at S$0.755 offers the same structural optionality as the initiation, with the SGX/Bursa multiple gap intact and the net cash floor at S$0.55/share, at a meaningfully lower premium. The sequential Q3 dip was non-operating; the operating business is holding. The Q4 KESM result in September is the next binary.

Data integrity notes

Sunright’s latest published filing is the 1HFY2026 Condensed Interim Financial Statements (31 January 2026). The attributable NAV/share of S$0.588 used in the valuation table reflects that filing. KESM book value is updated to the Q3 FY2026 figure (30 April 2026). There is a one-quarter timing mismatch between the two book values; it is immaterial to the analysis.

FY2025 full-year KESM capex (RM16.0 million) is sourced from the KESM FY2025 Annual Report cash flow statement.

MYR/SGD conversion at 0.323 throughout, consistent with the published initiation. Exchange rate fluctuations affect the look-through valuation arithmetic; this rate has been stable in the RM3.09–3.10/S$1 range in the period since publication.

References

[1] KESM Industries Berhad, “Unaudited Third Quarterly Report on Consolidated Results for the Financial Quarter Ended 30 April 2026”, Bursa Malaysia filing, 28 May 2026.

[2] KESM Industries Berhad, “Unaudited Second Quarterly Report on Consolidated Results for the Financial Quarter Ended 31 January 2026”, Bursa Malaysia filing, 10 March 2026.

[3] Sunright Limited, “Condensed Interim Financial Statements and Dividend Announcement for the Half-Year Ended 31 January 2026”, SGX filing, 13 March 2026.

[4] Sunright (S71.SI) and KESM Industries Berhad (9334.KL), share price and market data via Yahoo Finance, retrieved 30 May 2026. https://finance.yahoo.com/quote/S71.SI / https://finance.yahoo.com/quote/9334.KL

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore, nor a licensed adviser under the Capital Markets and Services Act 2007 of Malaysia. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author holds no position in the securities discussed and has not traded in them in the 30 days prior to publication, unless otherwise stated. This publication has received no compensation from any company discussed, or any related party.

On 25 September 2025, a small Singapore-listed dormitory operator did something unusual. It took fourteen of its best-stabilised assets, dropped them into a newly constituted real estate investment trust, and listed that trust on the same exchange where the parent had been trading for two decades. Centurion Accommodation REIT (SGX:8C8U) began trading at S$0.88 a unit. Centurion Corporation Limited (SGX:OU8), the sponsor, retained 42.9% of the new trust, kept full ownership of the trust's manager, and pocketed approximately S$520 million in cash for the assets it had handed over.

Eight months later, the trust is up. The sponsor’s share price is up. Both are up less than they should be if the market understood what just happened.

The easy version of this story is that Centurion’s share price has rallied from S$0.96 at the start of 2025 to S$1.46 at the 16 May 2026 close, a 52% move, and that the rally exhausted the mispricing. We disagree. The rally was the market crediting Centurion for executing the listing. It was not the market repricing what the listing structurally created: a Singapore-listed dormitory operator that now earns three streams of recurring income from one corporate vehicle, owns a directly-held bed count larger than the trust it sponsors, and still trades at 1.0x book and 11x trailing earnings, as if none of that had happened.

The rally was also not a smooth march upward. The market’s initial reading of the CAREIT IPO was bearish for the sponsor: OU8 drifted from S$1.50 in late September 2025 to roughly S$1.34 by late October 2025, even as CAREIT itself rose 16% from its S$0.88 issue price to S$1.02 in its first week of trading. The bear interpretation was straightforward — the best-occupancy assets had been carved out into CAREIT (the Initial Portfolio’s Singapore PBWA assets ran at 99.2% occupancy in FY2024 versus 94.0% for the broader sponsor group), leaving Centurion holding the residual lower-occupancy and ramping properties. Two things contradicted that read. Joint Chairman Han Seng Juan personally bought 300,000 OU8 shares at an average S$1.46 across 29 and 30 September 2025 — the family was buying, in size, into the drawdown. And the operating results since have vindicated the buyers: CAREIT beat its IPO forecast on every metric in its first reporting period, and Centurion’s own 1Q 2026 revenue rose 30% year on year. The asset-quality-dilution fear did not show up in the numbers. The recovery to S$1.46 since is partial credit for what the listing structurally created — but only partial.

We ran the look-through arithmetic on Centurion at the 16 May 2026 closing price of S$1.46. The sum of its three pillars, the directly-held portfolio of c.53,000 beds, the asset-management business running CAREIT, and the 42.9% unitholding in CAREIT itself, produces a fair value materially above the market price. The full numerical verdict, the segment-by-segment fair-value build, the forward earnings model, and the probability-weighted implied value are the subject of a companion institutional-length analysis published separately. Link below.

From one dormitory to three continents

Centurion as we know it today began in 2011, when a small Singapore-listed media-and-optical-storage company called SM Summit Holdings was reverse-acquired by Centurion Properties, a private vehicle controlled by two maternal cousins, Loh Kim Kang David and Han Seng Juan. Loh and Han had built their wealth in Singapore stockbroking, both spending years at UOB Kay Hian, both with stints at Hong Kong subsidiaries. The reverse takeover gave them a listed shell. What they put into it was a single purpose-built worker dormitory in Toh Guan, Singapore, with 5,300 beds.

Fifteen years later, the portfolio is materially larger. As at 30 June 2025, before the CAREIT spin-off, the Centurion sponsor group held 70,291 beds across 37 operating purpose-built accommodation assets, comprising 65,390 beds of purpose-built worker accommodation, 4,501 beds of purpose-built student accommodation, and 400 build-to-rent apartments. By 31 March 2026, after the CAREIT spin-off and a subsequent quarter of portfolio activity, Centurion’s directly-owned operating portfolio stood at 24 assets with c.52,993 beds per the 1Q 2026 Business Update (5 Singapore PBWA, 13 Malaysia PBWA, 1 Hong Kong PBWA, 2 Hong Kong PBSA, 1 Australia PBSA, 1 UK PBSA, and 1 Xiamen BTR), complemented by 16 managed assets with c.28,395 beds (CAREIT’s 15 plus Castle Gate Haus in the Centurion Student Accommodation Fund). The geographic spread went from Singapore-only to Singapore, Malaysia, Australia, the United Kingdom, Hong Kong SAR, and China.

A note on jargon before we continue. Centurion operates in two distinct accommodation segments and we will use the industry shorthand throughout: PBWA stands for purpose-built worker accommodation, the formal name for the licensed dormitories that house migrant construction, marine, and industrial workers (in Singapore, in Malaysia, and now in Western Australia for resource-sector workers). PBSA stands for purpose-built student accommodation, the formal name for the private-sector student housing typically located near universities (in Centurion's case, the United Kingdom, Australia, and Hong Kong). The third segment, build-to-rent (BTR) apartments, is a smaller category covering longer-stay rental housing for working professionals (Centurion's Xiamen property).

The inflection points were structural. In 2014, Centurion entered the United Kingdom PBSA market through the Dwell Student Living brand. In 2017, it added US student housing through a private fund structure. In 2020, the COVID-19 pandemic and the well-publicised migrant-worker dormitory outbreak forced a wholesale reset of Singapore's PBWA regulatory framework: the Foreign Employee Dormitories Act licensing regime, the Improved Dormitory Standards, and ultimately the New Dormitory Standards that will apply to all Singapore PBWAs by 2040. Centurion responded by buying or building NDS-compliant capacity early. Westlite Ubi became operational in December 2024 as the first fully NDS-compliant Centurion dormitory in Singapore. New blocks at Westlite Toh Guan (1,764 beds) and Westlite Mandai (3,696 beds) obtained their temporary occupation permits in October 2025 and January 2026 respectively.

Then in 2025, the largest single move. On 7 January 2025, the company announced it was exploring the establishment of a REIT. Listing application went in by July. Cornerstone book closed with sixteen institutional investors. The IPO was oversubscribed by 30 times on the public tranche and 16 times overall. CAREIT began trading on 25 September 2025 at S$0.88 a unit, with Centurion as sponsor and Centurion Asset Management Pte Ltd, a wholly-owned subsidiary, as manager. Fourteen assets were spun in: five Singapore PBWAs, eight United Kingdom PBSAs in the Dwell portfolio, and one Australian PBSA. The forward purchase of EPIISOD Macquarie Park in Sydney completed in January 2026 for A$345 million, taking CAREIT's portfolio to 15 assets and c.28,266 operational beds at 31 March 2026 per the 1Q 2026 Business Update (or c.30,246 including the 1,980-bed Mandai Expanded Capacity retained until 31 December 2030 pending FEDA license).

What remained at Centurion is the larger portfolio — 24 directly-held operating assets totalling 52,993 beds at 31 March 2026, spanning six markets:

• Singapore PBWA — 5 assets, 15,156 beds (ASPRI-Westlite Papan plus four Westlite Quick-Build Dormitories)

• Malaysia PBWA — 13 assets, 36,006 beds (eight long-standing Westlite properties plus five Harum Megah-rebranded assets acquired September 2025)

• Hong Kong — 3 assets, 653 beds (Westlite Sheung Shui PBWA; Dwell Prince Edward and Dwell Ho Man Tin PBSAs)

• Australia PBSA — 1 asset, 597 beds (Dwell Village Melbourne City)

• United Kingdom PBSA — 1 asset, 181 beds (Dwell Garth Heads, Newcastle)

• China BTR — 1 asset, 400 apartments (Centurion-Cityhome Gaolin, Xiamen)

Two Australian Key Worker Accommodation assets added in April 2026 (Karratha and South Hedland, 446 beds combined) take the post-1Q snapshot to c.26 assets and c.53,439 beds. The US PBSA assets were disposed in March 2026, completing Centurion’s exit from the United States. A c.7,000-bed PBWA development at Nusajaya, Iskandar, Johor is under exploration with NS Corp and is not yet operational. Westlite Toh Guan and Westlite Mandai sit inside CAREIT and are addressed under Pillar 3 below.

The shape of the business changed. Pre-September 2025, Centurion was an operator. Post-September 2025, Centurion is an operator, an asset manager, a property manager, and the largest unitholder in a separately-listed REIT. The strategy that took fifteen years to build did not change in 2025. What changed is the form in which it monetises.

What Centurion actually is now

The consolidated financial statements obscure the structure, and the structure is the point.

Centurion Corporation owns three things operationally. The first is the 24-asset directly-owned portfolio described above, totalling c.52,993 beds at 31 March 2026 (c.26 / c.53,439 including the April 2026 Australian additions), generating operating revenue from per-bed rentals. The second is the asset-management business, comprising Centurion Asset Management Pte Ltd (100% owned, manager of CAREIT) and the property management companies (100% owned, contracted property managers for CAREIT and increasingly for third-party owners). The third is a 42.9% unitholding in CAREIT itself, the SGX-listed REIT that Centurion sponsored.

The market’s mental model of Centurion is often that “CAREIT is the main business now; OU8 is the leftover holding company.” The bed-count picture is precisely the opposite. Of the c.81,388 operational beds in Centurion’s universe at 31 March 2026, 52,993 (65%) are directly owned and operated by Centurion, 28,266 (35%) are held in CAREIT (and Centurion owns 42.9% of those, equivalent to c.12,124 beds on a look-through basis), and 129 (<1%) sit in CSAF (Castle Gate Haus, Newcastle). A further c.3,548 beds across Singapore are under third-party property management agreements. CAREIT is the high-quality, stabilised, externally-financed slice. Centurion is the larger, broader, more diversified, and faster-growing whole.

These three pieces generate three flavours of income. The directly-owned portfolio produces operating profit. The asset-management business produces recurring fee income (base manager fee, performance fee, acquisition and divestment fees, property manager fees). The CAREIT unitholding produces investment income (Centurion’s 42.9% pro-rata share of CAREIT’s distributions). All three flow through Centurion’s consolidated income statement. But here is where it gets technical: CAREIT itself is consolidated into Centurion’s accounts, not just equity-accounted, because Centurion controls CAREIT through its 100% ownership of the manager. So 100% of CAREIT’s revenue appears on Centurion’s revenue line, 57.1% of CAREIT’s profit gets stripped out at the non-controlling interest line, and what remains at the bottom is Centurion’s economic share.

The non-controlling interest line on Centurion's balance sheet tells the story. At end-FY2024, NCI was S$82.9 million. At end-FY2025, three months after the CAREIT listing, NCI was S$939.7 million. That is a more than tenfold jump in a single year, reflecting the 57.1% of CAREIT's net assets attributable to non-Centurion unitholders that now sits inside Centurion's consolidated balance sheet.

Centurion's reported FY2025 revenue rose 17% to S$295.9 million. FY2026 is set to land materially higher, driven by five incremental items: Westlite Mandai's transition from equity-accounted associate to fully consolidated via CAREIT (the largest single contributor); the new Mandai block running for a full year; EPIISOD Macquarie Park's master-lease income for a full year; the Harum Megah Malaysian portfolio's first full year; and the two Australian Key Worker Accommodation assets for a partial year — offset by the US PBSA disposal. Putting these together, FY2026 consolidated revenue should land between approximately S$355 million and S$390 million (+20% to +32% YoY). The 1Q 2026 print of S$89.4 million annualises to about S$358 million, the lower end of this range before EPIISOD and the April 2026 Australian additions ramp into the full-year run-rate. The market sees the +17% FY2025 print and reads it as the steady-state run-rate; the FY2026 print is set up to land considerably higher.

A casual reader of the FY2025 press release sees revenue +17%, net profit -63%, EPS -67%, and concludes Centurion is in trouble. The actual story is that the FY2024 IFRS net profit was inflated by a S$219 million fair value gain on the Singapore PBWA portfolio that did not recur, while core profit (excluding fair value movements and one-off transaction costs) grew 9% from S$99.3 million to S$108.6 million. But the reader has to know to look at core profit, not IFRS profit, and most readers don't.

Three markets, three cycles

Centurion operates in three distinct industries that share one structural feature: each is undersupplied in professionally managed, regulation-compliant accommodation for a specific resident profile that has limited substitutes.

Singapore PBWA hosts approximately 460,300 work permit holders in the Construction, Marine Shipyard and Process industries as at June 2025, all of whom require licensed dormitory accommodation under the Foreign Employee Dormitories Act (figure varies with the construction cycle) [9]. After the 2020 dormitory outbreak, the Ministry of Manpower introduced new standards: Improved Dormitory Standards (IDS) as an interim measure, and New Dormitory Standards (NDS) as the long-run requirement. The Dormitory Transition Scheme (DTS), articulated in MOM’s 17 January 2026 press release [1], requires approximately 900 existing migrant worker dormitories housing roughly 200,000 workers to transition to IDS by 2030, with NDS by 2040 for early adopters. Crucially, dormitories that convert from 16 residents per room to 12 reduce their licensed bed capacity by 25% for the same building, so industry-wide bed capacity contracts during the 2026–2030 transition. Operators who cannot or will not retrofit lose their licences.

Centurion's positioning here is its single strongest competitive feature. The largest NDS-compliant PBWA capacity in Singapore — Westlite Ubi, Westlite Toh Guan with its new block, Westlite Mandai with its Expanded Capacity, Westlite Woodlands and Westlite Juniper — sits inside CAREIT, with the four Westlite Quick-Build Dormitories adding directly-owned NDS-compliant capacity at Centurion. The moat is the recycling platform rather than the legal-entity location of any individual building: Centurion develops the NDS-compliant pipeline, drops the stabilised asset into CAREIT, retains the manager fee on it for the life of the REIT, and recycles the proceeds. While competitors are losing licensed capacity, the Centurion–CAREIT platform is adding compliant capacity at scale — the new Toh Guan block contributed c.1,764 beds in October 2025 and the new Mandai block c.3,696 beds in January 2026 at the CAREIT-owned properties. Approved retentions of legacy capacity at the same sites preserve operating revenue during the transition: 664 beds at Toh Guan until 31 December 2028, and 1,980 beds at Mandai until 31 December 2030. Demand is anchored by Singapore's construction cycle: the BCA forecasts total construction demand of S$47 billion to S$53 billion in 2026, declining slightly to S$39 billion to S$46 billion annually through 2027 to 2030 [2].

Malaysian PBWA is a different story. Malaysia hosts approximately 2.4 million documented foreign workers, and enforcement of Act 446 (the Employees’ Minimum Standards of Housing, Accommodations and Amenities Act 1990) has intensified through 2024, 2025 and into 2026, with a “comply-or-lose-licence” mandate for Centralised Labour Quarters now reportedly in effect particularly across Selangor and the Klang Valley [3]. The Multi-Tier Levy Mechanism was implemented 1 March 2026 [4]. The maximum accommodation rental cap was revised to RM150 per worker per month [5]. Centurion is the largest privately-owned PBWA operator in Malaysia by bed count, with capacity exceeding 20,000 beds. The September 2025 acquisition of Harum Megah added six operating dormitories in Johor, expanding Malaysian capacity by approximately 25% in a single transaction.

Global PBSA, primarily UK and Australia, is undersupplied at the structural level. Australia hosts approximately 1.6 million enrolled university students against a total PBSA bed count of only approximately 90,000 beds. The Student Accommodation Council estimates that 84,000 new PBSA beds are needed by 2026, but only 7,700 are in the pipeline [6]. CAREIT’s acquisition of EPIISOD Macquarie Park at A$345 million for 732 beds (A$471,000 per bed) reset Australian PBSA pricing expectations and drew Singaporean REIT and European pension capital into the segment [7]. Centurion’s directly-held Australian pipeline includes c.644-bed EPIISOD North Melbourne (1H 2027), c.472-bed Perth (4Q 2027), and c.675-bed Mackenzie Melbourne. The UK is the most cautious market: Unite Group, the UK’s dominant pure-play PBSA REIT, trades at approximately 51% discount to NTA per share and has guided 2026 EPS down 12.6% versus 2025 [8]. Centurion’s UK assets have so far outperformed (98% occupancy FY2025), but the CAREIT prospectus already factors in mid-single-digit UK revenue decline in FY2026.

What cannot be copied

Centurion’s competitive position rests on four sources of durable advantage.

First, regulatory positioning in Singapore. Singapore’s PBWA market is licensed under the Foreign Employee Dormitories Act. New PBWA capacity requires a licence granted on a per-site basis after compliance with the New Dormitory Standards. NDS compliance is expensive: higher floor area per resident, larger common facilities, more demanding fire safety and infection control infrastructure. New entrants face a structural cost disadvantage relative to operators who have already amortised the compliance cost across a portfolio. Centurion controls the largest NDS-compliant PBWA portfolio in Singapore as at 1Q 2026 — most of it inside CAREIT, where Centurion is the manager and the 42.9% unitholder, with the four Westlite Quick-Build Dormitories adding directly-owned NDS-compliant capacity at Centurion.

Second, sticky corporate customer relationships. The PBWA customer in Singapore is not the individual worker but the employer. Major construction companies, marine contractors, and shipbuilders contract with dormitory operators for multi-year leases covering thousands of workers. Switching costs are real: a contractor moving its workforce between dormitories incurs operational disruption, transport logistics changes, and contract renegotiation. Centurion’s customer base of more than two decades includes most of the major Singapore construction names. CAREIT CEO Tony Bin disclosed in November 2025 [14] that renewal rates run above 85% on the Singapore PBWA portfolio, with roughly 60% of residents staying for more than five years.

Third, brand verticalisation in PBSA. The new EPIISOD premium PBSA brand, launched July 2025, complements the existing mainstream Dwell Student Living brand. The first EPIISOD property, EPIISOD Macquarie Park in Sydney (732 beds), commenced operations in January 2026. Two brands at two price points captures the full spectrum of student demand, whereas a single-brand operator captures only one segment.

Fourth, the sponsor-REIT capital recycling mechanism. The CAREIT structure gives Centurion a permanent capital recycling mechanism that did not exist before September 2025. Centurion develops or acquires an asset on its own balance sheet, stabilises operating performance over one to three years, then offers the stabilised asset to CAREIT under the right-of-first-refusal agreement. CAREIT pays Centurion a market-clearing price, generating revaluation gain on the way out, and Centurion redeploys the proceeds into the next development. The arithmetic only works if CAREIT trades at or above 1.0x P/B (currently 1.25x), if CAREIT has capital access (clean balance sheet post-IPO), and if the asset stabilises within Centurion's tolerance. All three conditions are intact as at May 2026. The model is the moat because no other Singapore-listed PBWA operator has built one.

The financial scoreboard

The six-year picture for Centurion, drawn from the published 5-Year Summaries in the FY2023 and FY2025 Annual Reports.

Three patterns are worth surfacing.

Revenue compounded at 18.2% per annum from FY20 to FY25. Top-line growth is the cleanest signal in the scoreboard because it is unaffected by fair value movements, deferred tax, or any of the items that distort net profit. 1Q 2026 revenue was up 30% YoY at S$89.4 million, which annualises to a FY2026 run-rate of approximately S$370 million before any additional capacity adds. Full-year FY2026 reported revenue should print materially higher, driven by full-year CAREIT consolidation versus three-month FY2025 consolidation.

Core profit attributable to shareholders compounded at 21.4% per annum from FY20 to FY25. The core profit measure adjusts for fair value movements and one-off transactions including the S$12.5 million of CAREIT listing costs in FY2025. Even after stripping out the FY2024 fair value gain of S$219 million that inflated reported IFRS profit, core profit continues to compound. Core EPS grew 9% YoY in FY2025 despite the asset spin-off.

Attributable NAV per share has more than doubled in five years. From 72 cents at end-FY2020 to 146.6 cents at end-FY2025, Centurion’s per-share equity has roughly doubled, supported by retained earnings and the FY2024 revaluation uplift on the Singapore PBWA portfolio. At the 16 May 2026 share price of S$1.46, Centurion trades at 0.996x book, basically at NAV.

Three pillars, priced as one

Here is the central tension. The market is pricing Centurion at 1.0x book and 11x trailing earnings. Those are operator multiples. They make sense for a single-pillar dormitory operator.

But Centurion is no longer a single-pillar operator. It is three things at once.

Pillar one is the directly-held portfolio: 24 operating assets, c.52,993 beds across six markets at 31 March 2026, generating operating revenue from per-bed rentals. This is the legacy operator business, just with more geographic diversity and a younger asset profile after the FY2024–FY2025 capacity adds.

Pillar two is the asset-management business. Centurion Asset Management Pte Ltd, wholly-owned, earns fees from CAREIT under the Trust Deed. The fee economics are detailed in the CAREIT prospectus: a base manager fee, a performance fee tied to DPU growth versus prospectus-projected DPU, acquisition and divestment fees, and property manager fees on each asset. The property managers, also Centurion-owned, additionally earn 2% of gross revenue plus 5% of NPI on each PBWA asset, and 4% of gross revenue on each PBSA asset. The same management platform additionally manages two private funds and, more recently, third-party PBWA properties for which Centurion bears no balance sheet capital. We have run the FY2026 fee math against CAREIT’s projected distributable income and built an estimate of the business’s annual fee revenue and operating profit. We do not run those numbers in this article; the multiple applied to value it is treated in a separate write-up.

Pillar three is the unitholding. As at 31 December 2025, Centurion held approximately 42.9% of CAREIT’s 1.722 billion units, equivalent to 738.6 million units worth S$805 million at the 16 May 2026 closing CAREIT price of S$1.09. After the proposed Dividend in Specie of 84.1 million units to Centurion shareholders (1 CAREIT unit per 10 OU8 shares), Centurion will hold approximately 38% of CAREIT. The CAREIT distribution income flowing to Centurion at the 42.9% stake against FY2026 projected distributable income gives an annual income figure of approximately S$48.8 million; post-Dividend in Specie this drops to approximately S$43.2 million. We have built a forward earnings model for CAREIT’s contribution to Centurion’s consolidated economics; the precise figures are not detailed here. The early operating evidence is encouraging: CAREIT’s first standalone reporting period (25 September to 31 December 2025) beat the prospectus forecast on every metric — DPU 1.739 cents versus forecast 1.630 cents (+6.7%), PBWA occupancy 97.6% versus forecast 95.8%, PBSA occupancy 99.1% versus forecast 97.3%, and aggregate leverage and financing costs better than forecast.

Adding the three pillars at market-observable values and applying credible multiples produces a per-share fair value materially above the 16 May 2026 close of S$1.46. The exact figure, and the segment-by-segment build that produces it, is not run in this article. What we will say here is that across the central case, the conservative case, and the optimistic case, the implied valuation lands above the current market price by a margin large enough to be worth understanding.

Why the market hasn’t priced this yet

Three explanations, in descending order of analytical weight.

The first is technical. The consolidated financial statements obscure the structure. A casual reader of Centurion’s FY2025 press release sees revenue +17%, net profit -63%, EPS -67%, and concludes Centurion is in earnings decline. The actual story is the opposite (one-time fair value gain in FY2024 distorted the prior year; underlying core earnings grew 9%) but the reader does not pause to do the adjustment. The CAREIT consolidation amplifies this by introducing NCI swings that further confuse non-specialist readers. The accounting is correct under SFRS(I) 10; the analytical inference from the reported numbers, without adjustment, is misleading.

The second is structural. Singapore institutional capital is concentrated in REITs as such, not in REIT sponsors. CapitaLand Investment is the exception, with the scale, brand, and S$125 billion AUM to attract institutional flows in its own right. Mid-cap REIT sponsors below CapitaLand Investment do not have a clean comp set on SGX; investors who like sponsor economics tend to buy the underlying REITs. CAREIT itself trades at 1.25x P/B and roughly 6% yield, attracting yield-seeking capital. The same investors do not necessarily buy OU8 alongside.

The third is governance. The cousin-controlled Loh-Han structure is unusual on SGX. Family-controlled mid-caps often trade at small but persistent discounts to non-family-controlled comparables of similar quality. The discount reflects governance risk pricing, a structural factor rather than evidence of any specific incident. The single material governance risk we monitor is the structural exposure to related-party transactions between Centurion family vehicles and the listed entities, which is the central risk we hold visible to readers of this article. The additional flip triggers tied to CAREIT unit price, Singapore occupancy levels, lock-up expiry dynamics, and ROFR cliff thresholds are not enumerated here.

The gap will close progressively, not immediately. The catalysts are CAREIT establishing a DPU track record supporting the manager fee economics, Centurion's directly-held pipeline (Australian PBSA, Malaysian Iskandar 7,000-bed development) demonstrating execution, any future drop-down transactions confirming the recycling model, and the analyst community modelling Centurion as a sponsor rather than a pure operator. By end-FY2026, with one full year of CAREIT operating performance and the projected DPU run-rate demonstrated, the market should be in a position to model the look-through more confidently.

The bottom line

Centurion at the 16 May 2026 close of S$1.46 prices a single-pillar dormitory operator. The September 2025 CAREIT IPO turned it into a three-pillar platform. The dormitory operator alone, valued on operator multiples, is worth roughly where it trades. The same business, framed as the operator-plus-manager-plus-unitholder it actually now is, is worth materially more. The transition from one frame to the other is where the analytical crux lies.

The full quantitative verdict, the forward earnings model, the look-through sum-of-the-parts, the scenario-weighted implied value, and the complete flip-trigger register are published in our institutional-length analysis. Link below.

Notes on the data

Three items material to readers of this article.

1. The detailed valuation arithmetic is treated separately. This article makes the case for the business and the structural argument. The segment-by-segment forward earnings model, the look-through sum-of-the-parts valuation across bull-base-bear scenarios, the probability-weighted implied value, and the complete flip-trigger register are written up in a separate piece.

2. Direct operating portfolio fair value is triangulated, not disclosed. Centurion’s consolidated financial statements present investment properties at fair value in a single line item that combines Centurion-direct properties with CAREIT properties post-consolidation. The split is not separately disclosed; our valuation segment derives the breakdown by deduction from segment data and from CAREIT’s standalone disclosures.

3. DPS history for FY2020 to FY2022 is not aggregated in published 5-Year Summaries. Individual half-year and full-year dividend announcements exist on SGXNet for those years but were not aggregated for this article. Marked as “n/d” in the scoreboard.

4. Post-publication correction (2026-05-29/31) — Westlite Toh Guan and Westlite Mandai are CAREIT-owned; portfolio totals re-anchored to the 1Q 2026 Business Update; three further factual corrections (Centurion management feedback). Centurion management noted that Westlite Toh Guan and Westlite Mandai are owned by CAREIT, and that the new redevelopment blocks at each property sit within the respective assets and are therefore also CAREIT-owned. CAREIT’s IPO Initial Portfolio comprises five Singapore PBWAs — Westlite Toh Guan, Westlite Woodlands, Westlite Ubi, Westlite Mandai and Westlite Juniper. The new block at Toh Guan (1,764 beds, October 2025) and the new block at Mandai (3,696 beds, January 2026) sit at those CAREIT-owned properties. Several passages in this article counted the new blocks in Centurion’s directly-owned bed total; they belong in CAREIT instead.

   The initial correction restated the directly-held portfolio from “24 assets, c.53,107 beds” at publication to “c.22 assets, c.47,600 beds”. The principle was right; the arithmetic was not. The 53,107-bed figure had incorrectly included the new blocks (5,460 beds combined) on the Centurion side but had also omitted Westlite Tampoi (5,790 beds) and Westlite Senai II (3,700 beds) from the directly-held list, so the headline magnitude was approximately right by coincidence. The 13 May 2026 1Q 2026 Business Update resolved the composition cleanly: at 31 March 2026 the directly-held portfolio is 24 assets totalling 52,993 beds, comprising 5 Singapore PBWA, 13 Malaysian PBWA, 1 Hong Kong PBWA, 2 Hong Kong PBSAs, 1 Australia PBSA, 1 UK PBSA, and 1 Xiamen BTR. Including the April 2026 Australian Key Worker Accommodation additions, the post-1Q snapshot is c.26 assets and c.53,439 beds. CAREIT’s portfolio is correspondingly 15 assets and c.28,266 operational beds (or c.30,246 including the 1,980-bed Mandai Expanded Capacity retained until 31 December 2030 pending FEDA license).

   The numerical thesis does not change. With thanks to Centurion management for the correction and to the 1Q 2026 Business Update for the definitive numbers.

5. Post-publication correction (2026-05-29) — FY2026 revenue bridge and Malaysian revenue weighting (Centurion management feedback). Centurion management noted that the FY2026 revenue bridge in the original article — which attributed roughly +S$160 million of ‘mechanical lift’ to the difference between three months and twelve months of CAREIT consolidation — was wrong, because most of the CAREIT-bound assets had been on Centurion’s revenue line for the full FY2025 (either as direct subsidiaries, as a 51%-owned consolidated subsidiary in the case of Westlite Ubi (held through Centurion-Lian Beng (Ubi) Pte Ltd at 51% Centurion / 49% Lian Beng Group per the Final Prospectus), or as a master-lease arrangement in the case of Westlite Juniper). The genuinely incremental items in FY2026 are Westlite Mandai’s transition from 45% equity-accounted associate to fully consolidated via CAREIT (an accounting transition that lifts the gross revenue line by approximately S$12 to S$19 million as Mandai’s pre-new-block annual revenue enters the line for a full year for the first time, plus a further S$14 to S$20 million from the new Mandai block running for a full year — without proportionally lifting attributable earnings, because Centurion’s economic share of Mandai net income drops modestly from 45% to ~42.9%); the new Mandai block running for a full year; EPIISOD Macquarie Park’s master-lease income for a full year; the Harum Megah Malaysian portfolio’s first full year; and the new Australian Key Worker Accommodation assets, offset by the US PBSA disposal. The realistic FY2026 revenue range is S$355 million to S$390 million (+20% to +32% YoY), not the S$420 million to S$460 million range cited in the article. The Harum Megah contribution has been re-sized against the disclosed acquisition figures (six Johor PBWA properties, 7,197 beds, RM110.8 million purchase price), with the implied per-bed economics of roughly S$650 to S$800 of revenue per bed per year putting Harum Megah’s annualised revenue at approximately S$5 to S$6 million. Centurion management also clarified that Malaysian PBWA generates materially lower SGD revenue per bed than Singapore PBWA — operating margins and ROIC are comparable, but Malaysian rents in local terms are lower and the Ringgit translates at a lower rate — so the bed-count comparison between Centurion-direct and CAREIT understates the revenue-weighted asymmetry. The thesis (look-through implied value materially above the market price across central, conservative and optimistic cases) does not change, because the SOP build relies on Layer 1 property value, Layer 2 fee economics and Layer 3 CAREIT market value, not on the FY2026 revenue bridge. What changes is the size and pace of the FY2026 catalyst the article was pointing to. The full quantitative restatement is set out in the institutional-length version (data-integrity note 13). With thanks to Centurion management for the clarification.

References

[1] Ministry of Manpower, “Applications for Dormitory Transition Scheme grant to open from 1 Mar to 31 Aug to help existing dormitories meet improved standards”, MOM press release, 17 January 2026. https://www.mom.gov.sg/newsroom/press-releases/2026/0117-dts-grant

[2] Centurion Corporation Limited, “Centurion Reports 30% Revenue Growth to S$89.4 Million in 1Q 2026”, SGX filing, 13 May 2026.

[3] UU.com.my, “Act 446 Malaysia Compliance Guide for Employer”, 2026. https://www.uu.com.my/act-446-malaysia-compliance-guide/

[4] Free Malaysia Today, “Multi-tier levy for foreign workers delayed to 2026”, 31 July 2025. https://www.freemalaysiatoday.com/category/nation/2025/07/31/multi-tier-levy-for-foreign-workers-delayed-to-2026

[5] Osadi Malaysia, “Malaysia Updates Act 446 Accommodation Rental Cap to RM150”, February 2026. https://osadi.com.my/malaysia-updates-act-446-accommodation-rental-cap-to-rm150/

[6] Australian Broker News, “Student housing surge in 2026 opens rich finance pipeline for Aussie brokers”, 2026. https://www.brokernews.com.au/news/breaking-news/student-housing-surge-in-2026-opens-rich-finance-pipeline-for-aussie-brokers-288866.aspx

[7] Cushman & Wakefield Australia, “Purpose-Built Student Accommodation in Australia”, December 2025. https://www.cushmanwakefield.com/en/australia/news/2025/12/purpose-built-student-accommodation-in-australia

[8] Motley Fool UK, “After tanking 46.5%, this FTSE 250 stock offers me an 8.1% dividend yield”, 3 May 2026. https://www.fool.co.uk/2026/05/03/after-tanking-46-5-this-ftse-250-stock-offers-me-an-8-1-dividend-yield/

[9] Centurion Corporation Limited, “Annual Report 2025: Evolving with Purpose”, SGX filing, 6 April 2026.

[10] Centurion Accommodation REIT, “Condensed Interim Financial Statements and Distribution Announcement for the Financial Period from 12 August 2025 (Date of Constitution) to 31 December 2025”, SGX filing, 23 February 2026.

[11] Centurion Accommodation REIT, “Prospectus dated 18 September 2025”, lodged with the Monetary Authority of Singapore.

[12] Centurion Corporation Limited (OU8.SI), share price and market data via Yahoo Finance, retrieved 16 May 2026. https://sg.finance.yahoo.com/quote/OU8.SI/

[13] Centurion Accommodation REIT (8C8U.SI), unit price and market data via Yahoo Finance, retrieved 16 May 2026. https://sg.finance.yahoo.com/quote/8C8U.SI/

[14] Julian Wong, “CAREIT CEO: The human touch behind Centurion’s living spaces”, The Edge Singapore, 14 November 2025. https://www.theedgesingapore.com/news/kopi-c-company-brew/careit-ceo-human-touch-behind-centurions-living-spaces

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author holds a long position in Centurion Corporation (SGX: OU8) as of the date of publication. This does not constitute a recommendation. This publication has received no compensation from Centurion Corporation or any related party.

On 25 September 2025, a small Singapore-listed dormitory operator did something unusual. It took fourteen of its best-stabilised assets, dropped them into a newly constituted real estate investment trust, and listed that trust on the same exchange where the parent had been trading for two decades. Centurion Accommodation REIT (SGX:8C8U) began trading at S$0.88 a unit. Centurion Corporation Limited (SGX:OU8), the sponsor, retained 42.9% of the new trust, kept full ownership of the trust’s manager, and pocketed approximately S$520 million in cash for the assets it had handed over.

Eight months later, the trust is up. The sponsor’s share price is up. Both are up less than they should be if the market understood what just happened.

The easy version of this story is wrong. The easy version is that Centurion’s share price has rallied from S$0.96 at the start of 2025 to S$1.46 at the 16 May 2026 close, a 52% move, and that the rally exhausted the mispricing. We disagree. The rally was the market crediting Centurion for executing the listing. The market has not yet credited Centurion for what the listing created: a Singapore-listed dormitory operator that now earns three streams of recurring income from one corporate vehicle, owns a directly-held bed count larger than the trust it sponsors, and trades at 1.0x book and 11x trailing earnings as if none of that had changed.

Read more

In October 2025, PropNex Limited (SGX:OYY) traded at S$2.63 [3]. On 19 May 2026 it closed at S$1.83 [3]. Seven months, a 30% drawdown, and the market has settled on a clean explanation. New private home launches in Singapore are guided down 17% in 2026. Project marketing commissions are PropNex’s largest revenue line. The market has done the obvious arithmetic, marked the stock down, and moved on.

That arithmetic is incomplete.

There are 13,500 Housing Development Board flats becoming eligible to be sold in 2026. They were bought five years ago at S$400,000 to S$600,000. Their current market value is 30% to 50% higher. The five-year minimum occupation period (the MOP, in Singapore property parlance) is the gate the government places between purchase and resale to deter speculation. When MOP releases, owners gain the legal right to monetise. Most do not sell immediately. But a meaningful share do, and most of those buy something else. The transaction is rarely a single sale; it is a chain. One household decision generates an HDB seller-side commission, a private buyer-side commission, and sometimes a rental commission while the private completes. Up to three fees from a single MOP exit.

This year’s MOP cohort is 69% larger than last year’s. That number, 13,500 versus 8,000 in 2025, is not a forecast. It is a mechanical consequence of when those flats were completed, which was the 2020 to 2021 COVID-era construction acceleration. It cannot be revised away.

PropNex earns from six segments. New launches were 39% of FY2025 revenue. The other 61% — private resale, HDB resale, rental, landed, and commercial — feeds directly off the MOP-driven upgrader chain. The market is pattern-matching to “launches down equals PropNex down” without doing the segment-level arithmetic.

This article makes the case for the franchise: what PropNex is, why it compounds, and why the market’s peak-cycle read deserves scrutiny. It stops short of the verdict — the precise FY2026 earnings range, the valuation scenarios, and the complete risk register belong to the longer analysis here.

Twenty-six years from one-man shop to S$1.4bn franchise

PropNex was founded in November 2000 by Ismail Gafoor, who is today executive chairman. The first decade was unglamorous: PropNex was one of several mid-sized Singapore agencies competing against ERA, OrangeTee, HSR and others, none of them dominant. The inflection arrived in 2010 with the formation of the Council for Estate Agencies, which tightened licensing requirements for both agencies and individual salespersons. For a fragmented industry, this raised the cost of legitimacy. PropNex spent the following ten years building a training and compliance infrastructure that turned this cost into an entry barrier for new competitors.

The SGX listing on 2 July 2018 priced at S$0.535 per share pre-bonus. On a post-bonus-adjusted basis, the IPO price is approximately S$0.27. The listing gave PropNex a currency for incentive grants and forced disclosure that strengthened developer credibility. The May 2023 bonus issue (one-for-one, doubling the share count to 740 million) deepened liquidity. All per-share figures in this article are restated post-bonus.

The most consequential recent event was the 2023 succession from Ismail Gafoor to Kelvin Fong as chief executive officer. Fong had spent his career at PropNex and rose internally from agency leader to deputy CEO to CEO. Gafoor moved to executive chairman with responsibility for strategy and capital allocation. This was a structured handover from a founder to an internal successor; not a reactive external hire. The founder remains in the building, the agency leadership layer remains intact, and the firm’s operating model was not disturbed.

The compound since IPO is steady rather than explosive. The 2018 IPO price of S$0.27 (post-bonus adjusted) versus today’s S$1.83 [3] represents roughly a 28% CAGR over 7.9 years, before the dividends paid along the way. Most of this return is franchise growth, not multiple re-rating.

What you actually own at S$1.83

PropNex is not a property company in any conventional sense. It does not own development sites. It does not carry inventory. It has S$1.6 million of fixed assets against S$1,116 million of FY2025 revenue. The economic engine is an asset-light intermediary at scale. PropNex’s licensed estate agency contracts with 14,333 self-employed salespersons [6], who pay PropNex a share of every commission they earn. PropNex’s share averages 12% to 14% across all transactions. There is no salary line for the salesforce because there are no salaries.

What this means in practice: when you buy a share of PropNex, you are not buying a slice of property or a slice of inventory. You are buying a slice of a business that takes a small cut of every property transaction one of its agents closes. The more agents the company has, and the more property changes hands in Singapore, the more cuts get taken. The capital required to add the next agent is essentially zero. This is the rare combination that makes an asset-light intermediary worth a meaningful premium to book value when it has scale, and worth very little when it does not. PropNex is at the scale end.

The six-segment FY2025 revenue mix matters because the cycle thesis turns on it.

Project Marketing was S$434 million (39%), Private Resale S$234 million (21%), Rental S$191 million (17%), HDB Resale S$153 million (14%), Landed Resale S$62 million (5%), and Commercial and Industrial S$34 million (3%). The market is anchored on Project Marketing because new launches are guided down 17% in 2026. The other 61% of revenue is where the upgrader chain operates.

International operations (Indonesia, Malaysia, Vietnam, Cambodia, Australia) are immaterial to the investment case. PropNex is functionally a pure Singapore residential agency.

Why the largest agency keeps getting larger

PropNex has 14,333 agents as at 12 May 2026 [6]. ERA Realty Network, the second-largest, has 8,891 [6]. Huttons has 5,760 [6]. OrangeTee has 3,163 [6]. PropNex is 1.6 times the size of its nearest competitor and the gap is widening, not narrowing. Total registered salespersons in Singapore are approximately 37,467, so PropNex employs nearly 38% of the industry [6].

The salesforce gap is the moat. A new agent surveying Singapore’s brokerage options sees PropNex’s project marketing pipeline (over half of FY2025 new launches were PropNex-marketed) as a steady inflow of inbound leads that flow to its own agents. New agents at PropNex earn more in their first eighteen months than at smaller agencies because they have lead access. This attracts more agents, which wins more project mandates, which generates more leads. It is a flywheel that has compounded for ten years.

There is also a relationship layer that is harder to see from outside. When a Singapore developer launches a new private project, they typically appoint two to four marketing agencies. PropNex sits on the list for the vast majority of major launches because the relationships have been built across many years and many launches. The developers know, from track record, that PropNex’s salesforce can clear 500 to 1,000 units in a launch weekend. PropNex has consistently been the lead or co-lead marketing agency at the largest private residential launches each year, including most of the major FY2025 and 1Q FY2026 launches. This is not a relationship you can buy with a marketing budget. It takes a decade.

ERA’s salesforce of 8,891 is broadly the same range as it was five years ago. The market is consolidating in PropNex’s favour, not against it.

The competitive battle is active — and PropNex is winning it on net. The Singapore agency industry is in a visibly active recruitment phase, and a fair read of the moat case has to acknowledge both sides. In March 2026, ERA’s CEO Marcus Chu launched the “ERA +1 initiative” — each ERA agent asked to recruit one newcomer this year — and ERA disclosed at the same event that 54% of its new agent joiners in 2025 came from PropNex; a former PropNex top earner (Rayne Chua) joined ERA in February 2026 with approximately 80 agents under her [16]. Two months later, PropNex announced the return of Adrian Lim, co-founder of PropertyLimBrothers, alongside 37 PLB salespersons — a homecoming for Lim, who had been a top-performing PropNex leader from 2010 to 2022 [17]. The net result: PropNex’s CEA-registered salesforce grew from 14,202 in February 2026 to 14,333 on 12 May 2026 [6], while ERA’s count declined from 8,828 (February 2025) to 8,427 (January 2026). The salesforce gap has widened, not narrowed. The competitive battle is real and active; PropNex is winning it on net.

PropNex’s overall market share across all segments was 62.5% in FY2023 (the most recent Frost & Sullivan number) [7] and has remained in a similar range through FY2025 per PropNex’s own business-slide commentary. By segment, PropNex held 65.8% of private resale, 64.7% of HDB resale, 49.7% of landed resale, 47.9% of new launches, and 35.9% of private leasing [7].

One framing point that protects the franchise: Singapore residential transactions are predominantly agent-mediated. By our analytical estimate, roughly 85% to 90% of HDB resale and 90% to 95% of private resale clear through a licensed estate agent rather than directly between owner and buyer. The structural reasons are genuinely Singapore-specific — HDB regulatory complexity (CPF disbursements, Ethnic Integration Policy quota checks, valuation procedures), the per-transaction stake at S$1.5m-plus median private prices, and active CEA professionalisation since 2010. The for-sale-by-owner channel exists but is small.

What that scale advantage looks like in dollars. ERA's listed parent is APAC Realty Limited (SGX:CLN), which filed its FY2025 results in February 2026 and provides a clean audited side-by-side. PropNex's revenue is 1.65× APAC Realty's (S$1,116m versus S$676m). PATMI is 3.42× (S$70m versus S$21m), because PropNex's larger scale spreads overhead across roughly twice the revenue base — net margin of 6.3% versus 3.0% [13]. The dividend comparison cuts two ways and is worth stating precisely. PropNex pays 9.50 cents per share against APAC Realty's 4.50 cents — a 2.11× gap in absolute per-share payout. But APAC Realty trades at roughly a third of PropNex's share price (S$0.555 versus S$1.83), so on a yield basis the smaller company is ahead: APAC Realty's trailing yield is about 7% to 8% against PropNex's 5.2%. The per-share figure measures payout scale; the yield measures income return. Gross margins are within ten basis points of each other (10.3% versus 10.4%), so the operating-margin divergence comes entirely from overhead intensity, not from commission economics. The agent-count gap is the input; the net-margin gap is the output.

The five-year scoreboard

Three observations from the table. Gross margin moves within a narrow band of about 150 basis points across the full cycle, between 9.1% in FY2024 and 10.6% in FY2021, because costs scale with revenue when commissions are the dominant line. The company did not lose money even at the FY2024 trough; it earned S$40.9 million of PATMI on S$783 million of revenue.

Second, the dividend has been a constant signal. The payout ratio has been 80% or higher for at least four of the last five years. FY2024 paid more than earned (140% payout including the special anniversary dividend) and FY2025 paid 99.9% of earnings. The dividend has not been cut through the trough years. PropNex’s track record across the FY2023 to FY2024 trough was to draw on cash to honour the headline DPS rather than cut it.

Third, the salesforce has grown every year. From 10,796 at end-2021 to 13,945 at end-2025 is a 6.6% CAGR. The acceleration in 2025, from 12,636 to 13,945 or a 10.4% rise, is notable. The 1.6x gap over ERA has widened, not compressed.

Returns on equity are headline-extraordinary at approximately 58% for FY2025. Return on equity is the profit produced by every dollar of book equity the company holds. PropNex’s number is high not because margins are wide (net margin is 6.3%) but because the equity base is small; the company distributes almost every dollar it earns as dividend, so nothing accumulates. This is the precise economic characteristic of an asset-light intermediary at scale: you can add a thousand agents next year without funding new capital.

One quiet structural tailwind worth noting before the cycle discussion. PropNex earns a percentage of transaction value across every segment. When Singapore property prices rise — and the Urban Redevelopment Authority’s Private Property Price Index has risen roughly 38% over the six years to end-2025, with the HDB Resale Price Index up a similar magnitude [4][5] — the absolute commission per transaction rises proportionally, even if volumes are flat. The franchise compounds even in flat-volume years.

The mispricing: where the market may be too bearish

This is the heart of the investment case. The market is pricing PropNex on the assumption that FY2026 earnings collapse the way FY2023 did, when project marketing led the cycle down. Run the numbers segment by segment and that assumption does not hold up, for three structural reasons.

First, the 4Q25 backlog. Singapore’s revenue recognition convention runs three to four months behind the option-to-purchase exercise. A meaningful share of the strong October to December 2025 launch sales lands in 1H26 results regardless of what FY2026 launch volumes do. The first half of 2026 is, in revenue terms, already partly written.

Second, the segment mix. Project marketing is 39% of revenue. The other 61% — private resale, rental, HDB resale, landed, commercial — is driven by volumes that management guides as flat to growing, not falling. A 17% decline in one segment that is 39% of the business is not a 17% decline in the business.

Third, the MOP wave. This is the structural event the market is under-weighting. The 13,500 HDB flats reaching their five-year minimum occupation period in 2026 are a mechanical supply event, 69% larger than the 2025 cohort. Not every MOP-eligible flat goes to market — the Ministry of National Development has published year-by-year cohort conversion data showing what share of each cohort actually transacts [10][11] — but a meaningful share does, and each one tends to generate a chain of commissions for PropNex across the HDB seller-side and the follow-on private purchase.

One clarification, because it matters: the 13,500 figure is the standard 5-year MOP cohort. The newer 10-year MOP regime, covering Prime Location Public Housing (introduced November 2021) and the Plus and Prime tiers (introduced under the August 2024 BTO framework reform), has not yet reached MOP and will not start clearing that gate until the mid-2030s [12]. The 2026 cohort is entirely standard 5-year MOP flats.

We ran the segment-level arithmetic through every revenue line: project marketing net of the 4Q25 backlog, the MOP wave modelled across three conversion-rate scenarios anchored to the MND’s published cohort data, and the resale, rental, landed and commercial segments built up individually. The result is a FY2026 earnings range that is materially higher than what the current share price implies. The gap between the two — between what the market is pricing and what the segment build produces — is where the value sits.

The full segment-by-segment build, every revenue line modelled, the MOP conversion scenarios laid out in a sensitivity table, the FY2026 revenue bridge, and the resulting PATMI range set against the market-implied number, is not laid out in this article. The full build is here.

What you pay at S$1.83

Two things in this table are worth unpacking for what they tell you about the downside.

P/Attributable NAV of 11.66x looks expensive, and it is the wrong multiple. P/Attributable NAV is the share price divided by the company’s book value per share. Book value is what is left over on the balance sheet after twenty-five years of distributing most earnings as dividends. For an asset-light intermediary like PropNex, the book value is a residual accounting number, not the economic value of the franchise. The salesforce of 14,333 agents, the project marketing relationships, the brand, the training infrastructure: none of these sit on the balance sheet. Comparing PropNex’s 11.66x P/NAV to a property developer’s P/NAV of around 1x is a category error. The right multiple for an intermediary is earnings-based.

Enterprise value over trailing PATMI is 17.2x, meaningfully lower than the 19.2x trailing P/E. The simple reason for the gap: PropNex sits on S$144 million of net cash, equivalent to S$0.20 per share or roughly 10% of the market capitalisation. When you back that cash out (which is what an acquirer would do), the multiple you are paying for the actual operating business drops from 19.2x to 17.2x. That cash is the margin of safety: it is idle on the balance sheet, available to fund the dividend through any cyclical trough, and not currently being used to generate earnings, so it represents real per-share value that the trailing P/E understates. The share price, market capitalisation, and the multiples derived from them are as at the 20 May 2026 close [3]; net cash, NAV, and DPS are from PropNex’s FY2025 audited results.

The yield, at least, is unambiguous. At the S$1.83 close [3] and an FY2025 DPS of 9.5 cents, the trailing yield is 5.2%. PropNex’s track record across the FY2023 to FY2024 trough was to pay out 92.9% then 140% of earnings, drawing on cash to honour the headline DPS. A scenario in which PropNex actually cuts the dividend would require a multi-year sustained earnings decline of 35% or more, which would also imply a broader Singapore residential market collapse that has not occurred in the recent two decades. The yield, in other words, is durable.

The risk that matters

Every investment case has a central risk, and PropNex’s is specific: a government cooling measure that targets the HDB resale-to-private upgrader chain.

Singapore’s government has actively managed the residential property cycle since the 1990s. The toolkit includes additional buyer’s stamp duty (ABSD), seller’s stamp duty, loan-to-value limits, and minimum occupation periods. The April 2023 ABSD package — which raised the rate on Singapore citizens’ second-property purchases from 17% to 20% and the foreigner rate from 30% to 60% — drove the FY2023 to FY2024 transaction trough that PropNex’s earnings reflect [14][15]. The MOP wave thesis turns on owners’ ability to sell their MOP-eligible flats and buy private property. A new measure that attacks that chain (a further ABSD increase on citizens’ second properties, or an extension of the HDB MOP period) would compress the thesis directly.

There is a reassuring data point here. In early May 2026, the government did act on the property market, but on executive condominiums specifically, doubling the EC minimum occupation period from five to ten years and scrapping the deferred payment scheme [8][9]. This package targets ECs, not HDB. The 13,500 HDB flats reaching MOP in 2026 are unaffected. More importantly, it signals that the government’s current preference is for surgical, single-segment intervention rather than blanket cooling, which is a positive signal for PropNex’s broader resale lines. It is not, however, an all-clear: the government has demonstrated it is in active intervention mode, and a follow-on HDB-targeted measure cannot be ruled out.

The bottom line

PropNex at S$1.83 is a high-quality Singapore residential agency franchise that the market has marked down on a peak-cycle read. The franchise case is not in dispute: a 14,333-agent salesforce that is 1.6 times its nearest competitor and still growing, 64% market share, asset-light economics that produce a ~58% return on equity, S$0.20 per share of net cash, and a dividend that has not been cut through the worst two years of the recent cycle. The competitive benchmarking against APAC Realty shows the scale advantage is real and compounding: same commission economics, double the net margin, roughly ten times the net cash.

The investment question is whether the market’s 30% drawdown correctly prices FY2026. The market is anchored on the 17% guided drop in new private home launches. The segment-level work (the 4Q25 recognition backlog, the segment mix where 61% of revenue is not new launches, and the 13,500-flat MOP wave) suggests the market may be pricing in a steeper decline than the franchise’s actual revenue structure warrants. The gap between the market-implied earnings and the segment-built earnings is the opportunity, if it is real.

This article has made the franchise case in full. What it leaves for the longer analysis is the quantification — the precise FY2026 earnings range, the forward valuation, the scenario-weighted price levels, and the complete four-trigger risk register — drawn from the same research base and the same figures, fully built out.

If the franchise case above has convinced you that PropNex is worth understanding properly, the institutional-length version is where the analysis is finished.

Data integrity notes

Correction (21 May 2026): An earlier version framed PropNex's higher per-share dividend (9.50 cents vs APAC Realty's 4.50 cents) as the number that matters "for a yield-oriented investor." That was misleading. Because APAC Realty trades at roughly a third of PropNex's share price, APAC Realty carries the higher dividend yield — about 7% to 8% on its FY2025 dividend, against PropNex's 5.2%. The dividend figures themselves were correct; the per-share gap measures payout scale, not income return. With thanks to the reader who flagged it.

All financial figures in this article are from PropNex’s SGX-filed press releases and audited financial statements FY2021 to FY2025 [1][2]. Industry agent counts are from the Council for Estate Agencies registry as cited in PropNex’s FY2025 business slides [6]. Market share figures are Frost & Sullivan FY2023 (the most recent comprehensive published baseline) [7] cross-referenced against PropNex’s own market-share disclosures in business slides. FY2026 guidance is PropNex’s own management guidance from the 27 February 2026 press release [1]. Share price and market data are from Yahoo Finance, retrieved 20 May 2026 [3]. APAC Realty comparison figures are from APAC Realty’s SGX-filed Condensed Interim Financial Statements 2H/FY2025 [13].

The MOP wave conversion analysis referenced in this article is anchored to the Ministry of National Development’s published parliamentary written answer covering HDB cohort conversion data for 2011 through 2020 [10][11]. The agent-mediated share estimates (85–95%) are our analytical inferences, not published statistics; Singapore does not publish a clean for-sale-by-owner share figure. Research notes from brokerage firms covering PropNex were read during the research process for context but are not cited in this article.

References

[1] PropNex Limited, “FY2025 Full Year Results Announcement”, SGX press release, 27 February 2026.

[2] PropNex Limited, “FY2025 Business Update Slides”, SGX filing, 27 February 2026.

[3] PropNex Limited (OYY.SI), share price and market data via Yahoo Finance, retrieved 20 May 2026. https://finance.yahoo.com/quote/OYY.SI/

[4] Urban Redevelopment Authority of Singapore, “Private Residential Property Price Index, 4Q2025”, quarterly release, January 2026. https://www.ura.gov.sg/Corporate/Media-Room/Media-Releases

[5] Housing Development Board, “HDB Resale Price Index, 1Q2026”, quarterly release, April 2026. https://www.hdb.gov.sg/about-us/news-and-publications/press-releases

[6] Council for Estate Agencies, “Registered Salespersons Statistics”, as at 20 February 2026. https://www.cea.gov.sg/aceas/public/svc101/

[7] Frost & Sullivan, “Singapore Real Estate Agency Industry Report — FY2023 Market Share Analysis”, commissioned by PropNex, 2024.

[8] Ministry of National Development of Singapore, statement on executive condominium scheme revisions (MOP extension from five to ten years, deferred-payment-scheme withdrawal, first-timer quota raised to 90%), early May 2026. https://www.mnd.gov.sg/newsroom

[9] Chong, Xin Wei, “New EC rules to cool prices: MOP doubled to curb flipping, no more deferred payments, and more units for first-timers”, The Business Times, May 2026. https://www.businesstimes.com.sg/property/new-ec-rules-cool-prices-mop-doubled-curb-flipping-no-more-deferred-payments-and-more-units-first

[10] Ministry of National Development of Singapore, “Written Answer on data on number of HDB flats eligible for resale and sold within one year, five years and ten years after five-year Minimum Occupation Period”, Parliamentary Q&A. https://www.mnd.gov.sg/newsroom/parliament-matters/q-as

[11] Ong, Ryan J., “13.4% Of BTO Flats Were Sold Within A Year Of MOP: What Does It Mean For Homebuyers?”, Stacked Homes, 22 September 2021. https://stackedhomes.com/editorial/13-4-of-bto-flats-were-sold-within-a-year-of-mop/

[12] Housing & Development Board, “Eligibility for Selling a Flat” — official policy page describing the MOP framework (5-year MOP for standard BTO flats; 10-year MOP for Prime Location Public Housing, Plus and Prime tiers). https://www.hdb.gov.sg/managing-my-home/selling-a-flat/eligibility

[13] APAC Realty Limited (SGX:CLN), “Condensed Interim Financial Statements for the six months and full year ended 31 December 2025”, SGX filing, February 2026 (FileID 875635). https://www.sgx.com/securities/company-announcements?value=APAC%20REALTY%20LIMITED&type=company

[14] Inland Revenue Authority of Singapore (IRAS), “Additional Buyer’s Stamp Duty (ABSD)” — historical rates schedule. https://www.iras.gov.sg/taxes/stamp-duty/for-property/buying-or-acquiring-property/additional-buyer’s-stamp-duty-(absd)

[15] Urban Redevelopment Authority of Singapore, quarterly residential transaction statistics — used to triangulate the historical transaction-volume response to ABSD tightening packages. https://www.ura.gov.sg/Corporate/Media-Room/Media-Releases

[16] Ho, Jovi, “ERA Singapore’s new initiative could double its salesforce this year”, The Edge Singapore, 24 March 2026. Source for the ERA +1 initiative announcement, Rayne Chua defection, and ERA salesforce counts. https://www.theedgesingapore.com/cityandcountry/property/era-singapores-new-initiative-could-double-its-salesforce-year

[17] PropNex Limited, “37 PropertyLimBrothers Salespersons, Including Co-Founder Adrian Lim, join PropNex”, press release, 13 May 2026. Source for the Adrian Lim/PLB return and the 14,333 CEA-registered salesforce figure as at 12 May 2026. https://www.propnex.com/news-details/12481/37-propertylimbrothers-salespersons-including-co-founder-adrian-lim-join-propnex

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

In October 2025, PropNex Limited (SGX:OYY) traded at S$2.63 [8]. On 19 May 2026 it closed at S$1.83 [8]. Seven months, a 30% drawdown, and the consensus has settled on a clean explanation. New private home launches in Singapore are guided down 17% in 2026. Project marketing commissions are PropNex’s biggest revenue line. The market has done the obvious arithmetic, marked the stock down to a cycle-trough multiple, and moved on.

That arithmetic is incomplete.

There are 13,500 Housing Development Board flats becoming eligible to be sold in 2026. They were bought five years ago at S$400,000 to S$600,000. Their current market value is 30% to 50% higher. The five-year minimum occupation period (the MOP, in Singapore property parlance) is the gate the government places between purchase and resale to deter speculation. When MOP releases, owners gain the legal right to monetise. Most do not sell immediately. But a meaningful share do, and most of those buy something else. The transaction is rarely a single sale; it is a chain. One household decision generates an HDB seller-side commission, a private buyer-side commission, and frequently a rental commission while the private completes. Up to three fee events from a single MOP exit.

This year’s MOP cohort is 69% larger than last year’s. That number — 13,500 versus 8,000 in 2025 — is not a forecast. It is a mechanical consequence of when those flats were completed, which was the 2020 to 2021 COVID-era construction acceleration. The cohort size is therefore set in advance and not subject to forward revision.

PropNex earns from six segments. New launches were 39% of revenue in FY2025. The other 61%, comprising private resale, HDB resale, rental, landed, and commercial, feeds directly off the MOP-driven upgrader chain. Inside the company’s own FY2026 guidance, four of these six segments are flat to up. The one segment that is guided down hard, new launches, is buffered for the first half of 2026 by a S$434 million order book of 4Q25 project marketing sales that has not yet been recognised. Singapore’s developer recognition convention runs three to four months behind option-to-purchase exercise. That revenue is already in the chute.

The stock is being priced as if FY2026 PATMI prints a sharp decline from FY2025’s record S$70.4 million. The supply data, the segment mix, and the recognition lag say something closer to flat. At S$1.83 the equity carries S$0.20 of net cash per share, a 5.2% trailing yield, and a 99.9% payout that survived FY2023’s earnings trough at 92.9%. The peak-cycle thesis assumes management cuts the dividend if earnings fall. The track record says they do not. The 14,333-agent salesforce [11], 1.6 times the size of the next competitor, is a scale advantage that is unlikely to be replicated quickly.

This is the question this long-form deep dive sets out to answer. Is PropNex Limited at S$1.83 a cyclical stock priced for the wrong cycle, or a permanent franchise priced at a fair discount to its peak? The arithmetic, run through every segment from new launches to commercial leasing, says the answer is mostly the former. But the margin of safety is narrower than the headlines suggest, and the flip triggers are sharp enough that this is not a position to take and forget.

Read more

The company behind those desks, though, has drawn far less scrutiny than the product it sells. On 22 May 2026, JustCo Holdings Limited lists on the SGX Mainboard, and the offer document gives us the first proper look at the numbers. The headline tension is visible from the first page. JustCo is raising S$100 million in gross proceeds. In its most recent financial year it earned a net profit of US$2.7 million. A raise of that size against a profit of that size implies the market is being asked to pay a very full price, and it invites the comparison every flexible-office IPO now has to answer: is this the next WeWork story, or something sturdier? We read the prospectus to find out.

From JustOffice to JustCo

JustCo began in 2011, not 2018. The 2018 date on the prospectus cover is when the current holding company was incorporated; the business is older. Founder Kong Wan Sing started it with two co-founders as “JustOffice”, a single 3,132 square foot space in Samsung Hub in the heart of the Singapore CBD. The bet was simple: office supply was tight, rents were rising, and the way companies wanted to use space was changing faster than traditional leases allowed.

Growth came in stages. Between 2017 and 2019, equity from Sansiri, GIC and Frasers Property turned a Singapore operator into a regional one, and JustCo expanded into Australia, Taiwan, Thailand, South Korea and Japan at a pace of roughly one new centre every three weeks. The pandemic was the first real test: occupancy fell to just above 60% at the worst of it. The company’s response is worth noting, because it is the opposite of the WeWork playbook. JustCo exited mainland China and Indonesia rather than defend every market. Today it operates 54 centres across 12 cities, with around 37,500 workstations, and it sells under three brands: The Collective at the luxury end, JustCo as the core premium product, and the boring office as an essentials line.

What the offer actually contains

The offer is 32,092,000 new shares at S$0.94 each, with a further 5,319,000 vendor shares available through an over-allotment option. Sitting alongside it is a much larger cornerstone tranche of 74,291,000 shares. Together the new shares raise S$100.0 million gross and S$92.2 million net to the company. After listing, JustCo will have 489,235,758 shares in issue, which at the offer price puts the market capitalisation just under S$460 million.

The register is heavily anchored. GIC holds 22.74% after listing, Frasers Property and the Charoen Sirivadhanabhakdi interests hold 17.63%, and founder Kong Wan Sing’s family vehicle holds 17.79%. The cornerstone investors, a group that includes JPMorgan Asset Management, Fullerton, Maybank Asset Management, Avanda and Amova, take another 15.19%. Hsieh Fu Hua, a familiar name in Singapore capital markets, chairs the board as lead independent director.

The money has a clear job. S$81.7 million of the gross proceeds is earmarked for expansion, fit-outs and capital expenditure, with S$56.8 million of that tied to 20 committed new centres. Another S$10.0 million is for working capital, and S$8.3 million covers the fees of the offering. In total, JustCo plans to open around 28 new centres in 2026.

A small float by design, not by accident

Notice what is missing from those numbers: any meaningful sale of existing shares. The 5.3 million over-allotment is just over 1% of the company, and it comes from the Kong family’s holding vehicle. GIC, Frasers, the Kong family and Pinetree are not using this listing to cash out. That leaves an unusually small free float of about 6.6%, rising to 7.6% if the over-allotment is fully taken up. A typical SGX Mainboard listing sells 15% to 25% of the company; JustCo sold the minimum needed to raise the capital it wanted, and not a share more.

Three things follow. The deal raised what was needed and no more, which is a capital-discipline signal in a market where IPOs are often sized to deliver an exit rather than to fund growth. The existing register is genuinely committed: GIC and Frasers came in between 2017 and 2019 and are choosing to mark their investment publicly rather than monetise it. And the tradable float will grow mechanically as lock-ups unwind. The standard SGX six-month moratorium releases the cornerstone tranche around the fourth quarter of 2026, taking effective float past 21%, with the controlling-shareholder shares coming off lock-up at twelve months. The post-listing share price in those early months will therefore partly reflect scarcity rather than fundamentals, which flatters it now and creates an overhang later, when supply normalises even if nothing about the business has changed.

The point underneath all of this is that the tight float is a design choice, not a forced outcome. JustCo could have sold more shares and produced a normal float, and it chose not to. That signals confidence in being able to come back to market later, and a reluctance to dilute further at what the existing register evidently sees as a still-early price.

The financial scoreboard

Revenue has compounded steadily, from US$113.8 million in FY2023 to US$128.2 million in FY2024 to US$144.2 million in FY2025, a little under 13% a year. The profit line is the part that needs care. JustCo lost US$12.5 million after tax in FY2023 and US$10.1 million in FY2024 before reporting a US$2.7 million profit in FY2025. That maiden profit, though, leans on a one-off. FY2025 other income included a US$3.7 million non-cash fair value gain on the remeasurement of JustCo’s pre-existing stake in its Japan operations, recognised when it bought out the rest of that business. Strip that gain out and FY2025 would have been a pre-tax loss of roughly US$1.8 million. The turn to profit is real on the reported line, but the underlying business has not quite crossed into the black yet.

The more useful trend is Cash EBITDA, the company’s measure of cash generated at centre level after actual rent is paid. It rose from US$3.4 million to US$6.2 million to US$13.5 million across the three years, and the margin widened from 3.0% to 9.4%. Occupancy improved from 78% to 84%, and the renewal rate climbed from 64.7% to 72.0%. The operating story is one of a business getting steadily more efficient as its centres mature.

The cash flow puzzle

One number in the scoreboard looks too good, and it is worth slowing down on. JustCo generated US$101.2 million of net cash from operating activities in FY2025. That is more than seven times its FY2025 Cash EBITDA of US$13.5 million, and around thirty-seven times its reported net profit. It is not a sign of a cash machine hiding inside the income statement. It is an accounting effect.

Under the lease accounting standard that applies here, the rent JustCo pays on its centres does not all run through operating cash flow. The interest portion does, but the much larger principal portion is recorded as a financing outflow. In FY2025 net cash used in financing was US$77.1 million, most of it lease repayments. So the US$101 million operating figure is, in plain terms, cash generated before paying most of the rent. The honest measure of what the business kept is further down: after rent, after capital expenditure, and after everything else, cash on the balance sheet rose by US$11.2 million. JustCo is cash generative. It is generative in the low tens of millions, not the hundred-million range the operating line first suggests.

A moat that is strongest when you need it least

A moat is whatever stops a competitor from copying a business and taking its customers. JustCo has one. The question for this offer is not whether it exists, but how well it holds when conditions turn, because the whole investment case rests on occupancy staying high and new centres filling up on schedule.

Start with what is genuinely defensible. JustCo is neither the biggest flexible-office operator in Asia nor the oldest. It competes against IWG, the listed owner of Regus and Spaces that has run this business since 1989, against the long-established premium operators The Executive Centre and Servcorp, and against a restructured WeWork. What JustCo has built instead is density in a handful of cities. The market study commissioned for the prospectus puts its share of flexible workspace stock at around 16% in Singapore, a comparable level in Bangkok, and higher in Taipei [1]. In those cities, a corporate real estate team drawing up a shortlist of options will almost always include JustCo. Being the default option in your core markets is a real advantage, and it is the strongest layer of the moat.

But notice what that advantage depends on. A network of workspace centres is only valuable to a member when the centres are full and active. This is what economists call a network effect: the product gets better for each customer as more customers use it. In a good year, full centres generate referrals, landlords compete to host JustCo, and the density looks like a fortress. In a bad year, the same network is a row of half-empty floors with the rent still due on every one of them. The moat, in other words, is pro-cyclical. It reinforces itself when times are good and erodes when times are hard. That is the opposite of what an investor wants from a moat, because the entire point of a moat is to protect a business when the cycle turns against it. JustCo’s is strongest exactly when it is needed least.

The management-contract model softens this, but only on one side. When a landlord funds the fit-out and shares the revenue, a weak year hurts JustCo less on those centres, because the pain is shared with the building owner. That protects the balance sheet. It does not make a single member more loyal, so it is not a demand-side moat.

And the demand side is where the moat is thinnest. JustCo’s members stay an average of about 15 months, so the moat has to be re-won, customer by customer, on a rolling basis: roughly 28% of the workstations due for renewal in 2025 were not renewed. The product itself is substitutable, because one operator’s private office differs from another’s mainly on location, price and fit-out quality, all of which a well-funded rival can match. Landlords who have watched the model work can choose to run flexible space themselves. And the city-level density, real as it is, sits inside a small niche. Flexible space is only about 6% of all office space in the region, so a 16% share of Singapore’s flexible market works out closer to 1% of the city’s total office stock. JustCo is a meaningful operator in a young, still-small slice of the property market, not an entrenched one in a large and mature market.

The WeWork question

The comparison is unavoidable, so we will take it head on. JustCo itself seems to know it: a sign in its centres reads “Let’s Make Work Better”, and the wordplay against the name of its largest cautionary tale is almost certainly deliberate. JustCo’s prospectus does not mention WeWork in its risk factors, but the structural feature that broke WeWork is present here too. JustCo signs leases with initial terms generally running three to ten years. Its members sign up for an average of about 15 months. That gap between long, fixed commitments on one side and short, cancellable revenue on the other is the central vulnerability of the leased-office model. It is why, at end-FY2025, JustCo carried US$402.2 million of lease liabilities against just US$40.4 million of total equity. When occupancy holds, this works. When occupancy falls, the rent does not.

What is genuinely different is almost everything else. WeWork at its 2019 IPO attempt carried around US$47 billion of lease commitments against roughly US$4 billion of rental income, was burning cash at scale, and had governance problems that became their own story. JustCo is a fraction of that size, grew at a measured pace, walked away from China and Indonesia rather than chase every flag on the map, and runs about three-quarters of its mature space under management contracts in which the landlord funds the fit-out and shares the risk. It is cash positive after everything. Its register is GIC and Frasers, not a single dominant venture backer. The honest answer is that JustCo is not WeWork. But it shares WeWork’s core structural risk, and an investor buying the IPO is buying that risk at a price that leaves little room for the occupancy cycle to disappoint.

What the market is asking you to pay

At S$0.94, the post-listing market capitalisation is just under S$460 million. Against FY2025 net profit after tax of US$2.7 million, about S$3.5 million at the rate the prospectus uses, that is a trailing price-to-earnings multiple of roughly 130 times. And because the maiden profit rests on a one-off gain, the underlying business produced no profit to multiply at all. On the company’s preferred measure, the offer values JustCo at around 27 times its FY2025 Cash EBITDA of US$13.5 million. There is no dividend policy, and none has ever been paid.

We are deliberately not putting a forward number on this article. Whether 130 times trailing earnings is the wrong price or simply an early price depends entirely on what FY2026 and FY2027 look like as 28 new centres open and season, and that forward build is a separate piece of work. What we will say plainly is what the offer price is, and what it is not. It is not a value entry point. It is a growth price, and it asks the buyer to underwrite the next two years of expansion going broadly to plan.

The bull, the bear, and the honest answer

The bull case is that JustCo is a real franchise at an inflection. Occupancy and renewal rates are both rising, the Cash EBITDA margin has tripled in three years, and the management-contract model lets the company keep growing without putting every fit-out dollar on its own balance sheet. The flexible-office market across Asia Pacific is still lightly penetrated relative to mature markets like central London, which leaves room to grow into [1]. And the quality of the register matters: GIC, Frasers and a serious cornerstone book do not anchor a business they expect to unravel.

The bear case is that the price gives you no margin for error. The maiden profit is flattered by a one-off, the structural lease-versus-membership mismatch is real and large, the free float is thin enough to make the early share price as much about scarcity as about fundamentals, there is no dividend to wait on, and the raise itself adds 28 centres of fresh lease liability and the associated drag before those centres mature. Every one of the bull points depends on the occupancy cycle staying friendly, and the moat that is supposed to hold occupancy up is, as we have seen, weakest precisely when the cycle turns against it.

The honest answer is that both cases are true at once, and the IPO price is what forces the choice. JustCo has built something durable enough that GIC and Frasers want to own it, and fragile enough, structurally, that the WeWork question is fair to ask. At nearly S$460 million on a business that has not yet made an underlying profit, the market is being asked to pay for the growth before it arrives. Whether that is a price worth paying is the question the offer puts to each investor, and it is not one we will answer for them.

Notes on data integrity

All financial figures in this article are drawn from the JustCo Holdings Limited Prospectus and the accompanying Product Highlights Sheet, both dated 15 May 2026. JustCo reports in US dollars; the offer is priced in Singapore dollars. Where we convert between the two, we use the rates the prospectus itself uses: approximately S$1.30 to US$1.00 for the FY2025 income statement, and S$1.2784 to US$1.00 as at the prospectus’s Latest Practicable Date. The trailing price-to-earnings multiple, the price-to-Cash EBITDA multiple, the post-listing market capitalisation and the underlying pre-tax loss excluding the Japan fair value gain are our own calculations from disclosed figures. “Cash EBITDA” is the company’s defined measure and is not a standard accounting metric; we use it as the company presents it. Flexible-office market penetration data is from the CBRE Independent Market Research Report commissioned for and reproduced in the prospectus. This is a focused first-look analysis of the offer, not a full research initiation, and it does not attempt a forward earnings estimate or a valuation target.

References

[1] CBRE Pte Ltd, “Market Due Diligence Report on Flexible Working Sector in Asia Pacific”, Independent Market Research Report reproduced as Appendix C in the JustCo Holdings Limited Prospectus dated 15 May 2026.

[2] JustCo Holdings Limited, “Prospectus dated 15 May 2026” and “Appendix 3 Product Highlights Sheet dated 15 May 2026”, lodged with and registered by the Monetary Authority of Singapore. Available via the SGX-ST website and the MAS OPERA portal.

[3] WeWork: comparative figures on its withdrawn September 2019 initial public offering and its lease commitments are drawn from contemporaneous public reporting; WeWork subsequently filed for Chapter 11 bankruptcy protection in November 2023.

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

That is the figure to anchor on. The reported profit decelerated 51.4% in FY2025 because the FY2024 comparable was inflated by fair-value gains; the same arithmetic now runs in reverse in 1HFY2026. What investors are paying for is the cash-generative operating engine, and that engine grew 13.9%: a real number, and a deceleration from FY2025’s reported 62.6% jump in core profit. That FY2025 figure, though, needs a closer look of its own — we return to it below.

So the first read of these results is a fork. Headline strong, underlying decelerating. Where you stand depends on whether you think the underlying number is depressed by the IPO/listing transition (S$1.2 million of cost still in the bridge) and the early phase of a room-ramp drag, or whether 13.9% is the new run-rate for a business that has now reached the gross-margin ceiling at roughly 71%.

The second thing the results did was reframe the strategy. The press release stated the goal of 10,000 rooms by 2030, the first public articulation of an explicit target, and announced a portfolio sale of seven freehold hospitality and living assets at a combined indicative S$218.5 million. Cushman & Wakefield ran the expression-of-interest exercise, bids closed 13 April 2026, and negotiations are reportedly underway [1][2]. Buyers can take vacant possession or sign a leaseback at a 3.5% gross yield. The properties cluster in three districts: three on River Valley Road, three in Balestier, one at 99 Rangoon Road. Two of the seven currently operate under management contracts rather than full ownership.

The sale is the strategically loaded piece of news in this period. If it executes, Coliwoo monetises roughly half of its S$428.2 million investment-property book and redeploys proceeds into master leases, management contracts, and selective acquisitions where mispricing or repositioning upside is available. Asset-light, capital-efficient, scalable. That model is well-understood. The Assembly Place (SGX:TAP), the only other listed Singapore co-living operator, has always run it. Coliwoo is converging on TAP’s model rather than running parallel to it.

What the numbers actually say

Read more

Those headlines sit alongside something more market-visible. DBS Group Research’s Chee Zheng Feng published a “buy” call with a 52-cent target price on 7 May 2026, five trading days before the result landed [1]. Volume on the day of the DBS publication ran 5.7 million shares against a three-month average of roughly 600,000 [2]. By the time the half-year numbers were released on 12 May, the shares had moved from 39 cents at the time of our April article, to a pre-DBS close of 39.5 cents on 6 May, before settling at 41.5 cents on results day [3].

The instinct is to declare the thesis strengthened. On a closer read, that conclusion overstates what the result actually shows.

Read more

For most of the past decade, Sunright Limited’s share price moved like a SGX small-cap nobody cared about: a few cents either way, dividend zero or near-zero, occasional flickers of activity around the AGM and the half-year results. Then in late 2025 something changed. The share price was 15.3 cents at its 12-month low. By 13 March 2026, the day Sunright reported its 1HFY2026 turnaround, it had reached 32.5 cents. By late April 2026, the Singapore financial press was running columns on the rotational interest into Sunright, AEM Holdings and UMS Integration as the city’s “semiconductor value-chain” stocks found an audience. By 7 May 2026, the price was 89.5 cents and the market capitalisation had crossed S$110m. Return from the 12-month low: approximately +485%.

The rally is propelled by a real operating turnaround — net profit of S$1.4m in the first half of FY2026 against a S$4.6m loss in 1HFY2025 — and by a credible AI-data-centre narrative that Executive Chairman Samuel Lim has been articulating consistently in press releases and AGM presentations since at least 2024. But behind the headline lies an arithmetic question the holding-company structure makes uncomfortable: 87% of Sunright’s FY2025 revenue is generated by a separately-listed Malaysian subsidiary, and that subsidiary trades at 0.58x book value on its own exchange, a fraction of where the parent now trades on the SGX.

This is an article about that gap.

How Sunright was built

Sunright Limited was incorporated in Singapore in 1978 by Samuel Lim Syn Soo, a fifty-year veteran of the local semiconductor industry credited with three joint patents for testing of devices. Lim’s career through the 1970s ran across U.S. multinationals in Asia and the United States, on the engineering, manufacturing and marketing side of test-and-measurement businesses. He launched Sunright on the conviction that the reliability bottleneck in semiconductor manufacturing — the long overnight stress test that filtered field-failure devices out of every batch — was a service business that could be productised.

KESM Industries Berhad, established by Lim’s group in 1978 in Kepong, Selangor, had by 1983 relocated to Petaling Jaya. Lim then established KESP Sdn. Bhd. in the Bayan Lepas Free Industrial Zone in Penang to expand burn-in capacity into Malaysia’s emerging electronics-manufacturing hub. KESM Industries listed on the Main Board of Bursa Malaysia in 1994, structuring the parent–subsidiary relationship that defines Sunright’s accounting and economics today: Sunright owns 48.41% of KESM, but consolidates KESM as a subsidiary because Lim — Sunright’s Executive Chairman and CEO — also holds the same titles at KESM, and Sunright’s directors are duplicated on the KESM board. De facto control flows through governance, not equity.

Sunright entered FY2026 with 122,806,266 shares outstanding, a Singapore Mainboard listing, and almost five decades of operating history almost entirely in burn-in/test services rather than equipment.

What you are actually buying

The principal activities of Sunright Limited as the parent entity are described in the FY2025 annual report as “investment holding and provision of management services.” The operating business — burn-in and testing services to global semiconductor customers — sits inside the consolidated group, and the dominant operating entity within that group is KESM Industries Berhad and its Malaysian subsidiaries.

The numbers are decisive. In FY2025 (financial year ended 31 July 2025), Sunright’s group revenue was S$72.98m. KESM’s contribution to that group revenue was S$63.75m, or 87.4%. Sunright Singapore’s direct revenue contribution — equipment manufactured under the Sunright brand and sold to customers globally — was S$5.3m, or 7.3%. The remainder came from smaller subsidiaries in China and elsewhere, several of which (KEST Taiwan, KES Shanghai) were liquidated in FY2024–FY2025 as the China–US trade environment compressed China’s role in the group’s footprint.

Two facts about that 87% are worth dwelling on. First, KESM is consolidated as a subsidiary under SFRS(I), meaning every dollar of KESM revenue, every dollar of KESM operating cost, and every dollar of KESM net asset shows up in Sunright’s consolidated financial statements. Second, only 48.41% of KESM’s economic interest belongs to Sunright shareholders. The remaining 52% is held by Bursa Malaysia investors, including KESM minority shareholders who can buy KESM directly without the holding-company layer. This 52% economic interest is presented in Sunright’s balance sheet as “Non-controlling interests” and at 31 July 2025 stood at S$53.39m, against attributable equity of S$69.24m. Group equity totalled S$122.63m. Sunright shareholders own less than 60% of the consolidated equity they read about in the headline announcements.

The Singapore-incorporated parent (Sunright Limited as a standalone entity) reported total Company-level equity of S$29.2m at 31 January 2026 against total assets of S$33.7m. Those assets are dominated by S$17.6m of cash and short-term deposits, S$9.5m of trade and other receivables, and S$5.6m of investment in subsidiaries (at carrying value), with small balances of investment securities, prepayments and intra-group loans against S$4.5m of liabilities (S$3.3m of loans and S$1.2m of payables and tax). The parent entity is essentially a holding-and-treasury function. The operating business is downstream.

The industry behind the numbers

Burn-in and test services sit between wafer fabrication and final assembly. After a chip is packaged but before it ships, it goes through hours or days of temperature, voltage and signal stress to filter out infant-mortality failures — the small percentage of devices that would fail in a customer’s product within months of deployment. For automotive, industrial, military and AI/data-centre semiconductors where field failure is unacceptable, burn-in is non-negotiable. For consumer parts, it has historically been done in-house by IDMs or skipped on commodity grades.

The addressable market for outsourced burn-in is a sub-segment of the broader OSAT (outsourced semiconductor assembly and test) industry. Multiple research providers size the global OSAT market at USD 39–47bn in 2023–2025, growing to USD 58–73bn by 2030 at single-digit CAGR (Grand View Research, Next Move Strategy, Virtue Market Research). The wafer-level burn-in and reliability test sub-segment specifically (including equipment and services) is forecast to grow at 14.8% CAGR from USD 2.26bn in 2025 to USD 4.51bn by 2030 (Virtue Market Research). The fastest-growing slice of the test stack is the slice nearest to AI processor reliability requirements — exactly the workload Sunright/KESM and Aehr Test Systems both serve.

That is the context for the rally, and for management’s repeated framing in the FY2025 annual report and 1HFY2026 press release of AI/data-centre and automotive semiconductors as the two pillars of the next leg of growth. Worldwide semiconductor revenue was USD 793bn in 2025 (+21% YoY, per the 1HFY2026 outlook commentary), and the company quotes industry forecasts of USD ~1tn by 2030. Sunright and KESM both describe themselves in their corporate materials as the world’s largest independent burn-in and test service provider, a relative position within a niche rather than an absolute scale claim. KESM’s standalone revenue of MYR 210.5m in FY2025 (~USD 47m) is a single-digit-percent share of the global outsourced burn-in services market.

The Malaysian semiconductor cluster mapping (Inari Amertron, Globetronics, Unisem, Pentamaster, MPI, ViTrox, Carsem and the customer-side IDM footprint) and the Aehr Test Systems competitive read-across in detail are in the institutional-length version of this piece.

Moat, with caveats

Two moat characteristics defend Sunright/KESM. First, the engineering integration with customer chips: every burn-in fixture and test program is co-developed with the customer over months of qualification work, and the switching cost (repeating that qualification cycle with another vendor) is real. Second, the geographic placement of capacity: KESM’s Petaling Jaya and Penang plants sit close to the Malaysian and regional packaging operations of major IDMs and OSATs, allowing tight integration with assembly logistics. These are durable advantages within the existing customer base.

The financial track record is equivocal. Across FY2020–FY2025, group revenue ranged from S$73m to S$111m and the income statement oscillated between profit and loss without a clear secular trend. ROE was negative in three of six years. KESM standalone (RM210.5m revenue, RM8.2m loss in FY2025) shows the same volatility on its own scale. The S$67.6m of net cash at 1HFY2026 is a real strength, but it sits alongside the S$11.1m one-half-year capex pulse that signals the company is now reinvesting in capacity, which can either pay off (if AI utilisation arrives) or become depreciation drag (if it doesn’t). A moat that does not deliver consistent earnings needs explanation, and Sunright offers a cyclical one (demand swings, customer concentration, capacity utilisation). That explanation is honest. It is not a moat in the sustainable-economic-rent sense.

Financial Scoreboard

What the capital actually earns

Across FY2020–FY2025, Sunright’s six-year cumulative net loss attributable to owners was S$7.7m, against an opening attributable equity base of S$82.5m at FY2019 year-end. Average attributable equity over the period was approximately S$77m, implying a cumulative ROE of approximately negative 10%, or roughly negative 1.7% per annum on average. This is below the cost of equity by any reasonable measure.

Returns on invested capital tell a similar story. Property, plant and equipment averaged S$50m over the period and operating profit averaged near zero, implying ROIC indistinguishable from zero on the operating asset base. Interest income on the S$80–100m cash pile contributed S$1.3–2.6m annually, meaningful relative to operating profit and material to the resilience of the headline P&L during cyclical downturns. The capital that earned its keep was the Treasury portfolio, not the operating asset.

The corollary: if 1HFY2026’s S$11.1m capex inflection signals a sustained reinvestment cycle, that capital must earn a meaningful return on a S$50m PP&E base. Management’s working assumption is implicit in the H1 print: they are betting that AI-driven burn-in volumes will absorb the new capacity at higher utilisation than the FY2020–FY2025 average. The bet is not unreasonable. It is also not yet evidenced.

A second view comes from the labour cost line. Employee benefits expense as a percentage of revenue rose from 38.2% in FY2020 to 45.9% in FY2025 as revenue (down 34%) fell faster than headcount cost (down 21%). Burn-in testing is a services-and-people business: KESM has to keep paying its engineers and operators whether the test cells are running near full or only half full. When semiconductor demand is weak the fixed labour bill crushes margins (which is why FY2025 turned into a loss year); when factories ramp back up, revenue grows while headcount cost stays roughly flat, and the spare capacity drops straight to profit. That dynamic is the engine behind the 1HFY2026 turnaround. In 1HFY2026 the labour ratio compressed to 41.3% (employee expense −6% YoY against revenue +15%), the first material sign of the leverage running in the right direction. Whether the FY2025 45.9% reading was cyclical drag (under-utilisation) that compresses with revenue recovery, or structural drag (Malaysian wage inflation plus a skill-mix shift toward AI burn-in engineers) that persists, is the underwriting question Q3 and Q4 FY2026 will settle.

Dividends, and the asymmetry that hides inside them

Sunright paid no dividend across FY2020–FY2024. In FY2025 it declared a 0.2 cent final dividend (S$246k total payout), described in the FY2025 chairman’s statement as recognition of shareholder support during a loss year. At the 7 May 2026 share price, that implies a yield of 0.22%. Symbolic, not income.

Beneath the headline a more interesting cash flow runs. KESM Industries — the 48.41%-owned subsidiary — has paid a dividend in every one of the past five years (6 to 9 sen per share, source: KESM Industries Berhad Annual Report 2025 five-year summary). In FY2025, despite reporting a RM8.2m net loss, KESM declared 6 sen per share. Sunright’s FY2025 consolidated cash flow shows S$504k of “Dividends paid to non-controlling interests”: cash leaving the consolidated group to KESM’s Bursa minority shareholders during the financial year. The corollary cash inflow to Sunright (the parent’s share of KESM’s dividend, ~48.41%) is netted against intra-group transactions and is not separately disclosed. The structural feature: KESM’s dividend policy is set by the KESM board (chaired by Samuel Lim, who is also chair of Sunright), and KESM’s policy of paying dividends through cyclical loss years means cash is distributed to the 51.59% Bursa minority even when the consolidated group is in loss-making mode.

This is the dual-listing tax. It is not abusive. It is not unusual. But it is a recurring, structural cost of the holding-company arrangement that the headline group financials do not isolate. In plain terms: every time KESM declares a dividend, only 48.41% flows up to Sunright shareholders; the other 51.59% leaves the consolidated group entirely, paid to Bursa minorities. Sunright shareholders also receive a 0.22% yield from their own company, but that low number is a separate problem — Sunright sits on S$84m of cash and could pay much more. The leak is structural; the meagre yield is a board choice.

Growth drivers, and what would have to be true

Three growth drivers are explicitly invoked by management across the FY2025 annual report, the FY2025 AGM presentation (delivered 21 November 2025), and the 1HFY2026 commentary: AI/data centre, automotive semiconductors, and an “expanded portfolio” of wafer, package and module-level burn-in and reliability test solutions.

The AI/data-centre driver is credible at the demand-signal level. Aehr Test Systems’ record USD 41m order from a hyperscale AI customer in April 2026 confirms that AI processor manufacturers are spending materially on burn-in. That order was for package-level burn-in (PLBI) — the same architecture KESM operates in (Aehr competes in both wafer-level via FOX-XP and package-level via Sonoma; recent hyperscale wins are on the package side). Translation into Sunright/KESM revenue therefore depends on whether hyperscalers consolidate PLBI spend with turnkey equipment vendors (Aehr) or with third-party service capacity (KESM). The outcome is binary at the customer level and probabilistic at the portfolio level.

The automotive semiconductor driver is more familiar territory. KESM has supported automotive customers for decades. The forecast cited in KESM AR2025 (automotive semiconductor revenue USD 77bn in 2025 to USD 88bn by 2027) is a low-double-digit growth runway. If KESM holds its share, automotive can plausibly contribute single-digit-percent annual revenue growth.

The third driver — wafer, package and module level expansion — was disclosed in the KESM FY2025 chairman’s statement as a new offering for FY2026. The S$11.1m of 1HFY2026 capex (against S$2.7m a year ago) is the financial expression. By the time the FY2026 annual report is published in September 2026, the early customer adoption data will be in.

Risks, with numbers attached

Customer concentration. In FY2025, three customers accounted for S$48m of the S$73m group revenue (66%). The identity of these customers is not disclosed. Loss of any one of them would produce a step-change to group revenue of approximately S$10–20m, equivalent to 14–27% of FY2025 revenue.

Geographic concentration. FY2025 revenue: Malaysia 60% (billing geography), China 18%, US 8%, Singapore 7%, others 8%. Malaysian electronics-export policy and US tariff actions affect the KESM cost base directly.

Cycle risk. Revenue declined for three consecutive years from FY2022 (S$100.7m) to FY2025 (S$73.0m), a 28% peak-to-trough. The cycle bottom is now plausibly behind, but the FY2026 recovery is one half-year of data.

Texas litigation. Weatherford v. KES Systems, Inc. (filed May 2019, Midland County, Texas) remains active as of the FY2025 annual report. Sunright has made no provision; financial exposure is unquantified. EDGAR full-text search of Weatherford International plc 10-K filings 2019–2026 returned zero hits for “KES Systems”; the case is not separately disclosed in Weatherford’s SEC filings, which suggests the company considers it immaterial to the plaintiff’s USD 5bn-revenue scale. The fact that Weatherford does not surface KES Systems in its disclosures does not bound Sunright’s exposure; it merely indicates the absence of a public quantum signal.

Holding-company governance. Samuel Lim holds 54.94% of Sunright and is Executive Chairman and CEO of both Sunright and KESM; Kenneth Tan Teoh Khoon is Executive Director of both. Capital allocation sits with overlapping boards under a single controlling shareholder.

Currency. KESM’s MYR revenue translates into Sunright’s SGD reporting; FY2025 reported S$3.5m of FX translation gain in OCI. Generally a wash, but volatile period to period.

Deep dive: the holding-company arithmetic

The central thing to understand about Sunright is not in the consolidated statement of profit or loss. It is in the relationship between two stock prices.

At the close of 7 May 2026, Sunright was at S$0.895 per share, with 122.806m shares outstanding, for a market capitalisation of S$109.91m. KESM Industries was at MYR 4.56 per share, with 43.0145m shares outstanding, for a market capitalisation of MYR 196.15m. At the spot exchange rate of MYR/SGD 0.323 (Yahoo Finance, 7 May 2026), KESM’s market capitalisation translates to S$63.36m. Sunright owns 48.41% of KESM, so the market value of Sunright’s KESM stake is S$30.67m.

Sunright’s market capitalisation decomposes look-through. Group equity attributable to owners at 31 January 2026 was S$72.18m. Of that book, approximately S$50m is Sunright’s 48.41% share of KESM’s standalone book equity (KESM standalone equity at 31 July 2025: MYR 339.17m). The remaining ~S$22m sits at the Singapore parent and smaller non-KESM subsidiaries.

When the market values Sunright at S$109.91m and 48.41% of KESM at S$30.67m, it is implicitly valuing “Sunright ex-KESM” at S$79.24m against an accounting book of approximately S$22m. The result is two very different multiples on the same balance sheet:

• KESM stake: market value S$30.67m, consolidated book ~S$50m → 0.61x P/B

• Sunright ex-KESM (Singapore parent + non-KESM subs + treasury): implied market value S$79.24m, attributable book ~S$22m → 3.6x P/B

In plain terms: the market pays about 61 cents on the dollar for KESM’s share of the operating business (factories, equipment, working capital, cash), but roughly $3.60 per dollar for the Singapore holding shell that owns it. Same physical assets, valued differently depending on which exchange you look through. The two multiples sit on either side of the headline 1.52x P/Attributable NAV, and they do not move together.

If KESM rerated to 1.0x book over 18 months (MYR 7.89 per share, a +73% move from MYR 4.56), Sunright’s stake would rise to S$53.0m, an uplift of S$22.4m or 18.2 cents per Sunright share. That is the size of the convergence trade available to a Sunright shareholder if the Bursa view of KESM closes the gap to consolidated book.

The convergence trade requires more than waiting. KESM has traded below book for most of the past five years. Closing the gap requires sustained earnings improvement at KESM specifically, not at Sunright in aggregate. KESM’s standalone 1HFY2026 result (Bursa, 10 March 2026) was a modest revenue uplift to approximately RM108m, +4% YoY. If Q3 and Q4 FY2026 continue that direction, the gap narrows. If they don’t, Sunright’s 3.6x ex-KESM multiple gets very hard to justify on a Singapore parent that generated S$5.3m of FY2025 revenue and is loss-making at the entity level.

Management

Samuel Lim Syn Soo, Executive Chairman and CEO since founding in 1978, is 71 years old. The succession question is not formally addressed in the FY2025 annual report or in the 21 November 2025 AGM presentation. Kenneth Tan Teoh Khoon, age 68, has been Executive Director since 1992 and is the long-standing financial steward of the group; he sits on both the Sunright and KESM boards. Ms Lim Mee Ing, age 74, is a Non-Independent Non-Executive Director on the KESM board (since 1990) — surname coincidence aside, her presence is itself a governance flag for minority investors who care about director-related-party concentration. Daniel Soh is Sunright’s Lead Independent Director (also age 71). The board added Dr Babak Alizadeh Taheri, an independent director with technology and governance background, on 22 November 2024, consistent with SGX corporate governance code refresh requirements. No internal successor has been named publicly for either Lim’s role.

The capital allocation track record is mixed. Cash has been preserved (S$84m at FY2025 versus S$93m at FY2019), but capex was held below depreciation for most of the post-FY2020 period, implying capacity contraction in real terms. Dividend distribution has been near-zero. The S$11.1m H1 capex pulse is the most material pivot in five years. Management has not provided forward guidance.

The most material governance disclosure is the Lim dual role. Samuel Lim is Executive Chairman and CEO of Sunright (Singapore) and Executive Chairman and CEO of KESM Industries (Malaysia). The two roles cannot, in principle, be conflict-free at all times — KESM’s dividend policy, KESM’s capex priorities, and Sunright’s capital allocation between Singapore and Malaysia all involve choices between Sunright minority interests and KESM minority interests. Lim’s 54.94% stake in Sunright aligns him with Sunright shareholders; the KESM stake (held through Sunright) aligns him with KESM majority. The two minorities — Sunright SGX retail and KESM Bursa retail — receive whatever is left after both controlling stakes have voted. There is no public evidence of mismanagement, but the structural arrangement creates a permanent asymmetry that minority investors should price.

Valuation

Bull vs Bear

Bull case. The 1HFY2026 print is the first half-year in three years where revenue and operating direction agree. Sunright/KESM describe themselves as the largest independent package-level burn-in service operators, and the AI hyperscaler capex cycle that drove Aehr’s record USD 41m PLBI booking in April 2026 is direct demand validation for the same architecture KESM operates in. The S$11.1m of 1HFY2026 capex is leveraged exposure to AI-driven utilisation gains. The S$67.6m of net cash supports the downside. If KESM reports a strong 2HFY2026 and Bursa reflects the recovery, Sunright shareholders capture both the consolidated earnings recovery and a partial closure of the P/NAV gap. With FY2027 attributable equity of ~S$80m (flat NCI, S$10m cumulative profit accrual) and Sunright at 1.5x attributable NAV, the share price is S$0.98 — modest single-digit upside. At 2.0x attributable NAV, S$1.30, or ~46% upside. Either requires KESM execution.

Bear case. The S$0.895 share price already reflects two consecutive halves of operating recovery and an AI narrative. The 12-month low was S$0.153; almost the entire upside has been delivered in the seven months since October 2025. KESM’s Bursa share price has not moved with comparable amplitude. If hyperscaler PLBI volumes flow to integrated equipment vendors (Aehr) rather than third-party services (KESM), the S$11.1m capex underutilises and depreciation drag pulls ROIC back toward zero. A second half-year of sub-MYR 200m KESM revenue combined with any Texas litigation development would compress the multiple toward 1.0x attributable NAV (S$0.59), a 34% drawdown. The bear case is not catastrophic — net cash supports a floor — but the asymmetry of upside-already-banked versus downside-still-possible deserves underwriting at current prices.

What would break the thesis

The bull case fails on any of the following:

• KESM execution: two consecutive flat or negative-growth quarters in 2HFY2026 (Q3 announcement ~10 June 2026, Q4 ~25 September 2026).

• Competitive displacement: Aehr Test Systems wins additional package-level burn-in orders from hyperscale customers that are also customers of KESM.

• Capital allocation signal: KESM declares a total FY2026 dividend substantially above the 6 sen FY2025 level, signalling capital being returned rather than reinvested and contradicting the H1 capex narrative.

• Customer concentration: any one of the three customers contributing 66% of FY2025 revenue migrates volume to a competitor.

• Labour leverage: FY2026 full-year employee expense ratio above 44% (vs 41.3% in 1HFY2026, 45.9% in FY2025). A higher reading would signal the labour cost is structural rather than cyclical and would invalidate the operating-leverage component of the bull case.

The bear case fails (i.e. the bull case holds) if the FY2026 full-year results published in September 2026 show group revenue above S$90m and net profit attributable to owners above S$5m. That print would re-anchor the multi-year baseline.

Data points to monitor:

• KESM Bursa filings — Q3 FY2026 due ~10 June 2026, Q4 FY2026 due ~25 September 2026.

• Sunright FY2026 results announcement — ~late September 2026.

• Aehr Test Systems FY2027 quarterly bookings disclosures — NASDAQ filings.

• Customer concentration disclosure in the next Sunright annual report.

The Bottom Line

Sunright is a real operating business going through a real recovery, controlled by a real founder and supported by a real net cash position. None of those things are in question.

What is in question is whether the price the SGX is currently asking for that combination — 1.5x attributable book, 0.85x group book, on a stock that has rallied roughly 5x off its 12-month low — has overshot the operating evidence. The answer requires a view on KESM, not on Sunright. KESM’s own market — Bursa Malaysia — currently rates the operating business at 0.58x book, and that view has not materially changed during Sunright’s rally. The Sunright premium is therefore borrowed against an expected closure of the Singapore-Malaysia valuation gap. That closure is plausible. It is not yet evidenced.

A buyer at 89.5 cents is buying optionality on convergence, on AI-driven utilisation, and on a capex pulse delivering returns. A seller is taking the gain on the rally and acknowledging that the convergence trade has timing risk. Neither side is wrong. The article offers no recommendation, only the observation that the asymmetry between the two listings is the most important fact about the share price today, and that fact deserves to be owned as a position whether one is long, short, or absent.

The institutional-length version of this analysis — the historical and structural context, the industry context, the math behind every number, and the data points to monitor going forward — is available to Paid members. Read it here.

Data Integrity Notes

This article uses only company-filed data from SGX and Bursa Malaysia announcement systems and the FY2020–FY2025 annual reports of Sunright Limited and KESM Industries Berhad. Share price and market-capitalisation figures are from Yahoo Finance, retrieved 7 May 2026.

Known limitations: (1) Weatherford v. KES Systems, Inc. (Texas, filed May 2019) remains active. No provision; financial exposure is unquantified. EDGAR full-text search of Weatherford International plc 10-K filings 2019–2026 returned zero hits for “KES Systems”; no public quantum is assignable. (2) Sunright reports expenses by nature rather than function — gross profit is not separately disclosed and “Direct materials cost” is the closest proxy in the Financial Scoreboard. (3) Detailed KESM segment data was sourced from KESM’s own Bursa filings rather than Sunright’s summarised disclosures. (4) The FY2025 Sunright AR discloses three customers at 66% of revenue but does not name them; customer-level analysis is directional. (5) KESM's 1HFY2026 quarterly result (Bursa filing dated 10 March 2026) was available to us at draft date; the +4% YoY revenue trajectory and the loss-to-profit PBT swing were cited based on two third-party summaries. The primary Bursa filing was obtained post-publication (2026-05-11) and verified: all third-party-corroborated figures match the source filing exactly (revenue RM107.95m, PBT RM6.66m vs RM8.08m loss, cash RM195m, 6 sen interim dividend). No corrections required. (6) MYR/SGD spot rate of 0.323 is used throughout.

References

[1] Sunright Limited, Annual Report 2025 (SGX filing dated 26 September 2025).

[2] Sunright Limited, Annual Report 2024 (SGX filing dated 27 September 2024).

[3] Sunright Limited, Annual Report 2023, Annual Report 2022, Annual Report 2021, Annual Report 2020, Annual Report 2019 (SGX filings).

[4] Sunright Limited, Condensed Interim Financial Statements for the First Half Year ended 31 January 2026 (SGX filing dated 13 March 2026).

[5] Sunright Limited, Full-Year Results announcements FY2020–FY2025 (SGX filings).

[6] Sunright Limited, Press Release — 1HFY2026 (SGX filing dated 13 March 2026).

[7] KESM Industries Berhad, Annual Report 2025 (Bursa Malaysia filing dated October 2025).

[8] KESM Industries Berhad, Annual Reports 2020–2024 (Bursa Malaysia filings).

[9] KESM Industries Berhad, Quarterly Results Q2 FY2026 (Bursa Malaysia filing dated 10 March 2026).

[10] The Edge Singapore, “Sunright returns to profitability in 1HFY2026, with net profit of $1.4 mil” (13 March 2026). https://www.theedgesingapore.com/capital/results/sunright-returns-profitability-1hfy2026-net-profit-14-mil

[11] The Edge Singapore, “As interest moves to semiconductor value chain stocks, the STI continues consolidation” (24 April 2026). https://www.theedgesingapore.com/capital/right-timing/interest-moves-semiconductor-value-chain-stocks-sti-continues-consolidation

[12] Aehr Test Systems Inc, “Aehr Receives Record $41 Million Production Order from Lead Hyperscale AI Customer; Second-Half Bookings Exceed $92 Million” (April 2026). https://www.aehr.com/2026/04/aehr-receives-record-41-million-production-order-from-lead-hyperscale-ai-customer-second-half-bookings-exceed-92-million/

[13] Yahoo Finance, Sunright Limited (S71.SI) share-price and market data, retrieved 7 May 2026. https://finance.yahoo.com/quote/S71.SI/

[14] Yahoo Finance, KESM Industries Berhad (9334.KL) share-price and market data, retrieved 7 May 2026. https://finance.yahoo.com/quote/9334.KL/

[15] Grand View Research, “Outsourced Semiconductor Assembly And Test Services Market To Reach $67.92Bn By 2030” (press release). https://www.grandviewresearch.com/press-release/global-outsourced-semiconductor-assembly-test-services-market

[16] Virtue Market Research, “Wafer-Level Burn-In & Reliability Testing Market | Size, Overview, Trends, and Forecast | 2026–2030”. https://virtuemarketresearch.com/report/wafer-level-burn-in-reliabilit-testing-market

[17] Minichart, “KESM Industries Berhad Q2 2026 Financial Results: Revenue Growth, AI Chip Demand, and Profit Recovery” (10 March 2026). https://www.minichart.com.sg/2026/03/10/kesm-industries-berhad-q2-2026-financial-results-revenue-growth-ai-chip-demand-and-profit-recovery/

IMPORTANT DISCLAIMERS

This article is published for informational and educational purposes only. It does not constitute financial or investment advice, a recommendation, or a solicitation to buy, sell, or hold any securities. The author is not a licensed financial adviser under the Financial Advisers Act 2001 of Singapore, nor a licensed adviser under the Capital Markets and Services Act 2007 of Malaysia. This content is exempt from the requirements of the Singapore Financial Advisers Act pursuant to Regulation 34 of the Financial Advisers Regulations, as it is published in a generally available publication. This publication does not take into account the specific investment objectives, financial situation, or particular needs of any individual. Before making any investment decision, readers should consult a licensed financial or investment adviser in their relevant jurisdiction. Past performance is not indicative of future results.

No Warranty: While the data and analysis have been prepared in good faith from public sources believed to be reliable, no representation or warranty, express or implied, is made as to the accuracy, completeness, or timeliness of the information. The author accepts no liability for any loss arising from the use of this material.

Disclosure: The author may or may not hold positions in the securities discussed. No compensation has been received from any company mentioned in this article.

For most of the past decade, Sunright Limited’s share price moved like a SGX small-cap nobody cared about: a few cents either way, divid…

Read more